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Abstract
Breast cancer is currently the most prevalent form of cancer in women with over 266,000 new
diagnoses every year. The various methods used for breast cancer screening range in accuracy and
cost, however there is no easily reproducible, reliable, low-cost screening method currently
available for detecting cancer in breasts, especially with dense tissue. Steady-state Infrared
Imaging (IRI) is unaffected by tissue density and has the potential to detect tumors in the breast
by measuring and capturing the thermal profile on the breast surface induced by increased blood
perfusion and metabolic activity in a rapidly growing malignant tumor. The current work presents
a better understanding of IRI as an accurate breast cancer detection modality. A detailed study
utilizing IRI-MRI approach with clinical design and validation of an elaborate IRI-Mammo study
are presented by considering patient population, clinical study design, image interpretation, and
recommended future path. Clinical IRI images are obtained in this study and an ANSYS-based
modeling process developed earlier at RIT is used to localize and detect tumor in seven patients
without subjective human interpretation. Further, the unique thermal characteristics of tumors that
make their signatures distinct from benign conditions are identified.
This work is part of an ongoing multidisciplinary collaboration between a team of thermal
engineers and numerical modelers at the Rochester Institute of Technology and a team of clinicians
at the Rochester General Hospital. The following components were developed to ensure valid
experimentation while considering ethical considerations: IRB documentation, patient protocols,
an image acquisition system (camera setup and screening table), and the necessary tools needed
for image analysis without human interpretation. IRI images in the prone position were obtained
and were used in accurately detecting the presence of a cancerous tumor in seven subjects. The
size and location of tumor was also confirmed within 7 mm as compared to biopsy-proven
pathology information. The study indicates that the IRI-Mammo approach has potential to be a
highly effective adjunctive screening tool that can improve the breast cancer detection rates
especially for subjects with dense breast tissue. This method is low cost, no-touch, radiation-free
and highly portable, making it an attractive candidate as a breast cancer detection modality.
Further, the developed method provided insight into infrared features corresponding to other
biological images, pathology reports and patient history.
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Chapter 1. Introduction

1.1 Motivation
Cancer is a deadly disease found all over the world in many different forms. Cancer involves the
rapid uncontrolled growth of diseased cells and can form anywhere in the body [1]. Positive
prognosis from cancer is dependent upon early diagnosis of abnormal (malignant) masses. Delayed
diagnosis can cause delayed treatment which can increase the necessary costs needed for tumor
shrinkage or removal. Many forms of cancer involve the growth of solid tumors, made of a mass
of tissue. However, some forms such as leukemia or bile duct cancer do not have a solid tumor.

Figure 1. Estimated cancer statistics for 2017 presented by the American Cancer Society [2].

In any form, it is a destructive and widespread disease that affects millions of people throughout
the world. A 2012 study estimated 14.1 million new cases of cancer were diagnosed with 8.2
million people killed from various forms of cancer [2]. In the United States alone, the American
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Cancer Society estimates about 1.7 million new cancer cases with approximately 600,000 deaths.
Lack of proper diagnostic techniques or treatment can lead to further loss of life and financial ruin.
The Agency for Healthcare Research and Quality (AHRQ) estimates that in the US in 2015, a
staggering $80.2 billion accounted for all cancer-related medical costs [3]. This sum accounts for
hospital visits, inpatient stays, treatments, and medicine. Many of the larger cancers present in the
world include breast cancer, prostate cancer, and liver cancer. As seen in Figure 1, breast cancer
remains as one of the highest occurring cancerous diseases in females. Figure 1 estimates the
amount of breast cancer cases in 2017 at approximately 250,000.

1.2 Breast Cancer
The breast, as seen in Figure 2, is also known as a mammary gland and is present in both men and
women. However, only women have functioning, lactating glands for infant nourishment. The
breast consists of 15-25 lobes, separated by tissue, that contain lobules. Nonpregnant girls and men
only have rudimentary ducts but when puberty is reached, the female breast experiences duct
growth and increased fat deposition. Many major breast cancers form in the lobules and duct
system. When detecting tumors in the breast, there are many factors to consider. Although all
women develop ducts and fat with puberty, there are four different types of breast density: fatty,
fibroglandular, heterogeneously dense and extremely dense. Extremely dense breasts have less fat
and more fibrous and glandular tissue than fatty breasts. Fatty breast tissue is more common among
younger females while extremely dense tissue is found in older women.
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Figure 2. Frontward and side view of the human breast [4].
Breast cancer can be invasive, spreading to surrounding tissue, or remain in situ and stay within
the breast. Rarer, inflammatory breast cancer only accounts for 1% of cancers [5]. The four more
common breast cancers are ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC),
invasive lobular carcinoma (ILC) and lobular carcinoma in situ (LCIS). DCIS and LCIS, both in
situ diseases, are non-invasive forms of breast cancer. Ductal carcinoma begins in the milk ducts
of the breast but does not spread. Although DCIS can be treated, it can lead to a higher chance of
developing an invasive form of breast cancer later in life [6]. The other in situ breast cancer, LCIS,
differs in growth and later life effect. The term ‘lobular’ refers to the lobules or a milk producing
gland, which can be seen in Figure 2 [7]. LCIS is not technically diagnosed as breast cancer but
instead as lobular neoplasia or an abnormal cell growth [8]. Major types of breast cancer and the
areas they afflict can be seen in Fig. 3.

17

Figure 3. The most prevalent forms of breast cancer found in women [9].

Invasive breast cancers involve spreading diseases that begin in one spot in the breast but slowly
metastasize to other parts of the body [10]. Invasive Ductal Carcinoma, similar to DCIS, begins in
the milk ducts and is the most common form of breast cancer, accounting for 80% of all diagnosed
cases [11]. Invasive Lobular Carcinoma, the second most common form of breast cancer, begins
in the lobules and spreads to surrounding breast tissue. ILC can spread to the lymph nodes or other
parts of the body and mostly affects older women [12]. The significance of these cancers for
different diagnosis studies is tumor size, shape, and growth pattern. While many tumors grow in
ball-like solid masses of cells, many tumors can form irregularly or in a stacked file. IDC tends to
see abnormal, star-shaped tumors while tubular carcinomas have no palpable tumor but instead
form in tube-like structures. Other rarer forms of breast cancer have softer tumors, sheet-like
18

tumors, or branching finger-like tumors [13] which can make it particularly difficult to use one
diagnosis method for breast cancer detection. Having a comprehensive understanding of breast
anatomy can lead to better detection methods for these rarer forms of cancer.

1.3 Cancer Biology
1.3.1 Hallmarks of Cancer
Cancer growth has been a widespread field of study for several decades. While the origin of the
disease is still unknown, the mechanics behind cancer cell growth is slightly more understood. In
2000, Hanahan and Weinberg [14] discuss the various principles that encompass the complexity
of cancer also known as the Hallmarks of Cancer. In 2011, Hanahan and Weinberg [15] added
additional factors to this list. All ten principles are discussed in length below and can be seen in
Figure 4.
1. Sustaining Proliferative Signaling – Unlike normal cells, cancer cells can sustain
proliferation. Normal cells can maintain homeostasis by controlling the production and
release of growth-promoting signals that cause the cell growth-and-division cycle.
However, cancer cells can acquire this same ability and can control the growth of more
cancer cells. They can do this through multiple methods, like producing the same signal,
permanently activating the signal, or destroying ‘off switches’ to allow excessive growth.
2. Evading Growth Suppressors – Not only is the human body able to control signals to grow
and divide cells, it is also able to regulate cell proliferation, halt cellular growth, and stop
dividing once the space is filled. Cancer cells can alter these suppressor proteins and grow
and divide into any surrounding space, whether it is full or not. Cancer cells want to
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continue growing, uncontrollably, to take over the surrounding area and spread throughout
the body.
3. Resisting Cell Death – Normal cells are programmed to have cell death or apoptosis in
order to maintain homeostasis and prevent potential abnormal growth. Cancer cells can
resist cell death and therefore become grossly abnormal.
4. Enabling Replicative Immortality – Similar to the point listed above, cells die after a certain
number of divisions in order to prevent abnormality. Unlike normal cells, cancer cells are
able to bypass this natural ability and can divide indefinitely. This causes the already
abnormal cells to spread their mutations and create more abnormalities.
5. Inducing Angiogenesis – Angiogenesis is a normal process that occurs in the body to grow
blood vessels for continued cell growth and production. Cells need oxygen and nutrients
from blood vessels in order to survive. Cancer cells are also able to create new blood
vessels in order to carry adequate oxygen and nutrients to the abnormal cells for continued
growth and replication.
6. Activating Invasion and Metastasis – A primary cause of cancer-related deaths is cancer
cell invasion and metastasis into surrounding tissues and organs. In order to metastasize to
the rest of the body, the cells must first spread to localized tissue. This is a difficult process
involving invading blood vessels and surviving in a harsh environment. Once the cancer
cells have surpassed this barrier, they are able to metastasize and potentially become a
larger concern.
7. Genome Instability and Mutation – For constant replication and growth, malignant or
benign cancer cells must alter the genomes of neoplastic cells. Small genetic mutations are
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often thought to be the beginning of tumor growth initially and begin to mutate at much
faster rates as the cells grow and divide.
8. Tumor-Promoting Inflammation – There have been many studies showing that
inflammation can lead to cancer development. More chronic inflammatory issues such as
infections, obesity, smoking, alcohol consumption, etc. are all potential risk factors linked
to cancer development through inflammation.
9. Deregulating Cellular Energetics – Cancer cells are able to generate energy in abnormal
ways using metabolic pathways. First discussed by Otto Warburg [16], this process is now
known as the Warburg effect. He hypothesized that tumors grow due to insufficient cellular
respiration caused by manipulation of energy production. Instead of creating more energy
(ATP), cancer cells convert acids into building blocks for more cancer cells.
10. Avoiding Immune Destruction – Similar to other hallmarks discussed above, cancer cells
are able to avoid detection by the body’s natural immune system. While most illnesses are
sensed and destroyed, cancer cells can avoid destruction and continue to grow.

Although there are many factors that affect how cancer cells grow and replicate, few of these
principles are hypothesized to contribute to hyperthermia. Two large factors that would allow for
successful infrared imaging include inducing angiogenesis and tumor-promoting inflammation.
Angiogenesis is a well-studied phenomenon within the body, both during normal cell growth and
cancerous cell growth. The increase of vasculature to a growing tumor creates an area of
hyperthermia. The increased metabolism in a tumor can also cause localized temperature increases.
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Figure 4. The ten factors that influence the growth and spread of malignant cells [17].

1.3.2 Necrosis
Necrosis involves cellular injury in which certain cells of living tissue are killed through autolysis.
Apoptosis refers to a living cell receiving a signal to initiate controlled death whereas autolysis is
cells dying in an uncontrolled manner, such as tumor necrosis. Additionally, cellular necrosis can
cause further harm to surrounding cells [18]. As a tumor grows in an outward fashion, the middle
of the tumor will be cut off from nutrients and oxygen, causing necrotic decay. This has been seen
briefly in a study performed by Gautherie [19] to cause a dip in temperature. The study, discussed
heavily in Chapter 6, presents the insertion of a temperature probe into the tumor of several
patients. The temperature region within the center of the tumor is seen to dip, leading to the
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assumption of necrotic tissue in more advanced, larger tumors. Gautherie concludes that a
temperature change observed in his experiments are potential indicators of more aggressive, larger
tumors with necrotic inner tissue.

1.3.3 Body Rhythms
There are many natural biological rhythms, affected by our body’s chemicals or functions. Many
often follow daily cycles or can be longer, depending on the type of rhythm. The four main
biological rhythms are as follows [20]:
•

Circadian rhythms: 24-hour cycle including physiological and behavioral rhythms

•

Diurnal rhythms: circadian rhythm synced with day and night

•

Ultradian rhythm: biological rhythms with a shorter period and higher frequency than
circadian rhythms

•

Infradian rhythms: biological rhythms that last more than 24 hours (such as menstrual
cycle)

There are many potential disorders that can impact natural biological rhythms such as anxiety,
sleep disorders, depression, etc. Some authors believe that natural biological rhythms can affect
the temperature flow throughout the body, subsequently affecting resulting thermograms.
Depending on the time of day or activities prior to imaging, the thermal results can change. Body
rhythms are heavily discussed by Gautherie [19] as potential guidelines for imaging.

1.4 Medical Diagnosis
Prior to screening, a patient’s risk level is identified based on many bodily factors and medical
history. If someone is identified as breast cancer positive, the tumor is localized in terms of its
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position on a clock, quadrant of the breast, distance from the nipple, and depth. Finally, they are
diagnosed based on the tumor pathology.

1.4.1 Risk
Patients are screened in different ways depending on their risk score. Risk is determined based on
medical history, previous exposure (radiation, cancer, surgery) and genetic predisposition and
family history. There are three main risk categories: high-risk, intermediate-risk and average-risk.
The concept of ‘risk’ is measured based on various factors pertaining to the patient. They are as
follows:
Table 1. Factors associated with high risk [21].
Unalterable
Factors

History

LifestyleRelated
Factors

Age
Breast Density
Genetic Mutation (BRCA1 or BRCA2)
Family History
Pregnancy or Breastfeeding
Previous history of cancer or breast disease
Treatment with radiation therapy
Physical Activity
Weight
Hormone altering substances such as oral
contraceptives
Alcohol and tobacco consumption

The image seen in Fig. 5 shows the National Cancer Institute’s statistical significance of the
mutated BRCA1 and BRCA2 gene. Women with either gene are considered high-risk and must
endure screening on a more regular basis, often with multiple modalities. Many women at highrisk will start receiving mammograms and MRIs every year, beginning at age 30.
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Figure 5. The significance of the BRCA1 and BRCA2 mutations on increasing the risk of
developing breast cancer [21].

While beginning breast cancer screening at a younger age can be beneficial and detect breast
cancer at an earlier stage, many argue that inducing radiative screening techniques can have
damaging effects. MRI is often used to screen for women younger than 30 with these mutations
but has been shown to have a low specificity or increased false-positive rate.

1.4.2 Cancer Classification
Once someone is positively diagnosed with cancer, it is classified based on where the cancer is
within the body. For example, if a tumor is found in the breast it is considered breast cancer.
However, there are different areas within the breast where cancer can occur. If a mass is found
within the epithelial tissue, it is considered a carcinoma whereas if cancerous cells are found within
the connective tissue, it is considered a sarcoma.
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Cancer is also identified by position and location. Characterizing a tumor or tumor location
depends on several commonly known medical methods. Four different breast densities are used
(as discussed above), three different depth parameters and several different locations. Figure 6
shows the tumor characterization widely used to localize location and position within the breast.
For the tumor placement, a clockwise pattern is used including the center, seen in Fig. 6a while on
the side view of the breast, there are anterior, mid, and posterior positions, seen in Fig. 6b. This
information is important in localizing the tumor for further management such as biopsy or surgical
resection and in correlating the findings with those of other imaging modalities.

(a)
(b)
Figure 6. (a) Tumor location based on the positions on a clock and (b) tumor depth with three
different classifications (interior, mid, posterior).

Once the tumor is examined and placed, it is assigned a grade. This grade is dependent on how the
tumor is growing and spreading throughout the body [7]. Tumor grade is different than cancer
staging, however. Cancer staging is dependent on three major factors: (1) Tumor (T), (2) Nodes
(N), and (3) Metastases (M). For (T), a number is assigned dependent on how far the tumor has
spread, how large it is, if it has begun to metastasize, etc. (N) involves the number of nodes affected
by the disease. If the cancer has begun to spread into the lymph system, then a higher number will
be assigned. Finally, (M) is dependent on whether cancer has started to spread to surrounding
organs. The official system, presented by the National Cancer Institute, can be seen in Table 2.
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Table 2. Different factors used in tumor staging [22].
Primary Tumor (T)

Regional Lymph Nodes (N)

Distant Metastasis (M)

TX
T0
T1T4

Main tumor cannot be measured
Main tumor cannot be found
Refers to size/extent of main tumor. Higher numbers
indicate larger tumors that have grown more.

NX
N0
N1N3

Cancer in nearby lymph nodes cannot be measured
There is no cancer in nearby lymph nodes
Refers to number and location of nodes that contain
cancer. Higher number indicates more nodes that
contain cancer.

MX
M0
M1

Metastasis cannot be measured
Cancer has not spread to other parts of the body
Cancer has spread to other parts of the body

In 2018, the AJCC (American Joint Committee on Cancer) [23] announced an addition to the
tumor grading system. Not only will the grade depend on TNM, but it will also include prognostic
staging. Prognostic staging involves receptor status, genomic tests, and histologic grade.
Receptor Status – Receptor status refers to the hormones progesterone and estrogen that can
drastically affect how cancer grows and spreads. When breast cancer is classified, proteins found
in the cells are tested for estrogen or progesterone receptors. The following three are tested:
•

ER (estrogen receptor) – Positive or Negative

•

PR (progesterone receptor) – Positive or Negative

•

HER2/neu – Positive or Negative

If a cancer is classified as receptor-positive, hormone therapy can be used to treat. The hormone
therapy drugs block the hormone receptors that are helping the tumor grow and cut off the supply
[24]. HER2 is a growth-promoting protein within the body that, if present within a tumor, can
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cause cancer to grow and spread faster [41]. Similar to hormone-rich breast cancers, HER2 positive
breast cancer can be treated with specified therapies. Breast cancers referred to as triple-negative
are negative for ER, PR and HER2. These breast cancers are much more aggressive as the therapies
and treatments normally used are not effective.
Genomic Tests – Genomic testing refers to the desired course of action following genetic testing
to measure cancer risk. For breast cancer, this primarily refers to the BRCA1 and BRCA2 genes.
As seen above in the discussion on risk, testing positive for one of these genes greatly increases
chances of breast cancer and ovarian cancer. If someone tests positive for either gene, the Oncotype
DX genomic test can predict aggressiveness of a tumor and what therapies will be most beneficial.
Genomic testing can also be beneficial for patients with a family history. A patient diagnosed with
cancer who also has a family history can participate in genomic testing to determine how the tumor
will be influenced within the body and how it will grow and spread.
Histologic Grade – The grade is determined by observing various morphologic features such as
tubule formation, nuclear pleomorphism and mitotic count [26].
•

Tubule Formation – The amount of cancer cells that are in tubular formation (as seen in
Fig. 7). The more tubules present in the cells gives a better score of 1 while a score of 3 is
considered the worst.

•

Mitotic Rate – This refers to the rate of multiplication and division of the cancer cells where
1 is the slowest and 3 is the fastest.

•

Nuclear Pleomorphism – Finally, the nucleus is examined and given a score (1 to 3)
dependent its appearance.

28

Figure 7. Slice of invasive ductal carcinoma with tubule formation in over 75% of the tumor
[27].

The three features are given a score between 1-3 depending on intensity and prevalence. The sum
of these scores designates the overall histologic score as seen below:
Table 3. Histologic grading system reported by the AJCC [26].
G

Grading Definition

GX

Grade cannot be assessed

G1

Low combined histologic grade (favorable), score of 3-5 points

G2

Intermediate combined histologic grade (moderately favorable), score of 6-7 points

G3

High combined histologic grade (unfavorable), score of 8-9 points

The currently classification of cancer primarily involves cellular and pathologic characteristics.
Cancer and tumors are classified based on their growth and gene expression. However, there is no
existing classification involving metabolic or thermal characteristics. There are many potential
thermal biomarkers indicative of specific tumor growth. Many of these are discussed by Gautherie
[19] and further presented below.
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1.5 Medical Imaging
Most medical imaging techniques require a different type of wave to capture information in the
body. Different forms of medical imaging simply manipulate different waves and frequencies on
the spectrum in order to see into the body. The electromagnetic spectrum, seen in Fig. 8, shows all
known detectable waves and their corresponding frequency range.

Figure 8. The electromagnetic spectrum with detectable waves and their accompanying
frequencies [28].

Ultrasound uses acoustics and sound waves, MRI uses radio waves and mammography uses xrays. Many medical systems utilize x-rays to visualize different parts of the body. X-rays are a
type of electromagnetic radiation, similar to other waves seen on the electromagnetic spectrum. Xrays involve highly energetic photons that break up molecules and damage or destroy living cells.
Some rays are absorbed into whatever material they are aimed at and others pass through. When
the x-rays pass through the body, we can image or see inside. Utilizing x-rays, especially over a
longer period, can cause radiation damage to the body and increase the risk of developing cancer.
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Early detection of breast cancer is associated with improved chances of survival and options for
curative treatment. The primary goal of cancer screening is to decrease cancer mortality through
detecting asymptomatic cancers at an earlier curable stage before spreading to lymph nodes or
distant organs, however overdiagnosis is a major concern in present screening techniques.
Although there are many imaging techniques for breast cancer and other maladies found within
the body, the three significant modalities (mammography, ultrasound, and MRI) are discussed
here.

1.5.1 Imaging Techniques
a. Mammography and Digital Breast Tomosynthesis (DBT)
Mammography is currently the most widely used form of early breast cancer diagnosis.
Mammography has been used since the 1970s for breast cancer screening in asymptomatic women.
The screening in women aged 40-74 has been associated with relative reduction in breast cancer
mortality of 15-20% [29]. Older methods involve 2D mammography while current techniques use
3D mammography or tomosynthesis. However, due to patient discomfort and radiation exposure,
mammograms are only recommended for older women above the age of 50 [30]. A mammogram
involves the compression of the breasts between an imaging plate and a clear plastic plate in order
to x-ray the breast for screening and diagnostic purposes.
When a tumor is present, it will appear as a white mass on a mammogram. However, denser breast
tissues also appear white. Women with scattered fibroglandular tissues, heterogeneously dense
tissues or extremely dense tissues have a risk of a mammogram missing an existing tumor. Varying
breast densities imaged mammographically are seen in Fig. 9. This is due to the white tumor mass
blending in with the denser tissue. In 2D mammography, several images are taken at different
angles to try and eliminate false positives or miss tumors behind dense tissues. Tomosynthesis,
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which was approved by the FDA in 2011, is considered an adjunct to mammography, but is also
expensive with a high radiation dose. Tomosynthesis is an imaging technique that utilizes x-rays,
often used in women who are asymptomatic [31]. In digital breast tomosynthesis (DBT), also
known as 3D mammography, the x-ray moves in an arc over the compressed breast, capturing
many images to form a three-dimensional representation. The added enhancement allows for many
views and therefore reduces any tissue overlap that could mask potential tumors [32]. The
detection accuracy improves with DBT because multiple views are obtained, and the possibility of
masked tumors decreases.
Breast density is an important consideration in all breast cancer screening. The four categories of
breast density are fatty, scattered fibroglandular, heterogeneously dense and extremely dense.
Heterogeneously dense and extremely dense breasts are considered “dense breasts” [33] (> 40%
of women) and are at higher risk of developing cancer. However, mammography, currently the
most widely used and available screening technique, is suboptimal in breasts with dense tissue;
this results in ~38% of tumors to be missed or misdiagnosed [34].

Figure 9. Mammogram of different breast densities [35].
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b. Ultrasound
Ultrasound, a common adjunct diagnostic technique, and screening tool, is operator-dependent,
and findings may be difficult to reproduce. Ultrasound imaging involves the manipulation of sound
waves sent through the breast and converted into images. Although ultrasounds can be an insightful
imaging technique, they are generally only used as a complement screening method to verify the
presence of a tumor or for ultrasound-guided biopsy. The images are captured in real-time as well,
which can allow for visualization of blood flow and any other movement occurring during
imaging. The imaging process is completely noninvasive and, unlike mammography, there is no
radiation involved in the process [36]. Although it is not generally used as a standalone screening
method, it is highly beneficial for younger women. Younger women, who generally do not receive
mammograms, are screened with ultrasound first if a lump is discovered before becoming exposed
to other invasive methods such as mammography or MRI. It can also be beneficial for women with
breast implants and women who are pregnant or breast-feeding [37].
Ultrasounds can be incredibly beneficial in differentiating solid masses (signifying malignant
tumors) and fluid-filled benign cysts or fat lobules. Identifying the difference between a benign
mass and a malignant tumor can spare emotional and financial burden and is therefore a crucial
component of diagnosis. The images seen in Fig. 10 show a benign cyst and malignant tumor. Fig.
7a has distinct edges and is much more circular indicative of a fluid-filled cyst. Fig. 7b is clearly
malformed, does not have clear, smooth edges and shows some potential branching patterns
indicative of tumors.
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(b)

(a)

Figure 10. (a) A benign cyst resting inside of the breast and (b) a malignant mass [38].

c. Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) uses magnetic fields and radio waves to reconstruct a threedimensional, accurate representation of the breast. The images can also provide in-depth
information on tumor characteristics and blood vessel networks. A breast MRI is generally used
after a biopsy has been performed to examine the extent of the tumor for further treatment. A
contrast dye is often used to enhance the images and make them easier to interpret. However, some
women can have an allergic reaction to the contrast or it can cause further complications to those
with kidney issues [39]. Fat saturation filters are used in post-processing to enhance certain
portions of the breast for clarity. Magnetic Resonance Imaging (MRI) is an option but is time
consuming and too expensive for general screening and as such is limited mainly to high risk
populations (known or suspected mutation in a breast cancer causing gene or lifetime risk > 20%)
by most insurers. In addition to its higher cost, MRI results in high number of false positives (low
specificity); further increasing the cost of cancer treatment and diagnosis.
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Women at high risk, such as women with >20% lifetime risk or known BRCA gene mutations, are
screened using mammography and MRI annually. For this group, screening MRI has a higher
sensitivity than mammography alone, the highest sensitivity occurs when both are combined [40].
In a study by Kriege et al. [41], 1,909 women at high risk were screened using mammography and
MRI, the sensitivities were 33% and 79.5%, respectively. However, MRI led to twice as many
unneeded additional examinations than did mammography (420 vs. 207) and three times as many
unneeded biopsies (24 vs. 7). Gorechlad et al. [42] pointed out that annual MRI screening would
incur significantly higher costs and is unlikely to improve overall survival.
An example of a breast MRI, before and after fat saturation can be seen in Fig. 11. The area with
biopsy can be seen as a small black spot in the post-fat saturation image. The tumor can be seen
either as dark gray (Fig. 8a) or bright white (Fig. 8b) with branching networks and vasculature
visible in both.

(b)

(a)

Figure 11. (a) MRI image of the breast prior to fat saturation and (b) fat saturation MRI image
of the breast.
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d. Other detection methods
Ultrasound, mammography/DBT and MRI are the most common methods used today for breast
cancer detection and diagnosis. However, there are other methods currently being studied to
improve imaging while reducing unnecessary protocol and invasive techniques.
Breast Specific Gamma Imaging – Breast Specific Gamma Imaging (BSGI) is a newer method of
study that has high sensitivities as a screening method for breast cancer. The method is based on
differences in metabolism, detecting how the injected radioactive agent accumulates in cancer cells
over normal cells. It is beneficial for denser breast tissue and can take images from multiple angles.
However, similar to MRI, it involves injection of a radiotracer and a longer exam of 40-45 minutes
and similar to mammography, involves the compression of the breast between two plates [43]. The
method is yielding good results, especially in women with dense breast tissue, but induces threeto four- times the amount of radiation used in a mammogram [44].
Positron Emission Mammography – Positron Emission Mammography (PEM) involves the
measure of an increase of glucose to an area after an injection of a radiopharmaceutical that
accumulates in a tumor. The materials injected are transformed into gamma rays and detected with
gamma radiation detectors [45]. Although highly specific, PEM is not recommended as a screening
technique due to higher levels of radiation. But the technique is valuable, especially for
characterizing tumors.
e. Thermography
Infrared radiation, discovered by William Herschel in 1800, was found by studying the heat
movement through different colored filters. Herschel measured the temperature outside of the
visible spectrum of color and noticed an increase in temperature in what is known as the “invisible
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spectrum of light” or infrared [46]. An IR camera uses a specific lens to detect temperature
variation and heat emission from the object of focus. The captured light is translated into electrical
impulses and, through signal processing, is translated into a color map with corresponding
temperature gradients.
Thermography for breast screening was introduced in 1956 and was approved by the FDA in 1982.
Infrared thermography fell out of favor due to poor sensitivity and nonstandardized clinical
protocol. Throughout the past few decades, IR technology has improved dramatically with
increasing sensitivity and better cameras. Companies such as FLIR boast thermal sensitivities as
low as 20 mK with an accuracy of ±1ºC or ±1% of the temperature reading [47]. A sensitivity and
accuracy as low as this can be very beneficial for a variety of applications including leak detection,
pipe blockage or biomedical imaging. With advances in infrared camera technology, there has
been renewed interests on the use of infrared thermography as an adjunct to mammography for
breast cancer screening with advantages such as lack of ionizing radiation, patient comfort
(touchless and does not require compressing the breast), and portability. Because of the great
promise for early breast cancer detection, many authors have studied thermography in different
capacities. Theoretical studies, numerical models and experimental prototypes have all been
studied to perfect thermography as a plausible tumorous detection method.

1.5.2 Statistical Considerations
In order to compare screening and diagnostic modalities more accurately, there are several
statistical considerations needed. These include sensitivity, specificity, positive predictive value,
and negative predictive value. Sensitivity and specificity are the statistical measures used to
evaluate effectiveness of medical application. Sensitivity refers to the true positive detection rate
whereas specificity refers to the true negative detection rate. High sensitivity is critical because it
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measures how often the test generates positive results for subjects being tested that have the
condition. Specificity measures how often the test generates negative results for subjects being test
that do not have the condition. High specificity means the test correctly detect almost everyone
without the condition. Positive Predictive Value (PPV) is the probability of a subject having a
positive screening test who truly has the disease and Negative Predictive Value (NPV) is the
probability of a subject having a negative screening test who truly does not have the disease. These
factors are discussed at greater length below. The classifications presented from Rao [48] give a
simplistic summary of the differences of these terms:
•

Sensitivity: “I know my patient has the disease. What is the chance the test will show that
my patient has it?”

•

Specificity: “I know my patient doesn’t have the disease. What is the chance that the test
will show that my patient doesn’t have it?”

•

PPV: “I just got a positive test result back on my patient. What is the chance that my patient
actually has the disease?”

•

NPV: “I just got a negative test result back on my patient. What is the chance that my
patient actually doesn’t have the disease?”
a. Sensitivity and Specificity

Sensitivity and specificity are two terms used widely throughout the biomedical field to evaluate
different techniques. They refer to the detection of different diseases through different modalities
in all areas of imaging and medicine. Sensitivity refers to the true positive detection rate and is
calculated using Eq. (1) whereas specificity refers to the true negative detection rate and is
calculated in Eq. (2).
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𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃

(1)

𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁

(2)

𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 =

𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁

𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 =

𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁+𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃

Sensitivity and specificity depend not only on whether a patient is positively diagnosed with a
disease but also whether or not the technology used for diagnosis is able to accurately diagnose.
An example of the calculations for sensitivity and specificity is seen below.
Example: 1000 patients are screened with NewModalityX to detect breast cancer. 730
test negative for breast cancer and the other 270 test positively.
Positive for Disease
Test is Positive
Test is Negative

230
40

Negative for
Disease
30
700

Out of the 270 that tested positively, 40 of them did not have breast cancer and were
diagnosed incorrectly. The 230 that were correctly diagnosed are referred to as True
Positive. To calculate sensitivity, we would do the following:
230
= 0.85 ∗ 100% = 85%
230 + 40

Out of that 730 that tested negatively, 30 of them actually did have breast cancer. The
700 that were correctly diagnosed are referred to as True Negative. To calculate the
specificity, we would do the following:
700
= 0.958 ∗ 100% = 96%
700 + 30
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This means that the NewModalityX will be able to correctly identify breast cancer 85%
of the time and will be able to affirmatively state a patient does not have breast cancer
96% of the time.
b. Positive Predictive Rate (PPV) and Negative Predictive Value (NPV)
Although sensitivity and specificity are important factors in considering the accuracy of screening
and diagnostic modalities, PPV and NPV are just as vital in determining the clinical relevance of
the modality or test [49]. Sensitivity and specificity are fixed for a particular type of test while
PPV and NPV are dependent on prevalence of disease in a population [48]. PPV is the probability
that a positive test is truly positive (Eq. (3)) and NPV is the probability that a negative test is truly
negative (Eq. (4)).
𝑃𝑃𝑃𝑃𝑃𝑃 =
𝑁𝑁𝑁𝑁𝑁𝑁 =

𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃

(3)

𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁

(4)

𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 𝑃𝑃𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜

𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁+𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁

Prevalence involves the proportion of a given population who have specific characteristics.
Equation (5) is used to determine prevalence:
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 =

# 𝑜𝑜𝑜𝑜 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑖𝑖𝑖𝑖 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑤𝑤𝑤𝑤𝑤𝑤ℎ 𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 # 𝑜𝑜𝑜𝑜 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑖𝑖𝑖𝑖 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠

An example of the calculations for PPV and NPV is seen below.
Example: 1000 patients are screened with NewModalityX to detect breast cancer. 730
test negative for breast cancer and the other 270 test positively. The same table as
presented above is used here:
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(5)

Positive for Disease
Test is Positive
Test is Negative

230
40

𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 =
𝑃𝑃𝑃𝑃𝑃𝑃 =
𝑁𝑁𝑁𝑁𝑁𝑁 =

Negative for
Disease
30
700

270
= 27%
1000

230
= 0.8846 ∗ 100% = 88%
230 + 30

700
= 0.9459 ∗ 100% = 95%
40 + 700

Temporarily ignoring prevalence, this means that 88% of the individuals who test
positive are truly positive for the disease and 95% who test negative are truly negative
or disease free. However, in order to properly consider the population in which the
disease is occurring, we must consider prevalence. The prevalence for this example is
calculated as 27%. This means that 27% of our population is diseased and the remaining
73% are considered healthy.
Prevalence is particularly important in considering predictive values. Higher values for PPV and
NPV suggest that the test is performing well. However, prevalence is directly proportional to PPV
and inversely proportional to NPV. As the prevalence increases, NewModalityX has an increased
probability of reading a true positive for a disease [50], [51]. Whereas if the prevalence is
significantly lower, the probability of reading a true positive decreases. Considering our patient
population is particularly important to the determination of accuracy of new methods.
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c. Patient Population Considerations
Prevalence of disease is calculated dependent on the population being observed. For example,
considering the number of women with breast cancer within the United States, there are several
populations that are considered for statistical significance. There is the general population as a
whole, those who are considered ‘high risk’ based on many different factors, those who have
history of breast cancer, those who have a positive screen, etc. Determining what population is
used to calculate prevalence can be vital in calculating accuracy of new screening modalities and
therefore making comparisons against gold standard techniques.
If the selected observable population are those with suspicious mammograms who are receiving
diagnostic mammograms, the prevalence of disease will most likely be higher than a general
screening population of women getting an annual exam. This determination of prevalence will
directly affect the probability of a positive or negative test being accurate. Careful considerations
of patient population must be made for any new modalities being researched, especially as they
are compared to gold standard. Additionally, the desired sample size may be dependent on the
prevalence of disease within the population being considered. For this work, a new method is
explored to screen and detect breast cancer. In order to determine the desired sample size for
statistical significance, the observable patient population must first be selected. Depending on the
selected patient population, the prevalence of disease may increase, requiring a smaller sample
size. More considerations on patient protocol and statistical considerations are discussed in
Chapter 3.
d. Determining Statistical Significance
Determining the sensitivity and specificity of a medical imaging technique is incredibly important
not only for future clinical screening but also to quantify different modalities. Some methods are
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highly sensitive and not very specific (such as MRI) while others are highly specific but not as
sensitive (mammography). This leads to the conclusion that for some patients, a combination of
methods may be the best way to screen for the most accurate results. Many authors have studied
different modalities and calculated varying sensitivities and specificities than those listed below.
However, the concluding statistics are dependent on the population studied, the number of patients
screened and many other determining factors. For the purposes of this study, we are observing the
sensitivity and specificity for various screening modalities for comparison. The values listed in
Table 4 [52]–[56] give the relative sensitivity, specificity and the subsequent cost for various
widely used screening and diagnostic methods.
Table 4. Diagnostic techniques with corresponding sensitivity specificity, and cost [57].
Technique
Mammography

Mechanism of
operation
Low energy Xrays

Sensitivity

Specificity

Cost

Recommended for

84%

92%

Moderate

Screening and diagnostic
evaluation

Magnetic
Resonance
Imaging (MRI)

Magnetic field
and pulsating
radio waves

90%

50%

High

Screening for women at
high risk and diagnostic
evaluation

Positron
Emission
Tomography
(PET)

Gamma rays
emitted by tracer
substance

90%

86%

High

Determine spread of
cancer

Ultrasound

High frequency
sound waves

82%

84%

Low

Screening in women with
dense breasts and
diagnostic evaluation

Tomosynthesis
(3D
mammography)

Low energy Xrays

90%

92%

Moderate

Screening and diagnostic
evaluation

1.6 Clinical Studies
A clinical study or clinical trial is identified as a specific intervention to medical care for willing
and informed participants. Interventions can include medical products, drugs, procedures, or
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changes to a participants’ behavior (such as diet) [58]. They may involve the comparison of
existing technology/pharmaceuticals or the introduction of brand-new products or approaches.
When a new approach or product is introduced, it is unknown how harmful or helpful it may
become. Prior to the implementation of a clinical trial, a clinical protocol is written discussing the
purpose of the study, how the technology works, the potential risks and benefits, and the intended
outcomes. Before recruitment can begin, the clinical protocol, clinical process, and informed
consent forms must be approved by an Institutional Review Board (IRB). Additionally, whatever
recruitment process and consent form will be used to recruit patients must also be IRB-approved.
The IRB varies depending on the institution in which the clinical study is performed. Furthermore,
some studies are also monitored by data monitoring committees to ensure the integrity and safety
of the clinical trial.
Clinical studies can involve a small population of patients in one location or can be massive,
involving thousands of patients and multiple locations. The standards set forth by the investigators
illustrate who is eligible to participate and any exclusion criteria, if any. Patients are required to
read and sign a consent form prior to participation. Informed consent is intended to protect
participants and serves to inform them of the potential benefits or risks of the study. Additionally,
participants can choose to withdraw from the study at any time throughout the process. For breast
imaging studies, some methods pose the risk of radiation, contrast materials or discomfort. For
example, the radiation risks associated with mammography or BSGI would be heavily discussed
with the patient prior to consent.
Patient population is selected dependent on many factors including age, gender, risk of disease,
type of disease, etc. For breast cancer studies, patients at higher risk may be selected over the
general public, depending on the desired outcomes of the study. Women over the age of 18 are
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generally selected because the risks of breast cancer are higher. Once the desired patient population
and trial size are confirmed, the study can begin. More details on the patient flow and clinical
process for this study are discussed in Chapter 3.

1.7 Conclusion
Breast cancer is currently the most prevalent form of cancer in women with over 266,000 new
diagnoses every year [59]. There are many well-known modalities used to screen for breast cancer
that range in accuracy and cost. However, many of these methods are invasive or inflict harm in
order to screen and can still miss or misdiagnose cancer, especially in heterogeneously and
extremely dense breast tissue. If someone is diagnosed with breast cancer, there are many
classifications including type, grade, stage, and tumor biology. Steady-state Infrared Imaging (IRI)
is unaffected by tissue density and has the potential to detect tumors in the breast by measuring
and capturing the thermal profile on the breast surface induced by increased blood perfusion and
metabolic activity in a growing malignant tumor. The details of the technology and scientific
validation are discussed in the following sections.

1.8 Dissertation Overview
Chapter 1: This chapter involved basic introductions to many components crucial for this study
including breast cancer, tumor pathology, medical imaging, statistical considerations, clinical
protocol, and thermal imaging.
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Chapter 2: An in-depth literature review is presented here including previous infrared imaging
studies, research gaps, and objectives for this work.
Chapter 3: The approach is discussed including ethical considerations, clinical protocol, patient
population, and experimental setup. The modeling work of Gonzalez-Hernandez [60] is discussed.
Chapter 4: The results of the study are presented showing patient data, IRI images, and methods
for post-processing.
Chapter 5: Potential modifications are proposed for a suggested future large-scale clinical study.
This includes recommendations on clinical updates and patient population sample size.
Chapter 6: Gautherie’s work is presented and the thermal biomarkers are discussed as potential
classifications. Additionally, angiograms are presented as an optional method to observe blood
perfusion.
Chapter 7: Overall conclusions and major contributions (technical and societal) are presented.
Chapter 8: Finally, future considerations are presented including changes to clinical setup and
infrastructure needed for a large-scale clinical study. The overall conclusions of this work are also
given.
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Chapter 2: Background

This chapter discusses the literature associated with bioheat transfer and thermography. These
include studies on experimental representations, numerical simulation, and clinical investigations.
The additional factors associated with thermography’s positive attributes and fallbacks are also
discussed.

2.1 Bioheat
The study of heat transfer throughout the body has been examined since the 1870s beginning with
a Claude Bernard [61] who measured the heat transfer between arteries and adjacent veins. He
focused on the measurements of arterial temperatures in animals. This pioneering work has been
referenced and explored in many different bioheat studies, exploring the thermal relationships
between different factors within the body.
In order to develop accurate mathematical models associated with the thermal transport within the
body, a clear understanding of the underlying parameters such as metabolic heat generation,
vascularity, and blood perfusion is needed. These factors greatly affect the thermal patterns that
can be detected on the surface. Quantitatively calculating heat movement requires in-depth
analysis allowing for blood flow and metabolic heat generation rate. The Pennes’ bioheat equation,
introduced by Henry Pennes in 1948 [62], is a widely recognized blood perfusion model based on
the transient heat conduction equation. The equation, seen below, assumes the porous capillary
beds are the only means of heat transfer and therefore a larger area is used for any heat exchange
between the blood and tissue. Thermal equilibrium is added into the equation to compensate for
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variations between the arterial blood temperature and the venous blood and tissue. Originally
computed to measure heat in the resting forearm, the Pennes’ bioheat equation is as follows:

𝜕𝜕𝑇𝑇𝑡𝑡

𝜌𝜌𝑡𝑡 𝑐𝑐𝑡𝑡 �

𝜕𝜕𝜕𝜕

� = 𝛻𝛻. (𝑘𝑘𝑡𝑡 𝛻𝛻𝑇𝑇𝑡𝑡 ) + (1 − 𝑘𝑘 ′ )𝜔𝜔𝑏𝑏 𝑐𝑐𝑏𝑏 (𝑇𝑇𝑎𝑎 − 𝑇𝑇𝑡𝑡 ) + 𝑞𝑞′′′𝑚𝑚

(6)

where ρ is tissue density, k is the thermal conductivity of tissue, c is the specific heat capacity, T
is temperature, ω is the volumetric flow rate of blood, k’ is thermal equilibration (either 0 for
steady-state or 1 for transient conditions) and q’” is the metabolic heat generation rate. The
subscripts b, t, and a stand for blood, tissue, and arteries, respectively. The Pennes’ bioheat
equation has been used extensively in the study of heat transfer within the body and living
organisms for a wide array of application.
In 1980, Gautherie [19] used a fine-needle thermocouple (0.8 mm in diameter) to measure the
internal temperature distribution of breasts, both healthy and with cancer. In his work, he reported
that a tumor results in a peak of ~3°C in the region surrounding the tumor when compared to the
internal temperature distribution of a healthy breast. Gautherie studied the natural progression of
cancer on 128 subjects who refused to receive treatment. He measured the metabolic activity and
blood perfusion in healthy and tumorous tissue (Figure 12). The following three categories of
growth and relative metabolic heat production are shown below where DT is doubling time and
q* is metabolic heat production.
•

Cancers with a fast growth rate (DT ≤ 150 days) and intense metabolic heat production (q*
≥ 20 × 10-3 W/cm3)

•

Cancers with slow growth rate (DT ≥ 250 days) and low metabolic heat production (q* ≤
10 × 10-3 W/cm3)
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•

Cancers with intermediary values of DT and q*, classified into (1) or (2) if lymphatic
spread is found or not.

Gautherie observed that fast growing tumors (doubling time < 100 days) have metabolic activities
of up to 70,000 W/m3. In contrast, slow growing tumors (doubling time > 250 days) had metabolic
activities of about 10,000 W/m3. He reported an exponential decaying relationship between tumor
doubling time and metabolic activity. In his study, he reported that the metabolic activity of healthy
breast tissues varies between 400 and 700 W/m3, demonstrating that tumors are at least 15 times
more metabolically active than healthy tissue. All patients within the study group had consistent
and identical sleep cycles and eating patterns. Gautherie also examined the natural thermal rhythms
of each patient and identified patient’s circadian, circaseptan, and circatrigintan rhythms. To
determine the metabolic heat generation rate, Gautherie measured the temperature of the patient’s
breasts using fine-needle thermoelectric probes over the span of 700 days. He plotted the growth
relationship between metabolic rate and double time of a tumor and this plot can be seen in Fig 12.
Gautherie concluded in 1983 [63] that the resulting thermal increases from tumors was due to an
increase in metabolism, localized or diffused increases in skin temperature due to convection and
vascular changes.
Additionally, Gautherie delves into great detail on the effects of circadian rhythm and growing
vasculature on the thermal relationships in the breast. Factors such as effective thermal
conductivity, perfusion rate and metabolic activity must be taken into consideration when
continuing any bioheat transfer study. Further details on the potential of Gautherie’s work and the
introduction of a thermal biomarker classification system are discussed in Chapter 5.
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Figure 12. Relationship between metabolic generation and doubling time [19].

2.2 Thermography
2.2.1 Breast Cancer Detection Demonstration Project
The studies that have led to these conclusions have varied in technological advancement, postprocessing techniques and scientific basis. The negative reputation of thermography begins with
The Breast Cancer Detection Demonstration Project (BCDDP), starting in 1973. The BCDDP
involved a large working group of biostatisticians, clinicians, and pathologists [64]–[72]. This
study involved the participation of 27 centers throughout the United States. The project was meant
to study early detection methods for breast cancer, among different populations and geographical
locations. A collaborative act between the American Cancer Society and the National Cancer
Institute, over 280,000 women participated. “Participants were screened for breast cancer on an
annual basis using a combination of medical history, physical examination, mammography and
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thermography to detect breast cancer in its earliest stages [73].” The majority of participants were
between 35-74 years old and did not have a previous history of cancer. Throughout the duration
of the project (1973-1981) 4,443 breast cancers were recorded, 80% of which were detected by the
29 centers.
At the beginning of an exam, every patient filled out a history form, received a physical
examination, a mammogram and a thermogram. Thermography was introduced as a promising
screening technique to replace mammography. The WG considered the use of thermography in
this multi-year study due to the growing popularity of the time. Authors such as Lawson [40] and
an increase in international use warranted further review, particularly because of the low-cost and
non-radiative nature of the technology. The goal of the BCDDP was to study the efficacy of
thermography as a pre-screening tool to reduce the number of women subjected to radiation from
mammography. The WG also reference a study performed by Lilienfeld et al. [74] that showed a
sensitivity and specificity for thermography similar to those from physical examination and
mammography. At the time, thermography was an up-and-coming technology with poor camera
sensitivity and unknown methods for image interpretation. The need for technological refinement
and the readiness of thermography for large-scale detection were listed as major concerns.
Data reporting, image interpretation and diagnosis are discussed further in the report. “Positive
physical examinations and mammographies were reported in various degrees of certainty about
malignancy or as suspicious-benign; thermography was reported as ‘abnormal.’” Physical
examinations were conducted by trained professionals and mammograms by trained technicians.
Mammographic data was initially interpreted by both trained technicians and radiologists. The
mammographic procedure, including radiation dosage, was consistently reviewed for quality and
procedure issues. The thermogram procedure and image interpretation was “conducted by a
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BCDDP’s trained technician”. Some sites utilized radiologists in addition to trained technicians
for image interpretation. Similar to mammography, quality control checks were introduced by the
project physicians. However, in several locations, the same technician reviewed and interpreted
both the mammography and thermography data. Introducing obvious human bias from visual
human interpretation could have contributed to the seemingly poor performance. Additionally,
using the same technician for both mammogram interpretation and thermogram interpretation
introduces further bias. Because mammography was considered the gold standard for screening, a
positive or negative result from a mammogram (whether accurate or not) would automatically
influence the technician’s decision about the outcome of a thermogram. Although the WG called
for batch reading separately of the images, any images interpreted by the same individual should
not have been considered in the final results for thermography over the duration of this project.
The WG also states “It is not known to what extent observations in one modality influenced the
interpretation of another. [67]”
The WG reported 41% of the abnormal thermograms were breast cancers while the other 59%
were interpreted as unknown or normal. Similar results are reported for the second screening. The
WG also state that if routine mammography were not performed, many of the negative or unknown
reports of thermography would have missed the cancer completely. They state, “Thermography
was positive in 43% of the breast cancers detected during the first two screenings, but very few
were negative in the initial interpretation of the mammography and physical examination
findings.”
The WG stress the importance of mammography has a routine screening method and determine
that thermography is not an adequate replacement. However, the FDA, in 1982, approved
thermography as an adjunctive technique, potentially due to the results of the BCDDP. While
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several studies support the evidence of the lack in accuracy while using thermography as a
standalone technique, the merits of the method as an adjunct to mammography and ability of
thermography to view the breast in a different light should not go overlooked. In the report
published in 1978, they conclude that thermography is not an adequate substitute for
mammography.
The potential downfalls of thermography in the BCDDP are discussed: “…conclusions on the
effectiveness of thermography in the BCDDP rest on available data, and these data do not reinforce
the hopes that had been held out for the procedure. This finding should not be taken as a
determination of the future of thermography. The procedure continues to be of interest because it
does not entail the risk of radiation exposure and it is apparently more economical than is
mammography.” The authors state that they are unsure if the limitations from thermography are
due to technologic limitations or procedure. The rest of the report continues to discuss pathology
results and accuracy of physical examination and mammography and thermography is not
discussed further. In the supplemental material [72], the WG state that “Analysis of the experience
with thermography in individual projects of the BCDDP suggests that several projects had results
that were more favorable than was the picture for the BCDDP as a whole. This finding encourages
investment in the development and testing of thermography under carefully controlled study
conditions, and the Working Group recommends that high priority be given to such studies.” The
WG does not discredit thermography as a technique but instead, recognize the potential and
recommend further study is warranted.
However, some sites involved in the BCDDP saw varying results than the rest of the project. In
1984, two physicians who led centers during the BCDDP, Margaret Abernathy, MD and JoAnn
Haberman, MD, spoke of the treatment of thermography during that time [75]. An interview
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published by JAMA Medical News highlights the shortcomings of the BCDDP’s handling of
thermography. According to Dr. Abernathy, only five centers that participated had personnel
experienced in obtaining or reading thermograms. “Expertise in mammography was a prerequisite
for being awarded a contract to operate a center, she said, but previous knowledge of thermography
was not required.” Additionally, she adds that the quality of the collected thermograms were
‘terrible.’ Haberman expands on the mistreatment of thermography by radiologists stating “The
radiologists who ran most of the BCDDP centers were quite uncomfortable with thermography.
They were having to learn all the basics. Also, they were facing a huge task in evaluating thousands
of women by mammography, and they just decided to cut down on their workload by tossing out
thermography rather than learning to understand it.” A third physician further expands on these
thoughts, mentioning the complexity of breast cancer as a disease. Dr. Logan states that
thermography offers an additional way to view the breast that would benefit patients. Furthermore,
utilizing thermography, Logan has been able to detect small cancers often missed by other
modalities. However, despite these assessments, Logan did not use thermography as a screening
technique “because the method itself, regardless of the experience of those who use it, gives many
more false-positive than true-positive results.”
Several authors presented follow-up studies discussing survival rates and BCDDP process. Baker
[73] wrote a five-year summary report of the BCDDP and their findings. They briefly discuss the
removal of thermography as a screening technique and mention that restrictions on mammography
were added for those under the age of 50. Smart [76] and Cunningham [77] both presented 25-year
follow-up reports on the findings of the BCDDP. Both studies discuss follow-up of the diagnoses
made during the BCDDP time-period. However, neither further discuss the usage of thermography
and its removal from the study.
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Although thermography was eventually FDA-approved as an adjunctive screening technique in
1982, the negative reputation surrounding thermography is ever abundant. The results from the
BCDDP have led to a significant stigma against thermography within the medical community and
additional factors have led to the propagation of thermography’s bad reputation, despite
technological progression. Predominantly, inconsistent imaging criteria dependent on empirical
observation and little medical validation.

2.2.2 Dynamic and Steady State Thermography
An in-depth review paper published by Gonzalez et al. [78] discusses the nature of dynamic
thermography and the many researchers that have employed this method. Dynamic thermography
(DT) was introduced to reduce the false positives and false negatives present in pioneering studies
using steady state thermography. The fundamental principles of DT involve the addition of a cold
stress by (1) forced convection aimed at the breasts, (2) reduction in ambient temperature or (3)
forced conduction by using ice packs on the breasts. In DT, sequential thermograms are captured
after a cold stress is removed and the thermal response of the breasts is analyzed. The resulting
thermal contrast between the tissue affected by a tumor and the ‘healthy’ or unaffected tissue
becomes detectable by an infrared camera. The cold stress aims to reduce the overall temperature
of the breasts in order to increase the thermal contrast in areas with abnormal vascularity and
metabolism. Despite the innate patient discomfort induced by the addition of a cold stress, dynamic
thermography has been widely studied by many in the field, for commercial use and for clinical
trials. There are two main imaging protocols used in DT: (1) static image capture and (2)
continuous imaging. Static image capture involves taking images at specified times, usually before,
during and after cold stress is applied. Continuous imaging utilizes videos or constant image
capture during the cold stress process to observe the cooling and rewarming of the breast. The goal
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is to observe the changing thermal characteristics more vividly in the breast while the cold stress
is applied. Kakileti et al. [79] state that continuous imaging is not as popular due the large
processing time. However, more information is captured with this method, especially since
“tumorous regions do not cool as fast as rest of the tissues.” Steady-state thermography is focused
on maintaining a steady ambient temperature and allowing for proper acclimation for the breast
temperature to reduce naturally prior to image collection.
The NoTouch BreastScan [80], developed by UE LifeSciences Inc., is an FDA cleared,
noninvasive and radiation-free imager. The system blows air at the breasts from different positions
to achieve an even air flow. Air is blown until the temperature on the breast surface decreases by
3-4°C. While air is blown, the IR cameras capture thermograms of each breast. Once the desired
level of cooling is achieved, the airflow ceases, and the exam ends; the exam usually takes between
5 and 6 minutes. The NoTouch BreastScan uses Artificial Neural Networks to identify the salient
features and compare them with known heat patterns typical for tumors.
Hu et al. [81], knowing that the majority of clinical thermography studies involved the use of
dynamic cold air, studied the effects of colder air on the breast surface. Ignoring environmental
factors such as perspiration or evaporation on the skin, they developed a 3D model of the breast
using GAMBIT. They embedded a tumor into the breast and added the geometry into a constant,
laminar air stream. Using Fluent, they tested five different tumor cases with air stream flowing
horizontally across the breast. The authors state, “Thus the simulation demonstrates that the
patterns of thermograms have strong dependence on the environmental cooling effect even in the
presence of low velocity airflow.” Additionally, the authors discuss that normal clinical screening
happens under looser controlled conditions, leading to inconsistent cooling, lack of repeatability
and further issues in image interpretation. Ultimately, they conclude that using dynamic cold air
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can greatly affect temperature distributions on the surface and create irregularities in tumor
analysis. An example of the airflow analysis over a breast with tumor is seen in Fig. 13.

Figure 13. Numerical breast model to examine effects of parallel convection on the breast
surface of a breast with tumor [81].
Ohashi and Uchida [82] performed a comparative study between dynamic and steady-state
thermography on 728 subjects with biopsy-proven breast cancer. They utilized a fan blowing air
over the breasts for a 2-minute duration. Infrared images were captured every 15 seconds over a
20-minute period. Although they saw improved accuracy with dynamic thermography (82%) over
steady-state thermography (54%), they also had an increase in false positives with dynamic.
Wishart et al. [83] used the Sentinel BreastScanTM (discussed above) to image patients with breast
cancer prior to breast biopsy. About 113 patients were recruited for this study and 106 core needle
biopsies were performed. Patients were asked to disrobe from the waist up and place their arms at
eye level on a support structure. Flowing air was directed at the breasts for 5 minutes while images
were taken simultaneously. 65 biopsies ended up malignant and 41 were benign with an additional
13 patients excluded due to system malfunction. Of the 65 with malignancy, 30 patients were
determined normal from the Sentinel Breast ScanTM. The maximum sensitivity (78%) and
specificity (75%) were seen in women who were under 50 years old.
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2.2.3 Numerical Studies
Utilizing the basics of heat transfer and the Pennes’ bioheat equation has resulted in many different
studies for tumor detection. Creating a three-dimensional numerical model with programs such as
COMSOL or ANSYS Fluent. Numerical simulations allow the user to create a model, impose a
tumor or heat source, apply varying boundary conditions, and quickly calculate the resulting
energy transfer and temperature profile through the system. Over the past few decades,
computational software has increased in popularity and complexity making it simpler to perform
in-depth simulations in a faster timeframe.
Many researchers have performed numerical simulations with varying breast models. Sudharsan
et al. [84] used a 2D model with realistic layer densities and assigned values. They used FEMAP
to generate their mesh and various other programs to calculate all PDEs and governing equations.
They assumed a tumor growth at various sizes and ultimately concluded that adjusting values such
as blood perfusion could assist in more accurate analysis or smaller/deeper tumor detection. A few
years later, the same authors (Ng and Sudharsan [85]) performed a continuing study with a 3D
model. Additional studies utilizing numerical methods for

2.2.4 Experimental Studies
Many authors discuss the reasoning for choosing thermography is improvement upon patient
comfort during breast imaging. Utilizing an experimental model with material properties similar
to those that are naturally occurring, such as agar-agar, can give an accurate depiction of resulting
surface temperature profiles with the presence of a tumor. Using these models to experiment with
different biological parameters can help characterize the effects of a cold stress on the breast and
can assist in tumor detection methods without the need for breast cancer patients.
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Feasey et al. [86] performed a theoretical and experimental study under steady state and dynamic
conditions. Using a mixture of Perspex and paraffin wax, a phantom model was created and heated
similar to the chest wall. A small resistor was used to replicate a tumor and the surface temperature
distribution was captured with an IR camera. An electric fan induced cooling horizontally onto the
model surface to simulate an added cold stress. The authors concluded that the addition of forced
air reduced the temperature difference between the maximum temperature and surface temperature
across the model “skin.” Due to promising results, a similar process was used on actual breast
cancer patients. Nilsson and Gustafsson [87], [88] performed two separate experimental studies;
one involved an embedded heat source underneath the skin of the rabbit and one involved the same
embedded heat source under the skin of a man. The heat source encompassed a titanium cylinder
wrapped in wire. The first study involved careful implantation to avoid any disruption to the
localized tissue in six different rabbits. Corresponding theoretical calculations were performed to
verify resulting temperature profiles. Maximum surface temperatures over the heat source were
recorded based on implantation depth and heater capacity. The experiment was continued [87]
further, and the heater was implanted into a human forearm. A constant ambient temperature was
maintained while the heater capacity varied. For this study, the authors implemented three different
ambient conditions of still air at 23°C and 17°C, and forced air convection at 23°C. The authors
noticed a reduction in resulting surface temperature with the addition of forced convection.
However, in a departure from more recent studies, the authors did not consider studying the
resulting thermal recovery period used in dynamic breast thermography studies. They also noted
that a change in ambient temperature did not have a significant effect on changing heater capacities
although they noted a slight temperature increase with the lower ambient temperature.
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Mital and Scott [89] utilized a cylindrical model with Difco Agar as the phantom tissue. A
resistance heater was embedded into the center of the model and allowed to sit for several hours
to ensure a steady state had been reached. Various wattage levels were tested to simulate changing
metabolic activity, but no cold stress was applied. The goal of the experiment was to observe the
relationship between heater location and power and the resulting surface temperature profiles. An
algorithm was developed to estimate the location and power capacity from the collected IR images.
Wahab et al. [90] used an agar-agar mixture with an embedded mica heater. A larger heat capacity
was used in order to accentuate the resulting surface temperature profile. An appropriate amount
of time passed to ensure thermal equilibrium before taking images with an IR camera. The main
objective for this study was the resulting image processing and the development of a hotspot
detection algorithm to assist with post processing. The authors noticed variations in the
temperature profile across the agar-agar model and concluded that a separate enclosure is needed
in the future to reduce ambient temperature effects.
Despite the potential of these models, not many researchers have explored this option. For any
future work, validating numerical or theoretical calculation with an experimental phantom model
could be crucial to ensure that a future participant of an IR clinical study will remain comfortable
and unharmed while still maintaining the efficacy of the technology.

2.2.5 Clinical Studies
Lawson [40] first introduced thermal imaging in 1956 using temperature probes on the breast
surface. Out of 26 patients with proven breast cancer, the average temperature increase was 2.27°F.
The largest temperature rise recorded was 3.5°C. Lawson speculated that examining temperature
could have diagnostic possibilities for detecting breast cancer earlier. In 2000, Head and Elliot [91]
published a long-term study involving multiple patient groups. The first portion of the study began
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in 1973 and involved the following three categories of patients: (1) 126 patients who died of breast
cancer and had IR imaging within a 1-year period after breast cancer diagnosis, (2) 100 randomly
selected living breast cancer patients who also had IR imaging within a 1-year period before breast
cancer diagnosis, and (3) 100 patients who had a variety of mastopathies but hadn’t been diagnosed
with breast cancer. Throughout the study, many statistical considerations were taken to determine
the significance of the collected results.
Stark and Way [92] explored the use of thermography using 4,621 women, using mammography
as an adjunctive technique for abnormal thermograms. They have termed their method as Aga
Thermovision and identified three basic results: (1) the avascular (normal without veins), (2) the
vascular (normal with visible veins), and (3) the mottled pattern. Their criteria for identifying
malignancy are as follows: localized area of heat emission or hot spot, localized increased
vascularity, generalized increase in temperature and increased heat of areolar area. They also noted
that the correlation between temperature and tumors is less related to tumor size and more related
to histologic activity. Similar to other authors, Stark and Way speculate that additional factors
influence the resulting thermogram such as pregnancy, menstrual cycle, and contraceptives.
Increased vascularity was seen during pregnancy and menstruation while varying results were seen
for oral contraceptives. Out of all the patients imaged, all patterns were seen in all age groups with
all different sized breasts. Ultimately, 628 women were identified as abnormal and given
mammograms. However, similar temperatures were seen for benign diseases such as fibroadenoma
and invasive ductal carcinoma. The authors conclude that thermography has great promise but may
cause interpretation difficulties due to hyperthermia in both malignant masses and benign
conditions.
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Gutierrez-Delgado and Vazquez-Luna [93] used a similar image capture process including a room
maintained between 18°-23°C and an acclimation period of 15 minutes. They imaged 911 women,
94% of which were diagnosed with cancer. In 1980, Gautherie and Gros [94] published a 12-year
clinical study involving approximately 58,000 patients. They classified their subjects based on five
separate stages (Th I – Th V) where Th 5 is the most suspicious. The first contact with each subject
involved recorded history, physical examination, mammography, ultrasound, and thermography.
If core needle biopsy was needed, a histologic report was obtained. 1,527 women were identified
as Th III, meaning their thermograms were suspicious but inconclusive. Some of these patients
were diagnosed with cancer at the initial visit but the remainder of the patients (1,245) were reexamined over the span of 12 years. Over the years, malignancy was eventually detected in 298 of
these patients were diagnosed with malignancy. Gautherie and Gros hypothesized that irregular
thermal patterns seen in healthy breasts could potentially signal cancer at an earlier, undetectable
stage.
Haberman et al. [95] developed a mobile breast screening unit to examine women in primarily
rural populations in South Dakota. Mobile clinics offered thermograms and physical examinations
traveled throughout the state and recruited over 39,802 women. Each participant was cooled for
10 minutes in the supine position (on the back) with arms extended. A Spectrotherm 2000 camera
was used to record three separate images of the breasts at different angles. Only 71 patients with
cancer were identified and later confirmed with pathology. Of these 71, 15 were not detected using
thermography leading to an overall sensitivity of 79%. Francis et al. [96] obtained thermograms
of 24 individuals without breast cancer and 12 individuals with breast cancer. Individuals were
imaged in prone position and 12 thermograms of each breast were obtained at both steady state
and after an applied cold stress. First, thermograms were obtained at steady state and after the
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temperature was reduced by 2 – 3°C and the breasts were re-imaged. The authors found an
accuracy of 83.3% using the steady state thermograms and 70.8% when using the thermograms
after cooling. However, the authors only obtained one thermogram at every position after cooling
and did not track temperature evolution during recovery.

2.3 Research Needs
In a recent publication by Gonzalez-Hernandez et al. [78], the number of scientific publications
related with breast thermography was reported to increase from 11 in the year 2000 to more than
55 in the year 2018 (Fig. 14).
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Figure 14. Number of publications related with breast thermography [78].

An extensive review paper written by Lozano and Hassanipour [97] discusses all clinical trials
utilizing infrared imaging up to this point and the varied results achieved. The contradictory
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sensitivity and specificity values achieved by many different studies examining the same
technology provides evidence of non-standardized clinical procedure and detection methods. Table
5 below has a comprehensive list of various thermography studies and the achieved sensitivity and
specificity values.

Table 5. Clinical thermography studies with reported sensitivity and specificity values [97].
Reported
Sensitivity

Reported
Specificity

Moskowitz et al. (1976)

24%

56%

Stark (1985)

86%

98%

Williams et al. (1990)

61%

74%

Head et al. (1993)

65%

72%

Keyserlingk et al. (1998)

83%

81%

Parisky et al. (2003)

97%

14%

Arora et al. (2008)

97%

44%

Wang et al. (2010)

72%

77%

Kontos et al. (2011)

25%

85%

Rassiwala et al. (2014)

98%

99%

Authors and Year

In all of these studies, many have explored different positions, different imaging durations,
cameras, detection criteria, possible biological or hormonal interference, etc. There are many
competing methodologies surrounding this technology that have created a negative stigma in the
medical community. In order for this technology to advance, scientific validation and standardized
clinical practice is needed.
The decrease in studies as well as the resurgence in thermography can be attributed to various
factors influencing the imaging process. Many key factors, discussed in greater detail below,
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include diagnostic criteria, image analysis, camera sensitivity, and imaging process. Researchers
have tried to prove the usefulness of thermography as a successful screening technique and have
arrived at the following contradictory conclusions:
1. Thermography is a useful tool with high accuracy and specificity.
2. Thermography is not a valid method for breast cancer screening.
Many of these aspects are discussed in the following subsections.

2.3.1 Imaging Protocol
The screening protocol involves several factors. These involve the process used by researchers to
screen individuals, additional considerations of thermal influence and the position in which
patients are screened. There is disagreement among researchers for proper protocol for
thermographic screening, leading to inconsistencies in results. When screening individuals,
especially when considering temperature-based diagnostic criteria, it is important to consider
thermally altering factors. Environmental conditions, engaging in activities prior to imaging that
cause thermal changes such as drinking coffee, exercising, wearing coats/scarves/warmer clothing,
smoking tobacco, etc. or normal body cycle such as menstruation or menopause can significantly
alter the temperature distribution throughout the body. Several studies have observed these
changes and recommend managing controllable extrinsic factors, imaging at specific times of the
day or month, or recording intrinsic factors that could influence the thermoregulation in the body.
Fernandez-Cuevas et al. [98] present a review paper that discusses many different environmental,
individual and technical factors that potentially influence the outcome of thermograms and image
interpretation. Environmental factors primarily focus on room conditions including humidity,
temperature, and size. The size of the room, although not a significant factor, can influence the
ambient temperature in the imaging space. Because thermography is highly dependent on
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temperature, the ambient conditions in the room are a key factor for imaging. The ideal ambient
conditions listed by the authors range from 18-25 °C, based on likelihood of shivering or sweating.
In dynamic cases, the ambient temperatures could cause sweating or shivering, creating additional
moisture on the skin surface. When an additional cold stress is applied, the increase in moisture
could create further issues and thermal inconsistencies on the breast surface, leading to difficulties
in image interpretation and an increase in false diagnosis. In steady-state thermography, the
ambient temperature is vitally important, controlling the temperatures of the body and the breast.
Letting the body to properly acclimate prior to imaging allows for steady state conditions and
thermal equilibrium without subjecting the patient to discomfort from added cold stress. However,
the ambient temperature and acclimation period are highly debated among researchers. The table
below (Table 6), adapted from Fernandez-Cuevas et al. [98], shows the variation in external
conditions for proper thermogram capture for a variety of medical conditions ranging from sports
medicine and thermoregulation to diabetes and breast cancer. Finally, the authors discuss the
additional room conditions such as humidity and atmospheric pressure affecting chances of
perspiration or shivering of the patient.

66

Table 6. Table adapted from Fernandez-Cuevas et al. [98] showing recommended ambient
temperature and acclimation time from various authors.
Authors

Year

Chudecka and Lubkowska
Akimov and Son’kin
Kolosovas-Machuca and Gonzalez
Bagavathiappan et al.
Merla et al.
Hildebrandt et al.
Bouzida et al.
Savastano et al.
Zaproudina et al.
IACT
Ammer
Ring and Ammer
Gratt and Anbar
Uematsu et al.
Devereaux et al.
Nickoloff
Gershon-Cohne and Haberman
Brakemark et al.

2015
2011
2011
2010
2010
2010
2009
2009
2006
2002
2002
2000
1998
1988
1985
1984
1968
1967

Ambient
Temperature (°C)
25
21-22
22 ± 1
25
23-24
21.5-22.3
24 ± 2
23.1 ± 0.2
23-25
18-23
24
18-25
21-23
23-26
20.5 ± 0.5
20
24
18-20

Acclimation Time
(minutes)
20
10
15
5
20
20
10
20
15
15
15
10-30
15
20
15
10
15
15-20

Individual factors such as age, anatomy, circadian rhythm and more can subtly influence thermal
interactions within the body. Circadian rhythm has been explored by several different authors as a
potential influencer into when a thermogram should be captured. Although there is variation in the
outcome of circadian rhythm, the majority of authors agree that there is approved performance in
the evenings due to the body’s ability to better remove heat loads. Gautherie [19] discusses
circadian rhythm in great detail, investigating the rhythms of mammary skin temperature on a
group of 26 women. They controlled their eating patterns, sleep, and ambient conditions prior to
thermal measurement of growing tumors. The most significant observation during this study is the
changes in the breast with tumor. “In 15 cases, the circadian rhythm of skin temperature was
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apparently desynchronized on the cancerous breast and replaced by components with periods that
did not correspond to any known external or internal cyclic phenomena.” Additionally, they
observed changing characteristics of the cancerous breast in the remaining patients although the
24-hour synchronized rhythm was maintained. Additional factors altering thermal imaging involve
factors that cannot necessarily be controlled such as blood flow, metabolic rate, and genetics.
However, there are controllable extrinsic factors that can be recorded or preempted before thermal
examination.

Some

of

these

factors

include

drinking

coffee,

exercising,

wearing

coats/scarves/warmer clothing, smoking tobacco, etc. The authors discuss certain medications
such as anti-inflammatory drugs or those related to hormonal changes (i.e. birth control) that can
alter daily body temperatures, sometimes by as much as 0.6 °C. Additionally, alcohol intake can
increase skin vasodilation and blood flow, leading to “an overall increased temperature and a more
diffuse thermal pattern than normal” [99]. Other factors that should be monitored or avoided prior
to imaging include tobacco, stimulants (caffeine), and food. Finally, the authors discuss other
extrinsic factors that are applied to the skin. Ointments, cosmetics, or deodorant can alter the
thermal emissivity of the skin, altering the way images appear. All of these factors can influence
the thermoregulation of the body or alter the skin surface causing thermal maldistribution and
altering collected thermal images. Additionally, not controlling these factors could potentially lead
to improper image interpretation or poor accuracy.
There are two positions primarily used in breast cancer screening: prone (on the patient’s stomach)
or upright. Methods such as MRI use prone, ultrasound primarily uses the supine position and
mammography and thermography generally utilize the upright position. In most ‘traditional’
thermography studies, the patient is seated upright with their arms above their head. The camera
or cameras are aimed at the chest and generally take several pictures from different angles.
68

However, when in this position, there is a significant risk of alterations. The gravitational
deformation alters the shape of the breast, potentially changing areas of increased hyperthermia.
A study performed by Jiang at al. [100] explores the breast alterations due to gravity through a
digital model. They considered the deformation due to gravity as well as the effects of dynamic
thermography. The model considers a normal breast and a breast with an imposed tumor towards
the surface. The initial breast geometry is assumed hemispherical and composed of glandular
tissue, fatty tissue, and skin. An elastic FE model was used to induce gravitational deformation
dependent on body posture. The authors also used elastic breast properties collected from MRI
studies. Jiang et al. [100] focused predominantly on the effects of deformation in dynamic
thermography studies where a cold stress is applied to the breasts while the patient is upright. The
resulting images suggest a maldistribution in temperature, whether a tumor is present or not.
studies. The model, seen in Fig. 15, shows two different breasts; one is normal and the other has
an imposed tumor on the top of the breast.
They concluded that malignant breast deformation has a major impact on surface temperature and
their results will help in optimizing future dynamic thermography studies. This is a particularly
important distinction, primarily because most thermography studies (both past and present) utilize
an upright imaging position where the patient sits, upright, with arms locked above her head. Many
of the thermography studies discussed previously that use scoring systems to determine
abnormality may have been inadequate or inaccurate due to the imaging position. The thermal
maldistribution through the breast due to the upright position could cause (1) abnormalities in the
breast identified as “potential malignancies” or (2) warmer average temperatures in the breast used
for comparison to identify abnormality.
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Figure 15. Breast models, elastically deformed by gravity, using thermography by Jiang et al.
[100].

Keyserlingk et al. [101] utilized the upright position for IR imaging and captured four images of
the patient’s breasts for analysis. The use of only four images to ascertain abnormality presents
several concerns. Mainly, the position in which images are captured is highly limiting, ignoring
any thermal abnormality on the underside of the breast or the inframammary fold. The authors
discuss obtaining one image of the ‘undersurface’ but do not discuss if they are simply capturing
a picture at the bottom of the breasts or if the patient moves during imaging to obtain images of
the inframammary fold. Any images taken of the ‘undersurface’ without proper acclimatization
could result in increased hypothermia due to the breast touching the chest wall and could skew
results greatly. Additionally, four images (anterior, undersurface and two lateral views) may not
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be enough to adequately analyze areas of concern. A larger surface image of both breasts may not
be able to capture smaller, intricate details indicative of slower growing or smaller tumors. Despite
the positive results of this study, the position was a limiting factor in determining the accuracy and
adequacy of thermography as an adjunctive screening modality.
Additionally, imaging in the upright position adds unwanted thermal distortions that can negatively
impact diagnosis. The area in between the chest wall and the underside of the breast is referred to
as the inframammary fold. When a patient is seated upright for imaging, the inframammary fold
becomes a pocket of heat. If a tumor is located in the lower part of the breast, the upright position
could cause a missed diagnosis leading to further cancer growth. Imaging in the prone position
allows the breasts to hang relatively symmetrically, inhibited by gravitational deformation with no
concerns of unwanted heat in the inframammary fold.
Despite the attraction of imaging in the prone position, very few researchers [102], [103] have
employed this technique. Francis et al. [102] imaged 36 patients in the prone position using a
specially made setup, referred to as Mammary Rotational Infrared Thermographic System
(MAMRIT). The authors utilize dynamic thermography to cool the breasts and take advantage of
the thermal recovery period once a cold stress is taken away. One breast is imaged at a time and
hangs freely in an air-conditioned closed chamber. The unit cools the breast sufficiently through
free convection to ensure a steady surface temperature. Due to the ease of access of the prone
position, the entire breast is imaged in a series of 12 images. The researchers take two sets of
pictures for each breast: a precooled series and a postcooled series. The precooled images were
taken right when the patient’s breast became exposed before any cooling took place whereas the
postcooled images were taken after the chamber temperature was reduced by 2-3°. Choosing the
prone position allowed for an unimpeded, 360° view of each breast. The authors also discuss that,
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due to the imaging position, the warmer regions such as the neck carotid, armpits and
inframammary folds do not affect the images, unlike normal thermograms. Because of the prone
position, the authors reported higher accuracy. They state that the use of this position allowed for
more overall coverage of the breast, leading to better post-processing and analysis. An example of
the captured images in the prone position can be seen in Fig. 16.

Figure 16. Breast in prone for imaging without gravitational or thermal deformation [102].
Parisky et al. [103] recruited 1,293 subjects, in five different institutions, who underwent breast
biopsy due to abnormal mammograms, clinical findings or both. The subject lay prone on an
imaging table with both breasts hanging through openings. Each breast was imaged individually
while the contralateral breast was shielded from both the forced cool air and imaging using a
protective gown. The authors utilized a refrigeration chamber with added cool air for the breast
being imaged. They captured images before and during the cooling phase. They use the prone
position in order to receive multiple views of each breast, primarily for post-imaging analysis.
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Gonzalez et al. employed the prone position and steady-state infrared imaging to image several
subjects with biopsy-proven breast cancer. They used the prone position to remove thermal
artifacts in the inframammary fold and remove gravitational deformation of the breasts.
Additionally, the utilized patient MRI images for validation and tumor characteristics. Because
MRI also uses the prone position, direct comparison and validation were simpler to perform with
the images in the same position.

2.3.2 Image Interpretation
The methods primarily used to determine malignancy are based in empirical observation or
dependent on changes in temperature. The studies involving criteria based on shapes of heating
patterns or dependent on the appearance of a hot spot lack scientific basis or validation. The studies
that use scoring systems or gradients based on changing temperature do not discuss the
involvement of vasculature, scar tissue, or other thermal abnormalities that could alter the detected
temperature of the breast surface.
a. Empirical Observation
Several studies and commercial systems have depended on empirical observation for diagnosis.
However, human bias can critically alter the accuracy of analysis. Areas they may be visually seen
as abnormalities could simply be a part of the breast anatomy or vascularity. The following criteria
have been suggested as signs of abnormality:
•

Increased heat of areolar area

•

Diffuse heat involving a quadrant of the breast, half of the breast or entire breast

•

Localized regions of hyperthermia

•

Visible vasculature in unusual or asymmetric locations

•

An increase in vasculature to a certain area
73

Many authors have also used observational techniques to determine malignancy without
considering quantifiable detection. Collett et al. [104] used a commercial system called the
NoTouch BreastScan (NTBS) to screen 121 women with suspicious previous images. The NTBS
uses an upright position and dynamic thermography in order to screen. Several images are taken
and the NTBS software assigns a score between 0 and 10 dependent on various parameters seen
in the resulting image. The software has several options for screening for increased accuracy such
as high specificity and high sensitivity. Using both approaches on patient screening resulted in
varying sensitivity and specificity results. The NTBS was developed in 2012 by UE LifeSciences
Inc. and boasts the “latest advancement in the field of clinical infrared imaging.” However, the
accuracy of the system itself is highly debated as many authors report sensitivities ranging from
45.5%-87% and specificities ranging from 48.6%-88.9%. This massive range in performance
could account for negative or skewed results. The NTBS utilizes a scoring system, similar to other
thermography studies, to calculate thermal gradients throughout the breast and determine
suspicion. Similar to other scoring systems used by many authors studying thermography, the
scoring systems do not discuss differentiation between tumors and other thermal abnormalities
such as veins, scars, etc. Additionally, the system utilizes scoring factors from 1-10 and concludes
those with a “green” score between 1-3 are healthy. An earlier stage tumor, slow growing tumor
or very deep tumor could give a much smaller temperature profile during treatable stages before
becoming much warmer and subsequently more aggressive. Twenty one patients were removed
from the study due to inaccurate results such as (1) scan too blurry, (2) portion of image cut off,
(3) artifact on breast, (4) poor initial positioning, (5) nonbreast primary malignancy, and (5) biopsy
not performed. The authors acknowledge that the approach taken was potentially limiting as the
‘high specificity’ mode provided inaccurate sensitivity data and provided biased results. Due to
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negative experience while using NTBS, the authors do not recommend the technology as a viable
option for screening. Further, they agree with the Society of Breast Imaging’s statement that
thermography should not be used. However, the study only considered one commercial software
and piece of equipment for study. The authors do not discuss the scientific methodology behind
the technology, how malignancy is determined or how the ‘thermography expert’ operated or
diagnosed patients using the technology.
Stark and Way [92] explored the use of thermography using 4,621 women, using mammography
as an adjunctive technique for abnormal thermograms. They have termed their method as Aga
Thermovision and identified three basic patterns: (1) the avascular (normal without veins), (2) the
vascular (normal with visible veins), and (3) the mottled pattern. Their criteria for identifying
malignancy are as follows: localized area of heat emission or hot spot, localized increased
vascularity, generalized increase in temperature and increased heat of areolar area. They also noted
that the correlation between temperature and tumors is less related to tumor size and more related
to histologic activity. Out of all the patients imaged, all patterns were seen in all age groups with
all different sized breasts. Ultimately, 628 women were identified as abnormal and given
mammograms. However, similar temperatures were seen for benign diseases such as fibroadenoma
and invasive ductal carcinoma.
b. Temperature Dependent
Rassiwala et al. [105] utilized infrared imaging involved 1,008 women for screening purposes.
Initially, the results appear very promising with a high reported sensitivity of 97.6% and a high
reported specificity of 99.17%. However, at closer review, the criterion used to determine if a
patient tests positive for cancer is disconcerting. The initial patient pool of 1,008 women was
drastically reduced to 41 through a process of elimination dependent on the temperature changes
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between the contralateral breasts. The patients are screened in the upright position with arms above
their head. Several images are taken in the frontal view and from the sides. Commercial software
is used to detect the average temperatures throughout both breasts. The temperatures are compared,
and suspicion is determined. The temperature scale used to determine suspicion is seen below.
Table 7. Temperature scale and assessments performed in the Rassiwala study [105].

The patients who were determined malignant were then tested for breast cancer using clinical,
radiological, and histopathological examinations and malignancy was verified. However, there are
several flaws with the process used to identify a region of interest. The authors discuss the
temperature gradients above but do not explicitly state their method of analysis. The values do not
appear as gradients but instead are fixed temperature differences. It appears that these temperature
differences are calculated by identifying regions of interest on the suspicious breast and comparing
the same region on the contralateral breast. However, the authors fail to mention how veins or
other areas that could potentially influence thermal profiles are analyzed. Further, the authors do
not discuss the process of temperature changes due to smaller or deeper tumors. A temperature
change of 2°C could have signified a smaller tumor but instead, these patients were determined
“healthy.” These patients received a clinical examination but did not have any other further testing
or a mammogram. Therefore, the presented results used to calculate sensitivity and specificity are
skewed towards those with large temperature differences. Larger temperature differences generally
signify a larger tumor or a more advanced tumor. Ignoring any other smaller temperatures could
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mean missing cancer at the earliest, most treatable stages. Further improvements are needed in
processes used to identify and differentiate malignancy from other thermally altering factors.
Additionally, more universal detection criterion is needed for accuracy and repeatability.
c. Scoring Systems
Some studies have looked at combinations of temperature variations and empirical observations
to assign a “score” for classification and diagnosis. Several authors [101], [106], [107] have used
the Ville Marie IR Grading System. The system uses several different parameters and
corresponding descriptors. A comprehensive table of these factors can be seen in Table 8. The
Ville Marie Grading System, used by Keyserlingk et al. [101], [108], identifies abnormal
temperature signatures as well as various factors that identify cancer. Pertinent clinical information
is examined, and both the breasts are observed for symmetry. For diagnosis, the Ville Marie IR
Grading System was used to determine existence of abnormality. If significant asymmetry or
temperature differences are present, the patient is assigned a number (IRI1 – IRI5). The resulting
numbers are defined as the number of abnormal signs and the respective abnormality.
Keyserlingk et al. [101] examined 128 patients with an initial breast cancer diagnosis. Their
scoring system relied on clinical information, comparison between both breasts and comparison
of current images with previous images. In order to be considered abnormal, the presence of at
least one abnormal sign was necessary. The authors discuss, at great detail, their results, and the
statistical significance of their imaging technique. Overall, they achieved a sensitivity of 83% and
compared all findings with mammography and clinical evaluation. The use of a scoring system
provided an increase in suspicious areas deemed ‘abnormal’, especially in some patients with
nonspecific mammograms. The authors had a limited screening population but produced adequate
results for the technology, warranting further research. Further discussion on the imaging positions
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they utilized are discussed in section 5. Keyserlingk et al. presented a well-rounded study with
details of tumor pathology and in-depth comparison between infrared imaging, mammography,
and clinical examination. Utilizing medical validation in determining the validity of a new method
is crucial to understand impact and accuracy.
Table 8. Table adapted from Keyserlingk et al. [101].
Abnormal Signs
1. Significant vascular asymmetry
2. Vascular anarchy consisting of unusual tortuous or serpiginous
vessels that form clusters, loops, abnormal arborization or aberrant
patterns.
3. A 1°C focal increase in temperature (ΔT) when compared to the
contralateral site and when associated with the area of clinical
abnormality.
4. A 2°C focal ΔT versus the contralateral site
5. A 3°C focal ΔT versus the rest of the ipsilateral breast when not
present on the contralateral site
6. Global breast ΔT of 1.5°C versus the contralateral breast
Infrared Scale
IR1 = Absence of any vascular pattern to mild vascular symmetry
IR2 = Significant but symmetrical vascular pattern to moderate vascular
asymmetry, particularly if stable
IR3 = One abnormal sign
IR4 = Two abnormal signs
IR5 = Three abnormal signs

In 1980, Gautherie and Gros [94] published a 12-year clinical study involving approximately
58,000 patients. The first contact with each subject involved recorded history, physical
examination, mammography, ultrasound, and thermography. If core needle biopsy was needed, a
histologic report was obtained. They classified their subjects based on five separate stages (Th I –
Th V) where Th V is the most suspicious. This scoring system is dependent on varying temperature
factors as well as probability of cancer. 1,527 women were identified as Th III, meaning their
thermograms were suspicious but inconclusive. Out of these patients, 51% had no abnormal
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findings, 30% had benign masses and the remaining 18% had biopsy-proven malignancy. This
system is similar to BI-RADS (Breast Imaging Reporting and Data System) used primarily after
ultrasound or mammogram to ‘grade’ someone based on identifying factors, histopathology, and
patient history. However, similar to BI-RADS, the scoring system has many flaws. BI-RADS is
subjective and dependent on the consulting radiologist. Similarly, the Th I – Th V system provides
a subjective screening value for further diagnosis. This can clearly be seen in their definition of
patients diagnosed as Th III. Firstly, the classifications of the scoring system are up to the
thermographers interpreting the images. Similar to other diagnostic techniques, depending strictly
on subjective observation will inevitably lead to misdiagnosis. The authors also state that the
thermograms initially assumed as malignant but proved benign have no explainable basis.
Although the authors were pioneers in this field, the analysis provided to determine diagnosis with
a bias scoring system has proved faulty.
Wang et al. [107] utilized statistical factors to determine accuracy of a scoring method used to
malignancy. They screened a population of 276 women with suspicious mammographic findings.
Consulting radiologists were used to evaluate the corresponding images and assign a score ranging
from IR1 – IR5. Although they utilized a scoring system for diagnostic purposes, they introduced
biostatistical characteristics to further analyze the thermograms and diagnostic accuracy. Using
statistical software to find the correlations of diagnostic IR (infrared) signs, they categorized
lesions as malignant or benign. Additionally, they used a univariate logistic regression model and
a multivariate regression model to compare the individual IR signs with the final disease status.
The authors did see strong correlations between malignancy and higher IR score but discovered
that the scoring system they used (IR1 – IR5) can be varied and highly dependent on the existence
of vasculature. Utilizing biostatistics, Despite the issues with scoring systems for initial analysis,
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they reach the conclusion that combining thermography with additional modalities will provide a
more convincing diagnostic result. Similar to other studies, the consulting radiologists who
interpreted the images were aware of the lesion site and size (discovered through conventional
screening methods) prior to analyzing the infrared images.
Scoring systems could potentially be beneficial for screening purposes to determine whether more
expensive techniques are needed for diagnosis, particularly as an adjunctive modality. However,
using the observational process to provide the score delivers inconsistent results. If the scoring
system is used in the future for screening, it should depend on computational methods rather than
bias human interpretation.
d. Computational and Mathematical Methods
Francis et al. [102] utilized dynamic thermography in the prone position to image twenty-four
healthy women and twelve women with cancer. Using their method, Mammary Rotational Infrared
Thermographic System (MAMRIT), they extracted abnormal features and textures within the
infrared image to determine abnormality. They extracted statistical features such as mean,
variance, skewness, and kurtosis from each abnormal region of interest for further analysis. The
authors captured images of the breast before the cold stress is applied and after in order to compare
the statistical image features. While the authors are using statistical image features to determine
abnormality, they are additionally focused on non-biased analysis. The system first crops the breast
image and identifies a Region of Interest (ROI). It then utilizes an automatic detect system to
extract features and determine abnormality. They report sensitivity and specificity for pre-cool and
post-cool conditions using both statistical features and texture features. They calculate higher
sensitivity and specificity for precooled conditions, using texture features as performance
measures for analysis. The authors approach the post-processing and analysis of their images from
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a scientific, computational, and mathematical standpoint. The accuracy achieved, with technology
that has already been surpassed with new methods, shows the great potential of thermography
without the bias of human interpretation.
Ng and Kee [109] analyzed thermograms using artificial neural networks (ANN) and different
statistical methods for their study. Using a combination of computational and mathematical
methods is meant to analyze large amounts of temperature data for more rapid diagnosis of
malignancy. The authors collected data from 90 breast cancer subjects, selected at random, to test
their diagnostic process. Specified thermal characteristics were compiled including mean, median
and modal temperatures. First, linear regression (LR) correlates between observable variables in
thermographic images and the actual health status of the patient (classified through mammogram
and biopsy). A radial basis function network (RBFN) is then used to produce the desired outcome
of ‘positive’ or ‘negative’. Finally, receiver operating characteristics (ROC) is used to measure
statistical significance of the produced results including sensitivity, specificity, and accuracy. To
conclude the study, the authors state that combining ANNs with biostatistics and thermographic
advancements could lead to a viable adjunctive screening technique. Determining precise tumor
diameter and position is the next step to advancing this method further.
EtehadTavakol et al. [110] employed machine learning to train a program for thermogram image
processing. They used 32 collected images (9 malignant, 12 benign, 11 normal) from various
thermography centers around the United States and Australia. Using a Canny edge detector, they
found the edges and boundaries of the breasts. The algorithm then defines regions of interest
dependent on clusters of pixels correlating to hotter areas. The features are extracted and a fast
Fourier transform (FFT) is used to differentiate bispectrum of the images. The defining features
and compared with the pathology of the images for classification. Finally, the resulting images and
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classifications are used to train an image processing system for abnormality detection and rapid
diagnosis. Additionally, the authors discuss that the methodology can be mass employed for
preliminary thermography screening.

2.3.3 Scientific Validation
A letter published by the Food and Drug Administration (FDA) in 2019 [111] warned against the
risks of using thermography alone as a breast cancer screening technique. There are many
thermography clinics around the country that screen for multiple afflictions without scientific
proof of accuracy.
Although thermal imaging holds great promise, more research is needed in order to validate this
modality as a specific and sensitive detection method. Despite the warnings of the FDA, there are
individual boutiques that have popped up throughout the United States, offering full body thermal
scans ranging from $ and breast scans ranging from $200 - $350, screened by a Board Certified
Clinical Thermologist. The breast exams involve a baseline thermogram with an additional
screening at three months. If asymmetry is present, further screening is warranted. Otherwise, an
annual thermogram is recommended. However, an asymmetrical baseline could be the result of
maldistribution of heat or a change in hormones [112]. Some tumors that are more ‘slow-growing’
or do not have an extensive vascular network may be missed. The correlations developed could
potentially be flawed but are ideally compared with other methods to ensure accuracy. Similar to
previous studies, the patient is seated upright with their arms above their head. This causes
gravitational deformation and an increase in hyperthermia in the inframammary fold. Additionally,
any changes in heat from tumor closer to the underside of the breast will be inaccessible and more
difficult to detect.
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The warnings from the FDA against thermography as a valid screening technique lie within these
centers. The core technology associated with Digital Infrared Thermal Imaging (DITI) is not
approved as a standalone technology and not recommended for as a standalone screening method.
While some women use DITI exclusively for their breast screening, this is not recommended by
the American College of Clinical Thermology (ACCT). They additionally report that when used
as an adjunct to mammography, sensitivity is increased. ACCT discusses the value of DITI or
other thermographic tests and the comparisons of mammography and thermography as comparing
tests of physiology and anatomy. Although the scientific basis used to analyze the breast are
different for each screening modality, comparing the accuracy and statistical significance assists
with medical choices.
The International Academy of Clinical Thermology (IACT), founded in 1983, is a non-profit
organization dedicated to providing resources on thermography for both the healthcare community
and general public. The IACT requires that all candidates looking to become Clinical
Thermologists or Thermographic Technicians are qualified health care providers with a license to
diagnose pathology [113]. The recommended education guidelines put forth by the IACT involve
training courses, formal classroom hours and practical imaging experience. There are three
qualified positions: (1) Certified Clinical Thermographic Technician, (2) Certified Clinical
Thermologist and (3) Breast Thermologist. Recommended courses for certified clinical
thermographic technicians involve basic thermal imaging principles, patient management,
laboratory and imaging protocols and practical imaging experience. For clinical and breast
thermologists, the list expands to include anatomy and physiology, pathophysiologic processes
and image analysis and interpretation. The training required to work in a center does not account
for the changes in technological improvement and screening process. In fact, the standards and
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protocols in clinical thermographic imaging listed on their website were last updated in September
2002 [114].
Another organization, the Professional Academy of Clinical Thermology (PACT) have developed
a training course for thermography training that involves a 12-hour online intro course, specialty
training for $399 (certified technician, neuromuscular thermologist, full body thermologist and
breast thermologist), a 500-page manual, and a certification exam. PACT also offers interpretation
services, analyzing images with three separate interpreters within seven days. For full body scans,
they report on many bodily diseases that create thermal abnormalities. These include the following:
breast cancer screening, fibrocystic breast ratings, cerebrovascular function, abdominal
inflammation, thyroid function, nerve issues, localized inflammation, arthritis, and vascular
conditions [115].
All three of these organizations, ACCT, IACT and PACT offer some form of certification to
perform and interpret thermograms and guide thermologists in best practices. However, with
constant changing technology, the importance of continuing education is vital. The ACCT
programs require continuing education credits in order to maintain certification. The focus of these
different organizations is to train thermologists on current thermography technology and
interpretation. But if the previous methods of analysis are flawed, additional training will only
propagate the problem. Scientific validation using techniques that are known to detect (such as
mammography, ultrasound, or MRI) are key to refining thermography as an adjunctive technique.

2.3.4 Thermal Biomarker Classification
The Hallmarks of Cancer [14], [15], discussed above, involve factors that could potentially
influence hyperthermia. Inducing Angiogenesis – Angiogenesis is a normal process that occurs in
the body to grow blood vessels for continued cell growth and production. Cells need oxygen and
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nutrients from blood vessels in order to survive. Cancer cells are also able to create new blood
vessels in order to carry adequate oxygen and nutrients to the abnormal cells for continued growth
and replication. Tumor-Promoting Inflammation – There have been many studies showing that
inflammation can lead to cancer development. More chronic inflammatory issues such as
infections, obesity, smoking, alcohol consumption, etc. are all potential risk factors linked to
cancer development through inflammation.
Although there are many factors that affect how cancer cells grow and replicate, few of these
principles are hypothesized to contribute to hyperthermia. Two large factors that would allow for
successful infrared imaging include inducing angiogenesis and tumor-promoting inflammation.
Angiogenesis is a well-studied phenomenon within the body, both during normal cell growth and
cancerous cell growth. The increase of vasculature to a growing tumor creates an area of
hyperthermia. The increased metabolism in a tumor can also cause localized temperature increases.
Additionally, certain biological factors such as hormonal receptors or cancer type could potentially
alter tumor growth within the system. Understanding the underlying cause of increased
hyperthermia in tumors can assist with detection. Infrared imaging has the unique ability of
capturing thermal activity in breast tissue resulting from a tumor. Thermal activity, characterized
as thermal biomarkers, include cellular metabolism, increased vascularity due to angiogenesis, and
increased blood perfusion which create areas of increased hyperthermia. Gautherie [19] initially
presented a model, described above, to compare tumor doubling time with respective metabolic
activity. He also explored the effect of vasculature on the heat transfer properties in the breast
(effective thermal conductivity) when a tumor is present.
Developing these correlations cultivates a scientific basis in infrared imaging that could alter the
negative reputation of the technology. Currently there are no studies comparing the metabolic
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activity of growing tumors with the tumor biology. However, developing correlations is vitally
important in order to understand the correlative nature between tumor diameter and metabolic
activity. Some tumors may be smaller and grow more aggressively while others, considered “cold
tumors” have low metabolic activities resulting in smaller temperature changes [26]. In the
following sections, thermal biomarkers are discussed as potential factors for classification of
different types of cancer.

2.4 Objectives
Based on the previous work performed and discussed in the literature review, many components
were identified to determine the efficacy of steady-state infrared imaging (IRI) and address
research needs. This dissertation addresses several key factors involving the study of IRI as an
adequate adjunctive screening technique to detect breast cancer. In order to effectively evaluate
this technology, many factors must be considered including bodily heat and mass transfer. The
specific objectives of the proposed work are as follows:
1. Develop steady-state infrared imaging (IRI) as an effective breast cancer screening
technique.
At present, there is no easily reproducible, reliable low cost screening method
available for detecting cancer in breasts with dense tissue. The success of
thermography in previous studies has been limited due to (i) lack of standard
protocols during clinical screening [116] and (ii) lack of thermal sensitivity of IR
detectors to capture subtle temperature variations [5]. The steady-state IRI method
discussed below relies on the thermal characteristics (metabolic rate,
neoangiogenesis) of a tumor, and thus is highly complementary to mammography
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in cancer detection. Additionally, this project has identified the tumor in terms of
its position on a clock, quadrant of the breast, distance from the nipple, and depth.
This information is important in localizing the tumor for further management such
as biopsy or surgical resection and in correlating the findings with those of other
imaging modalities.
2. Establish clinical protocols and patient process for adequate screening using IRI.
Currently, there are no consistent methods or standards used for clinical
thermography. One major goal of this study was to develop consistent protocols for
patient observation and imaging. This includes imaging process, patient handling,
informed consent, and data management. Additional factors needed to evaluate IRI
include patient population, image interpretation, and scientific validation. The
details of this study are presented below along with extensive future
recommendations for the continuation of steady-state IRI.
3. Identify factors that influence heat production and develop thermal biomarker
classifications.
While optimizing infrared cameras and patient protocols are vital in advancing
thermography as a screening technology, studying heat movement from the tumor
through the tissue will lead to a better understanding in the underlying heat transfer.
An in-depth discussion on the thermal factors affecting heat movement in the body
is presented. Additionally, a new classification system for thermal biomarkers
present within the body, dependent on different forms of cancer is discussed.
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Chapter 3: Approach
3.1 Overview
The work performed in this study involves two different aspects: clinical and numerical. Through
a collaborative study with the Rochester General Hospital, patients have been recruited and imaged
using steady-state infrared imaging. The collected images are then analyzed, and the regions of
hyperthermia associated with malignant tumors are studied. The numerical portion, discussed
heavily in Chapter 4, was the groundbreaking work of my research partner Jose Luis GonzalezHernandez [60]. Together, the overall detection algorithm and the IRI images were used in
validating the IRI steady-state algorithm for detecting breast cancer. The detailed approach is
discussed below.

3.2 Clinical
Steady-state Infrared Imaging (IRI) is unaffected by tissue density and has the potential to detect
tumors in the breast by measuring and capturing the thermal profile on the breast surface induced
by increased blood perfusion and metabolic activity in a rapidly growing malignant tumor. In this
new clinical approach, subjects with biopsy-proven breast cancer are imaged with steady-state IRI
in the prone position and results are compared with preceding MRI images. The prone position is
able to provide a thermal profile of the entire breast without any abnormalities from the
inframammary folds.
The clinical protocol, design and process have changed throughout the duration of examination.
The first is classified as IRI-MRI and the second is classified as IRI-Mammo. They are discussed
at length below. All clinical work was conducted at the Rochester General Hospital (RGH) in
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collaboration with the Rochester Institute of Technology (RIT). The study began in March 2018
and is ongoing.

3.2.1 Ethical Considerations
All personnel working on the project undergo human subjects training (Good Clinical Practice and
Good Documentation Practice) and complete Collaborative Institutional Training Initiative
certification. Additionally, all patient data is deidentified prior to transfer to RIT. The study is
conducted in compliance with the protocol, 21 CFR 50 Protection of Human Subjects, 21 CFR 56
Institutional Review Board (IRB), Good Clinical Practice (GCP) as set forth in the International
Conference on Harmonization Guidelines of GCP (ICH E6), and Health Insurance Portability and
Accountability Act (HIPAA). Patients are assigned a number, starting with 001 and increasing
incrementally. Because there were two separate protocols with two different patient populations,
we have designated patient files as 001a and 001b.

3.2.2 Clinical Study – IRI-MRI
i.

Patient Population

The first half of this study required MRI images that we could use for scientific validation and 3D
model generation. Because of these qualifications, we recruited patients who have a breast cancer
diagnosis and require an MRI in their clinical process. Although many women do not require an
MRI prior to surgical resection, it was vital to participate in this study. An MRI is generally
recommended if there is a possibility of cancer spread throughout the breasts that did not appear
on a mammogram. Sometimes the MRI images would change a lumpectomy to a full mastectomy,
depending on the type of cancer and amount of spread present.
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ii.

Patient Flow

MRI examination was recommended by the consulting breast surgeon on the project and the
women were referred through her. Once a list of potential patients was generated, the clinical
department contacted them for interest. On average, we screened 1-2 patients per month.

Figure 17. Screening and diagnostic imaging patient flow.
The patient imaging process generally looked like the one in Fig. 17. First, a mammogram is
performed on an annual basis, after a suspicious physical examination or because of higher risk.
Next, an additional mammogram is performed observing the area of suspicion for diagnosis. A
core needle biopsy is then performed using ultrasound to find the area of suspicion. A report is
generated detailing the extent of cancer and pathology of tumor. An MRI is performed in the prone
position, recommended by the consulting breast surgeon. Images are stored on a disc and
deidentified prior to transfer to RIT. Infrared imaging is conducted in the prone position, on the
same day as MRI, capturing 8-24 images around the circumference of both breasts. Finally, the
patient undergoes surgical resection by lumpectomy (removing the tumor and surrounding areas)
or mastectomy (removing the entire breast).
Patients were recruited for IRI on the day of their MRI exam. The patient would arrive at the
hospital for the MRI, proceed with the 45 minute – 1-hour long exam, and then receive IRI
screening. Contrast material and inflammation from biopsy were considered problematic for this
clinical study. However, given the ideal patient population, their potential effects were ignored.
Prior to IRI, patients were given a few minutes for water and snacks to recover. Any tape markers
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on the breast used for biopsy or surgical purposes were removed. After the patient was screened,
they were brought back to the entrance of the hospital.
iii.

Clinical Protocol

An Institutional Review Board (IRB) approved protocol has been developed for recruiting patients
and acquiring IRI images. A copy of the IRB-approved protocol and consent form are seen in the
appendix. As I am not a medical professional, the patients are consented by one of the RGH
Research Coordinators in the clinical department. The protocol briefly describes the IRI
technology and modeling process in layman’s terms. This includes a step-by-step detailing of how
their images and data are transferred to RIT and utilized. Additional details include study duration,
study population and data collection techniques.
The risks and benefits are discussed with the patient prior to examination. The technology does
not involve any contact with the patient and does not induce any radiation. Additionally, the
treatment plan for each patient is not interrupted or influenced by this study. The only foreseeable
risk involves the prone position; some patients are uncomfortable lying in this position for longer
periods of time. In fact, we have had women complain of back pain or rib pain on the imaging
table. Extra pillows and blankets are available to those who are experiencing discomfort.
Furthermore, there are no direct benefits related with this examination. At the most, patients are
participating in a study with a potentially beneficial future technology. Once the patient has asked
any questions and feels satisfied with the terms and conditions, they sign and date the form.
iv.

Patient Questionnaire

The first portion of the questionnaire involves a line of questioning corresponding to the patient’s
activity prior to the examination. The temperature of the room, the weather outside, hormonal
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influences and factors such as coffee/alcohol consumption, smoking habits, exercise prior to
examination, etc. [18–20] can potentially influence the surface temperature distribution. These
include the following:
•

Have you sunbathed within five days prior to the exam?

•

Have you used lotion/cream, makeup, deodorant on the breasts on the day of the exam?

•

Have you exercised today?

•

Have you smoked or had alcohol today?

•

Have you had coffee or tea today?

•

Were you wearing tight-fitted clothing?

The latter portion of the questionnaire asks for details of the patient’s screening and diagnostic
history including details of tumor size, stage, and location. This portion is filled in after biopsy and
MRI are completed.
v.

Clinical Setup

The initial imaging room was a small patient room in the hospital, approximately a 10-minute walk
from the MRI imaging offices. The room had a small curtain for privacy and large windows. The
windows posed a risk for reflection on the breast surface, potentially causing issues during
imaging. Additionally, the fluorescent lights and lack of ambient control introduced additional
concerns.
The table for capturing IRI images was a retrofitted massage table. Because the clinical screening
room was actually a doctor/patient examination room, it was key for the table to be easily moved.
The massage table could handle about 300 lb and was short enough for a simple step stool. The
legs folded in and the table could fold in half, allowing for easy transport. Four 2-inch blocks were
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purchased to raise the bed. A 9-inch hole was cut in the table for the breast to hang down and a
pillow was provided for comfort. Several hospital sheets were donated, and a hole was cut in each
to ensure the breast could hang in the hole, unimpeded. Finally, hygienic paper was placed on the
bed and taped down. Images of the bed can be seen in Fig. 18 and Fig. 19 (a) and (b).

Figure 18. Portable massage table retrofitted for infrared imaging.

Figure 19. IRI screening table in the screening room with curtain.
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However, the sturdiness of the table was a big concern. Unfortunately, the massage table was very
thin and could only support a maximum of 300 lb. One patient who began to get on the bed almost
tipped it over, and there were times when ‘cracking’ was heard when the bed was laid on. These
are obviously major concerns, especially with patients in a delicate mental, emotional, and physical
state. Additionally, the distance from the IRI camera and the bed was not enough to allow for
sufficient focal distance. The bed needed to be stronger and needed more height. The table was
redesigned to address these issues.
The details of the preliminary camera mount are shown in Fig. 20(a). The resolution of the IR
camera is 640×512 pixels, with a thermal sensitivity of 0.02°C (FLIR SC6700). The camera rotates
on a stand below the table and hole. Eight images are taken, beginning at the head, separated by
45° looking up at 25° angle to vertical. The angle and focus of the camera vary based on the breast
size of the subject being tested. Larger breasts will hang lower in the hole requiring a different
focal distant compared to smaller breasts. Eight images are taken for each breast, beginning at the
head, separated by 45° looking up at 25° angle to vertical, as seen in Fig. 21.

(a)

(b)

Figure 20. (a) Camera table setup with turntable and (b) FLIR infrared camera used for
imaging.
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Figure 21. Camera positions for 8 views of breast in prone.

The new table for capturing IRI images is a sturdy retrofitted table (2’ × 7’) with a 9” hole for
breast imaging. A 2-inch layer of foam is placed on top for comfort and fabric was added to hold
the foam in place. An image of the lab table with added foam can be seen in Fig. 22. The bed was
raised considerably, allowing for a 4-foot height between the camera and breast instead of a 2-foot
height. Because of this adjustment, a larger stepstool was needed. A sturdy staircase with railing
was added to help individuals get on top of the bed. The stool can handle 500-lb and the railing is
welded together to ensure no movement during ascension. Images of the staircase prior to added
handle and an example of the height of the bed (myself standing next to it) are seen in Fig. 23 (a)
and (b). Finally, a black curtain was added around the edge of the table to hide the camera
equipment and provide a consistent backdrop and ensure no reflection or stray thermal artifacts
during imaging. The same sheets were added on the bed and a layer of disposable paper is used
for hygienic purposes. The imaging table with staircase can be seen in Fig. 23(a) and Fig. 24.
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Figure 22. Image of table with 2-inch foam, prior to covering with fabric.

(a)
(b)
Figure 23. (a) Staircase with table, prior to addition of railing and (b) myself standing next to
table to show examples of height.
96

Figure 24. Images of the imaging room with the table design, sturdy staircase, and black curtain
along the edges of the table.

vi.

Data Collection

For this study, we collected the MRI images of all patients on a deidentified disc, a patient
questionnaire with the questions above, infrared images and additional medical information. This
involves the following information:
•

Age

•

Date of birth

•

Initials

•

Breast density
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•

Bra size

•

Breast cancer details including size and location of tumor, type and stage of cancer,
and reports from ultrasound, mammogram, and MRI

3.2.3 Clinical Study – IRI-Mammo
i.

Patient Population and Patient Flow

The patient population for the second portion of the study is significantly different. After the
process was scientifically validated (discussed further below), the population was adjusted for
several reasons. Firstly, the addition of contrast material and screening after biopsy was cause for
concern. Therefore, screening needed to occur prior to these activities. Second, we had already
collected patients with biopsy-proven breast cancer and had proven that we could pinpoint the
tumor. The obvious next step in determining the specificity of the technology was recruiting
patients without known breast cancer. However, the technology is not yet at a stage to recruit from
the general population. Finally, we still want to be able to scientifically validate the images we are
collecting. This means we would need images of the breast from a source known for imaging
success.
We therefore decided to collect patients classified as BI-RADS 3, 4, or 5 who were receiving a
diagnostic mammogram. The results from the IRI studies are not used in clinical decision making.
We did consider the ethical implications of this policy. All of our subjects will either be undergoing
standard evaluations such as ultrasound or biopsy (BI-RADS 4 and 5) or monitoring (BI-RADS
3). It remains possible that some subjects will have a thermal profile suggestive of cancer but will
be classified as BI-RADS 3 and therefore not undergo immediate intervention, though close
follow-up will be planned. It is possible that IRI will find suspicious thermal profiles in subjects
without cancer to avoid causing unnecessary distress. We believe this approach is acceptable since
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all subjects will be getting the current standard of care and no clinical benefit or harm will ensue
from the IRI based study. This is one of the reasons we have chosen not to pursue more “normal
controls” with BI-RADS 1 and 2 mammogram readings. These would present a more challenging
ethical dilemma on how we would handle the results since these subjects would not be followed
as closely.
Using this population, we were able to collect patients with suspicious masses, many of which are
later determined as benign, prior to biopsy. This reduced the risk of additional thermally altering
factors from biopsy or contrast. Additionally, we can use the screening and diagnostic
mammogram images for validation of our programs. The new patient flow can be seen in Fig. 25.

Figure 25. New patient flow for IRI-Mammo study.

ii.

Clinical Protocol

No changes were made to the clinical protocol or process in which patients were consented.
iii.

Patient Questionnaire

In addition to the questions from the IRI-MRI patient questionnaire, we added several questions
about biological influence on bioheat. This includes the following:
• Is the patient menstruating or menopausal?
• Is the patient on any type of hormonal birth control?
o If yes, what product?
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• Has the patient had breast cancer before?
• Has the patient had breast surgery before?
o If yes, which surgery: lumpectomy, mastectomy, breast reduction, breast
implant, other
Based on other studies that show normal heat transfer throughout the body, especially during
menstruation or menopause, these questions are vital to the further development of this technology.
This could involve adapting the technology to account for hormonal changes or selectively
imaging patients during more regular time periods.
iv.

Clinical Setup

The clinical setup of the table has remained the same for the new study. However, the camera setup
has been upgraded. More images were desired, especially from a horizontal and vertical view.
Therefore, the camera setup needed much greater modularity. The three positions can be visualized
in Fig. 26 (a), (b) and (c). The table can spin 360° for a full view of the entire breast circumference,
the arm holding the camera can slide up and down and rotate a full 360°, and the camera can tilt
180°, if desired.
Additionally, in order to have a more modular setup, the camera needed to be significantly smaller
and lighter. The updated camera is an ICI 8640, with similar properties to the FLIR camera.
However, the size and weight are significantly smaller. A comparison of the FLIR camera (IRIMRI) and ICI camera (IRI-Mammo) can be seen in Table 9. The actual camera and camera stand
setup can be seen in Fig. 27 (a) and (b). Because the camera is moved to the table in position 2
(Fig. 26 (b)) to obtain a horizontal view, the camera stand has to match the height of the table.
Further iterations of this clinical setup will involve lowering the table and camera stand to ensure
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better patient safety and easy getting onto the bed. Finally, an increase in images are captured for
smoother model generation. Twenty-four images are captured at each position with an additional
image of the breast straight-on (a total of 29 images). A schematic of this can be seen in Figure 28.

(a

(b

(c)
Figure 26. (a) Camera observes the breast at an angle similar to IRI-MRI study, (b) camera
tilted to observe the breast horizontal, and (c) camera tilted to look straight up at the breast.
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Table 9. Comparison of major factors impacting imaging with the IRI-MRI FLIR camera and the
IRI-Mammo ICI camera.

Temperature Range
Pixel Resolution
Accuracy
Dimensions
Weight
Pixel Pitch
Spectral Band

(a)

FLIR (old)

ICI 8640 (new)

-20°C to 50°C
640 x 512
±1°C
8.6 × 5.64 × 6.21 inches
10 pounds
15 µm
7.5 µm – 10.5 µm

-20°C to 120°C
640 x 512
±1°C
1.7 x 1.5 x 1.5 inches
74.5 grams
17 µm
7 µm – 14 µm

(b)
Figure 27. (a) Modular camera stand and (b) ICI 8640 camera.
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Figure 28. Positions of camera at a 45° angle and a horizontal view; allows for capture of 49
images around the circumference of the breast.

v.

Data Collection

Unlike the IRI-MRI study, collecting MRI images is not necessary for this portion of the study. In
addition to the patient questionnaire from both the IRI-MRI and IRI-Mammo studies, the following
data is collected and deidentified:
•

Age

•

Date of birth

•

Initials

•

Breast density

•

Bra size

•

Mammography reports and eventual histopathology reports, if necessary

•

If the patient gets an MRI due to a malignant diagnosis, the images will be provided
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3.2.4 Image Acquisition
The ambient conditions in the room are held constant at 71°C and there is no active airflow during
examination. After the patient has signed the informed consent form and filled out the patient
questionnaire, she is then requested to disrobe from the waist up and wear a hospital gown that has
an opening in the front. The patient lies down on the table in the prone position with one breast
placed in the opening in the table. An example of this can be seen in Fig. 29.

Figure 29. Medical illustration of subject in prone position with camera table underneath.

When the patient lies on the table, a timer is started. Based on data from previous studies [14–17],
the acclimation time is approximately 10 minutes to reach proper steady state conditions. Images
are taken during acclimation time to measure the changes in temperature throughout the ten
minutes. However, it is possible that this amount of time is too lengthy or too short for steady state
to be reached. The process of capturing all images only takes 90-120 seconds. When this process
is complete, the patient is asked to switch to the contralateral breast and an identical process is
completed. For each patient, the time to acclimate and the time taken for imaging is recorded.
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3.3 Numerical
The numerical portion of this project was completed by Gonzalez-Hernandez [60]. The following
images in this section are from his thesis work. Additional details can be found in two of his
published papers [124], [125].

3.3.1 MRI Images
A digital breast model is created using the corresponding MRI images from the IRI-MRI study.
Using a commercially available software called ImageJ, the inner breast architecture is removed
(veins, tissue, etc.). A silhouette of all the MRI breast images in the series are created and stacked
on top of each other. Finally, the breast geometry is smoothed using a mix of commercially
available software (Autodesk Recap, MeshMixer, and ANSYS SpaceClaim). An example of this
process can be seen in Figure 30.

Breast cancer
patient’s MRI

Stack of MRI images

3D geometry after
smoothing

Figure 30. Patient-specific breast model generation process using MRI images [60].

This process creates a patient-specific digital breast model for each patient. This is important due
to the intricate details on the breast surface that could potentially alter the resulting thermal
profiles. Some of these intricacies can include concave surfaces, observable especially in the prone
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position, as seen in Figure 31. After the geometry is generated using MRI images, the modeling
process is started.

Figure 31. Breast model of Patient 013a from two different angles, showing the intricacies of the
geometry.

3.3.2 3D Modeling Process
The modeling process involves importing the geometry into ANSYS and simulating the heat
transfer effects of a tumor. A mesh is applied onto the model and boundary conditions are added
(constant core temperature of 37°C, constant convection to the breasts through a steady ambient
temperature). Initial parameters are used to develop a baseline CFD model with the patient-specific
breast geometry. The values seen in Table 10 are generated from literature. Finally, a tumor is
estimated and placed within the digital breast model to create a computed temperature distribution.
From the simulations, computed temperature images are generated which are rearranged to match
the same views as clinical IRI images. An example of this can be seen in Figure 32.

106

Table 10. Parameters used in the simulations [60], [124], [125].

Figure 32. (a) Brest geometry with added mesh and boundary conditions and (b) breast model in
ANSYS with imposed tumor in the right breast [60].

3.4 Conclusions
Through the clinical portions of this study, we were able to create a database of patient images for
analysis and pathologic correlations. Additionally, we were able to study the patient protocol and
potential adjustments for further optimization. The numerical study provided a patient-specific
digital breast model capable of tumor detection and localization. Combining the clinical and
numerical portions of this study, steady-state infrared imaging is seen as a more viable adjunctive
technique to breast cancer detection. Further results are seen in Chapter 4.
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Chapter 4: Results
4.1 Acclimation Time
As discussed in Chapter 3, IRI involves the acclimation of the body part to be imaged in order for
steady state to be reached. Acclimation includes quasi-steady state conditions where temperatures
are reasonably steady over a sufficient time. This period may be increased or decreased depending
on the acclimation time needed for the breast surface to reach near thermal equilibrium state with
the surroundings. Additional acclimation time may be given for the acclimation of the contralateral
breast because the subject was lying on that breast on the table during the imaging of the first
breast. This causes the breast to warm and takes longer for steady state to be reached.
The desired acclimation time to reach steady state is between 5 minutes and 20 minutes for efficient
throughput with good imaging quality for accurate detection. A faster acclimation time may be
reached by providing loosely fitting clothing or minimal clothing during wait period. The time
used for the IRI-MRI and IRI-Mammo study was 10 minutes. The series of images in Fig. 33
shows the left breast, the breast without a tumor, of Patient 23 (further patient data found in Table
11). This patient had a lot of random vascular throughout the breast, some more striking or larger
than other areas. The larger visible blood vessels running through the breast do not have a drastic
temperature difference from the beginning of acclimation to the end. However, the smaller, deeper
blood vessels do change over time and reflect differently on the surface.
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Figure 33. Breast cooling over a period of 10 minutes; first image is at 0 minutes, second image
is at 5 minutes and third image is at 10 minutes.

The series of images in Fig. 34 show the acclimation period of 10-minutes for a breast with tumor.
These images involve the left breast of Patient 25. The tumor is suspected to be in the upper right
quadrant of the breast and is confirmed by the corresponding MRI seen in Fig. 35. The area
surrounding the suspected malignancy is cooling throughout the period and the area of suspected
malignancy is seen to stay red. The vascular system becomes more defined and the area of
suspected malignancy becomes more defined throughout this time.

Figure 34. Acclimation time of Patient 25 left breast, with malignant tumor. Breast cooling over
a period of 10 minutes; first image is at 0 minutes, second image is at 5 minutes and third image
is at 10 minutes. Tumor is suspected to be in the upper right quadrant.
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Figure 35. MRI of Patient 25, tumor can be seen in upper right quadrant with biopsy spot.
The change in acclimation time can change the visible thermal profiles on the breast surface,
particularly where the blood vessels and tumor(s) effects are apparent. The resulting changes in
thermal features related to vasculature can be observed over a period of time. The observable
cooling period for the breast once exposed to the ambient temperature can help in differentiating
hot spots due to tumors vs. hot spots due to vasculature. Hot spots are also referred to as an area
of increased hyperthermia. As the breast cools, the lines of vasculature become more defined and
linear while the thermal regions induced by the tumor remain more diffuse. Some changes are
expected when the tumor is closer to the skin surface and the intensity of the thermal changes is
considered.
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4.2 IRI-MRI Study
For the first phase of this clinical trial, we needed to develop a system to localize and detect the
tumor within the breast. The characteristics of the location of the tumor were essential for this
portion of the study. The ultimate goal of the IRI-MRI study was to examine the position, size,
and depth of the tumor within the breast. These factors were provided by pathology reports and
confirmed with the corresponding MRI images. The additional data on the pathology reports that
was collected include breast density, tumor grade and cancer type. These factors were collected
primarily for future studies.
The IRI-MRI study recruited 30 adult women with biopsy-proven breast cancer who required a
diagnostic MRI over the course of their clinical process. Table 11 shows the individual subject
data for 30 individuals showing the tumor grade, type of cancer, breast density and tumor
characteristics. IRI images were obtained with only 29 subjects as the images could not be obtained
for Subject 5 due to camera malfunction. All women studied had tumor in one breast, except for
Subject 6 and Subject 20 who had bilateral breast cancer.
As discussed in Chapter 3, the patients in the IRI-MRI study had eight images taken around the
breast. Examples of the series of images are shown in Figure 36 - 39. One major issue with this
clinical setup is the asymmetry of the breast. Although the camera setup may be centered, capturing
the entire breast may be difficult. Additionally, with the weight and size of the camera the setup
made it difficult to move and orient. This made getting consistent centered images difficult. The
IRI-MRI study is still actively ongoing and recruiting patients, with the updated imaging system
and ICI camera. The new modular camera setup is able to better capture the breast, despite how
the table is setup or how the patient is positioned. This is primarily due to the high modularity in
the system, allowing for more camera movement specific to each patient.
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Table 11. List of subjects with age, tumor location (size/position/depth) for breasts with tumor
(BWT) and additional details such as cancer type, breast density and subject classification.
Breast
Tumor Cancer
Position
Size (cm)
Depth (cm)
Density*
Grade Type**
001a
60
R
HD
10:00
1.6×1.0×1.1
Posterior
2
DCIS
002a
70
R
SF
11:00
0.8×0.7×1.1
Middle
2
IDC
003a
71
R
PF
10:00
0.9×0.6×0.9
Anterior
1
IDC
004a
62
L
SF
4:00
2.0×1.1×1.4
Middle
3
ILC
005a
Data not collected due to technical computer malfunction
R
12:00
3.5×2.4×2.3
Middle
3
IDC
006a
68
SF
L
2:00
0.8×0.6×0.4
Middle
1
ILC
007a
51
L
SF
5:00
2.6×1.1×1.2
Anterior
2
IDC
008a
67
L
SF
10:00
1.8×1.2×1.3
Posterior
1
IDC
009a
43
R
SF
12:00
1.2×0.8×0.8
Middle
1
IDC
010a
67
L
SF
12:00
1.0×0.8×0.8
Anterior
1
IDC
5:00
1.1×0.8×1.0
Middle
1
IDC
011a
46
R
HD
5:00
1.0×0.8×0.7
Posterior
1
IDC
012a
48
R
SF
10:00
1.1×0.8
Posterior
2
IDC
013a
64
R
PF
11:00
1.5×0.9×1.2
Middle
1
IDC
014a
68
L
HD
2:00
MCs□
Middle
1
DCIS
015a
68
L
SF
3:00
1.7×1.1×1.3
Posterior
3
IDC
016a
56
L
SF
1:00
0.9×1.1
Middle
2
IDC
017a
70
L
SF
5:00
0.5×0.5×0.6
Posterior
3
IDC
018a
42
R
HD
10:00
0.4
Posterior
3
IDC
019a
49
R
SF
6:00
2.6×2.3×2.0
Middle
2
IDC
L
12:00
2.1×1.3×1.8
Anterior
2
ILC
020a
70
SF
R
12:00
0.8×1.0×0.7
Posterior
1
LCIS
021a
65
L
HD
12:00
1.7×1.4×1.3
Middle
1
IDC
□
022a
67
L
ED
11:00
MCs
Middle
2
LCIS
023a
72
R
SF
10:00
1.8×1.1×1.3
Middle
2
IDC
024a
72
L
SF
11:00
0.7×0.7×0.9
Anterior
3
IDC
025a
64
L
SF
2:00
1.9×1.7×2.4
Middle
1
IDC
□
026a
63
L
HD
11:30
MCs
Posterior
1
IDC
027a
75
R
SF
10:00
1.0×0.8×0.7
Middle
1
IDC
028a
57
L
SF
10:00
1.4×1.0×0.7
Middle
2
IDC
029a
76
L
US
1:00
2.4
Anterior
1
IDC
030a
69
L
HD
2:00
0.7×0.6×0.3
Posterior
1
ILC
*SF = Scattered Fibroglandular, HD = Heterogeneously Dense, PF = Predominantly Fat
**DCIS = Ductal Carcinoma In-Situ, IDC = Invasive Ductal Carcinoma, LCIS = Lobular
Carcinoma In Situ, ILC = Invasive Lobular Carcinoma
□MCs = Microcalcifications
Subject

Age

BWT
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For the first 20 patients of the IRI-MRI study, the average temperatures are calculated for the breast
with tumor and the breast without tumor. The difference between the values are reported in Table
12. There is a temperature difference in nearly every case between the mean temperature of the
BWT and the BWoT.

Table 12. Average temperature values in the breast without tumor and breast with tumor, for
each subject imaged with IRI and the maximum temperatures seen at the tumor hot spot.
BWoT*

Subject
1
2
3
4
5

BWT**

Temp Difference
Average BWT Hot Spot
Average Temp.
Average
Maximum Temp
– Average
– BWT
(°C)
Temp. (°C)
at Hot Spot (°C)
BWoT
Average
31.1
31.2
31.8
0.1
0.6
30.9
31.0
31.7
0.1
0.7
27.5
27.8
31.5
0.3
3.7
28.7
29.1
30.3
0.4
1.2
Data for subject 5 has been omitted due to technical malfunctions resulting in
unsaved images

Bilateral Breast
cancer, no
30.7, 30.8
BWoT
7
30.2
31.1
8
29.5
31.4
9
32.0
32.7
10
31.1
32.1
11
27.5
29.0
12
28.9
32.1
13
29.9
30.2
14
27.7
28.3
15
30.8
32.0
16
30.0
30.5
17
27.9
29.1
18
30.2
30.1
19
29.5
29.7
20
29.9
31.2
*BWoT – Breast Without Tumor
**BWT – Breast With Tumor
6
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32.2, 32.8

NA

1.5, 2.0

32.9
33.5
33.8
33.3
32.5
34.7
32.7
29.2
33.5
32.5
30.2
31.5
33.4
32.8

0.9
1.9
0.7
1.0
1.5
3.2
0.3
0.6
1.2
0.5
1.2
-0.1
0.2
1.3

1.8
2.1
1.1
1.2
3.5
2.6
2.5
0.9
1.5
2.0
1.1
1.4
3.7
1.6

Figure 36. Image sequence of Patient 6a’s left breast and right breast. This patient had bilateral
breast cancer with a tumor in both breasts. A detailed analysis is presented below.

Figure 37. Image sequence of Patient 13’s left breast and right breast. The malignant tumor is in
the right breast, right above the nipple.
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Figure 38. Image sequence of Patient 18’s left breast and right breast. The malignant tumor is in
the right breast.

Figure 39. Image sequence of Patient 29’s left breast and right breast. The malignant tumor is in
the left breast.
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Our preliminary results have shown visible hot spots by IR imaging, consistent with tumor, in each
subject with known breast cancer. Patient 6 exemplifies the utility of infrared imaging as a potential
adjunct to mammography in subjects with dense breast. Patient 6 is a 68-year-old woman who
presented with a palpable abnormality in her right breast at 12:00. Bilateral breast tomosynthesis
was performed which revealed a 3.5×2.4×2.3 cm mass at 12:00 in the area of palpable concern.
This mass was a biopsy proven invasive ductal carcinoma. In retrospect, this mass was present but
was smaller in size on the mammogram a year prior. The mass was masked by overlapping
fibroglandular tissue and not visible mammographically by the radiologist. An incidental
0.8×0.6×0.4 cm invasive lobular carcinoma was also found in the left breast. This mass is not
evident on the prior mammogram, even in retrospect. As both masses are seen on the IRI, we may
have been able to detect the patient’s breast cancer if thermography was used as an adjunct to
screening mammography. The images of the left and right breast of Patient 6 can be seen in Fig.
40(a) and (b), respectively.

(a)

(b)

Figure 40. Images of subject 6 with bilateral breast cancer, (a) the left breast with hot spot in
area of known 0.7 cm tumor and (b) the right breast with hot spot in area of known 2.7 cm
tumor.
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Further analysis of the thermal signature observed in the IRI images is performed to identify
thermal features indicative of abnormalities associated with the presence of malignant tumors.
Figure 40(a) shows an infrared image of the right breast for Patient 6 with a 2.7 cm tumor.
Although the hot spot that correlates with the tumor is easily visible in the image, further
quantification is performed by adding profile lines through the visible hot spot and through a cooler
neighboring region of the breast.

Figure 41. Temperature distribution of right breast of patient 6: (a) IR image with two profile
lines along the breast and (b) temperature profile for A and B.
A temperature plot depicting the variations along these profile lines (Line A and Line B) are shown
in Fig. 41(b). Line A passes through the hot spot correlating to a deep tumor and line B passes
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through unaffected region. The temperature along Line B varies between 30-30.5 °C whereas the
temperature at the hot spot corresponding to the tumor along Line A has a higher temperature of
~33 °C. The slope of the profile lines can further help in determining whether the thermal
abnormality is associated to a malignant tumor or a superficial blood vessel. The hyperthermic
lines seen faintly from the tip to the central region in Fig. 41(a) are indicative of blood vessels
through the tissue in that region. The smaller temperature fluctuations seen between 4 cm and 8
cm distance observed in Line B of Fig. 41(b) correlate directly to the blood vessels clearly seen in
the MRI rendering in Fig. 42. This approach enables differentiation between thermal signatures of
a blood vessel from a malignant tumor.

Figure 42. MRI, renderization from MRI, and IRI images for three subjects [126].
In this study, we determined that there are certain temperature profiles which establish whether a
detected hot spot on the breast surface should be considered a malignant tumor or suspicious mass.
In a given image, while there may be clear hot spots at the location of the tumor, there will also be
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several hyperthermic lines present throughout the breast surface. These lines have been determined
and correlated with MRI as superficial vasculature and the heating pattern they emit is different
than those from the tumor. The images will be corrected for such thermal artifacts. Both tumors
and blood vessels cause local temperature rises. Tumors generally have a larger area of diffusion
from the center of the hot spot to the surrounding breast tissue. Other factors such as veins have a
more secluded, well-defined hot spot. An example of this can be seen in Figure 43.

Figure 43. (a) The hot spot created by a malignant tumor and (b) the hot, short lines created by
vasculature in the breast.

4.3 IRI-Mammo Study
For the second phase of this study, the focus shifted from tumor localization to determining
specificity of the technology, understanding the bioheat transfer within the breast, and developing
pathology correlations with the tumors and respective heat patterns. The patient population
changed from those with biopsy-proven breast cancer to those with suspicious masses. The reports
collected for this phase of the study mainly involve mammography reports and patient
questionnaires. A pathology report was provided for any patient screened with an eventual
malignant result. Additionally, the BI-RADS classifications seen in Table 13 are the classifications
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given at the time of IRI screening. Two of the patients screened with a malignant result are Patient
005b and Patient 006b. However, the detection and localization process has not yet been performed
on these patients. An example of some of the patient data collected in this part of the study is seen
in Table 13.
Table 13. Patient data from the IRI-Mammo study for the six recruited patients.
Patient Breast Breast with
Number Density Suspicion
001b
SF
Left
002b
HD
Left
003b
HD
Right
004b
SF
Left
005b
HD
Left
006b
SF
Left

BI-RADS Classification
BI-RADS 3 – Probably Benign
BI-RADS 1 – Negative
BI-RADS 0 – Needs Additional Imaging
BI-RADS 3 – Probably Benign
BI-RADS 6 – Biopsy Proven Malignancy
BI-RADS 4 – Suspicious

Benign or
Malignant?
Benign
Benign
Benign
Benign
Malignant
Malignant

Additionally, the number of images captured at each angle for each breast increases. Images are
taken in two different positions: horizontal, to receive and better outline of the breast, and at an
angle, similar to the IRI-MRI study. Additionally, the new setup and camera introduced new
challenges, primarily with image focus. The new camera requires a significant reduction in
distance for accurate focus (FLIR required ~3 feet, ICI required ~1.5 feet). The focus of the camera
was a challenge for the horizontal views. Examples of this can be seen in Patient 001b in Fig. 44.

Figure 44. Glow around patient images due to poor image focus.
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Figure 45. Image sequence of the left breast of Patient 003b from the horizontal and 45° angles
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Figure 46. Image sequence of right breast of Patient 003b from the horizontal and 45° angles.
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Figure 47. Image sequence of the left breast of Patient 004b from the horizontal and 45° angles.
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Figure 48. Image sequence of right breast of Patient 004b from the horizontal and 45° angles.
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Similar to the IRI-MRI study, images (from all angles) are shown in Figures 45, 46, 47, and 48.
The number of images has been reduced from 24 of each angle to 12 of each angle to show a
comprehensive 360° view. A zoomed in view of the images of Patient 005b can be seen in Fig. 49.

Figure 49. Horizontal (left) and angled (right) view of the right breast of Patient 005b.

4.4 Detection and Localization
Similar to Chapter 3, the detection and localization portion of this project was completed by
Gonzalez-Hernandez [60]. The following images in this section are from his thesis work.
Additional details can be found in two of his published papers [124], [125].
A tumor is estimated and placed within the digital breast model to create a computed temperature
distribution. From the simulations, computed temperature images are generated which are
rearranged to match the same views as clinical IRI images. The difference between the clinical
and computed temperature distributions are further quantified by aligning the corresponding
images in the same view in a process called image registration.
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Once all digital model positions are identified to match the clinical IRI images, an iterative
program is run in order to localize any tumor within the breast. The program identifies temperature
variations on the clinical IRI images and compares them to the computed temperature distributions
in the digital breast model. If a match is found, the program verifies that there is a tumor and
computes its size and position. If a match is not found, the program continues to run until the match
criterion (0.1 °C between actual and predicted values) is satisfied. Using this technique, we have
been able to accurately detect a tumor and calculate its exact size and position within the breast. A
flowchart of this process is shown in Fig. 50. Further study into this technology can potentially
benefit subjects with dense breast tissue, which can mask tumor on mammography.

Figure 50. Flowchart of detection and localization process from Gonzalez-Hernandez [125].
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The results for seven subjects are shown in Fig. 51(a) with the corresponding difference in
predicted tumor diameter and actual tumor diameter in Fig. 51(b). It can be seen that the predictions
were very accurate, within 2 mm for diameter and 2-7 mm for location.

Comparison Between Predicted & Actual Size and Location of Tumor
Subject
1R
2R
3R
6R
6L
7L
8R
10R

Actual
Diameter (cm)
1.4
0.8
0.9
2.7
0.8
1.9
1.7
1.1

Predicted
Diameter (cm)
1.3
1.0
1.0
2.7
1.0
1.9
1.9
1.2

Actual
(x, y, z) cm
(7.6, 6.0, 11.8)
(5.8, 6.8, 13.0)
(5.2, 8.1, 11.8)
(10.5, 14.5, 11.5)
(4.5, 12.4, 10.3)
(12.1, 12.8, 17.1)
(4.7, 7.3, 12.3)
(5.3, 4.8, 12.5)

Predicted
(x, y, z) cm
(7.4, 5.7, 12.1)
(6.5, 7.1, 12.5)
(5.2, 7.5, 11.2)
(10.7, 13.9, 10.9)
(3.9, 11.9, 9.6)
(12.0, 13.2, 16.5)
(5.1, 6.7, 11.6)
(5.2, 5.2, 13.1)

Tumor Diameter (cm)

Comparison of Predicted and Actual
Tumor Diameters
Actual

3

Predicted

2.5
2
1.5
1
0.5
0

1

2

3

4

5

6

7

8

Subject Number
Figure 51. Comparison between predicted and actual values for tumor size and location within
each breast.
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The comparison between clinical IR and computer temperature distributions for Patients 003a,
006a and 007a are shown in Figs. 52-54, respectively. The two respective views shown in these
figures correspond to the same views of the individual breasts. It is seen that the temperature
distributions in the computer-generated thermal images accurately predict the trends.

Figure 52. Comparison of clinical and computed temperature distributions for Patient 003a
[126].

Figure 53. Comparison of clinical and computed temperature distributions for Patient 006a
[126].
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Figure 54. Comparison of clinical and computed temperature distributions for Patient 007a
[126].

4.5 Conclusions
The IRI-MRI study has shown that IRI in prone has the capability of detecting malignant tumors
irrespective of breast densities. Further, the numerical modeling process has shown great promise
in localizing tumors in subjects with biopsy-proven breast cancer. For the first phase of this study,
we were able to recruit and image thirty patients with biopsy-proven breast cancer. This allowed
for the development and testing of the detection and localization process. We have shown the
efficacy of the technology as an accurate detector of the method, particularly to find and localize
a tumor within the breast.
The next phase of this study involves the specificity of this technology and determining the limits
of detection. We have only recruited six patients to date but are eagerly recruiting to continue the
clinical study. The new modular camera setup has shown great promise in obtaining more images
from multiple angles and will undoubtedly prove beneficial in determining the specificity of this
method. Slight modifications may be made in the future to further optimize the patient experience
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and streamline the imaging process. The numerical process will be further refined to consider
bioheat transfer within the breast, the effects of vasculature and breast architecture, internal and
external influencers on the body, and more. The numerical modeling process can be automated to
ensure faster diagnosis for each subject. While exact localization of the mass is important, the
position will be translated into position on a clock, quadrant of the breast, depth, and distance from
the nipple. These identifiers are used heavily in the medical realm for surgical resection and needed
core-needle biopsy (CNB). Furthermore, the imaging process will be further refined for rapid
diagnosis and wide-scale general population screening. Additional components will be considered
for a potential future large-scale clinical study involving general population screening. Further
details on the additions and modifications can be found in Chapter 5.
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Chapter 5: Design of a Large-Scale Clinical Study
This chapter focuses on the potential of a large-scale clinical study in the Rochester General
Hospital. The infrastructure needed has been designed and developed for this study and presented
below. There are additional future recommendations that can be found in Chapter 8.

5.1 Patient Population
By recruiting patients with biopsy-proven breast cancer, the IRI-MRI method was tested and
validated. Testing the simulation process using patients with a known, palpable mass allowed for
validation against an MRI. As discussed in Chapter 3 and 4, the MRI images were used extensively
to develop a patient-specific digital breast model, observe the actual shape of a tumor and compare
the resulting thermal profile with the tumor placement in the breast [60], [124]–[126]. Now that
the method has been proved and validated, further evaluation is needed to determine efficacy in a
blind trial. The obvious next step includes patients that may or may not have breast cancer to
ascertain the detectability limits of this technology and method.
When considering a sample size to determine the efficacy of this technology, there are many
factors to consider. A study published by Bujang and Adnan [127] considers the reality that most
researchers are not statisticians and also discuss the requirements needed for a minimum sample
size in screening or diagnostic studies. Obviously two major factors used to compare various
screening techniques lie in the sensitivity and specificity of the modality, discussed above. Bujang
and Adnan [127] state the following for studies involving the value of a screening method over
diagnostic tools: “If an objective of the research study is to determine whether (or not) a specific
tool or instrument can be used as a screening tool; then researchers will have to ensure that it has
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a sufficiently high degree of sensitivity but a lower degree of specificity can be tolerated.”
However, once the method is considered for diagnostic purposes, both a high sensitivity and
specificity are desirable. This following analysis first considers the sample size for infrared
imaging as a base-level screening method and then as a diagnostic tool.
The primary factors used to determine sample size include prevalence of the disease (Prev),
sensitivity and specificity. Observing the sensitivities and specificities reported for various
screening techniques as seen in Table 14, relative values can be used to determine statistical
significance. As thermography is often compared against mammography or used as an adjunctive
technique with mammography, the sensitivity and specificity for mammography are used to
determine screening sample size. The reported sensitivity is 84% and specificity is 92%.

Table 14. Overall sensitivity and specificity of select screening techniques for comparison.
Technique

Sensitivity

Specificity

Mammography

84%

92%

Magnetic Resonance Imaging (MRI)

90%

50%

Positron Emission Tomography (PET)

90%

86%

Ultrasound

82%

84%

Tomosynthesis (3D mammography)

90%

92%

A paper by Buderer [128] discusses the exact process of calculating sample size for sensitivity and
specificity while incorporating prevalence. The author presents several steps accounting for set
parameters, prevalence, true and false positives and negatives, and sensitivity and specificity. They
also provide the required equations necessary. Table 15 is adapted from Buderer [128].
Table 15. Screening parameters and corresponding equations adapted from Buderer [128].
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Screening Parameter
Sensitivity (SN) the proportion of those
who are diseased, who are labeled positive
by the diagnostic test
Specificity (SP): the proportion of those
who are disease-free, who are labeled
negative by the diagnostic test

Estimate
𝑆𝑆𝑆𝑆 =
𝑆𝑆𝑆𝑆 =

𝑇𝑇𝑇𝑇
𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹

𝑇𝑇𝑇𝑇
𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹

Standard Error
��

𝑆𝑆𝑆𝑆(1 − 𝑆𝑆𝑆𝑆)
�
𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹

��

Positive predictive value (PPV); the
proportion of subjects with positive
diagnostic test results, who have the
disease

𝑃𝑃𝑃𝑃𝑃𝑃 =

��

Negative predictive value (NPV); the
proportion of subjects with negative
diagnostic test results, who do not have
the disease

𝑇𝑇𝑇𝑇
𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹

𝑁𝑁𝑁𝑁𝑁𝑁 =

𝑇𝑇𝑇𝑇
𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹

��

𝑆𝑆𝑆𝑆(1 − 𝑆𝑆𝑆𝑆)
�
𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹

𝑃𝑃𝑃𝑃𝑃𝑃(1 − 𝑃𝑃𝑃𝑃𝑃𝑃)
�
𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹

𝑁𝑁𝑁𝑁𝑁𝑁(1 − 𝑁𝑁𝑁𝑁𝑁𝑁)
�
𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹

Where TP = True Positive, TN = True Negative, FP = False Positive, FN = False Negative

Prevalence involves the proportion of a given population who have specific characteristics. To get
a general estimate of prevalence, data was taken from a study examining women from the New
Hampshire Mammography Network [129], [130]. BI-RADS 0 are classified as ‘incomplete
examinations’ and were removed from this dataset. Poplack et al. [130] provides the breakdown
of BI-RADS classifications for the 47,112 patients, as seen in Table 16. Patients who were
classified as BI-RADS 3, 4 and 5 were included in determining prevalence for screening.
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Table 16. Data collected from Poplack et al. [130] from the New Hampshire Mammography
Network.
BI-RADS
1
2
3
4
5

Negative
Benign
Probably Benign
Suspicious
Highly Suggestive of Malignancy
TOTAL

Screening
37995
80.6%
4930
10.5%
3345
7.1%
766
1.6%
76
0.2%
47112
100%

The following equation is used to determine prevalence:

𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 =

# 𝑜𝑜𝑜𝑜 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑖𝑖𝑖𝑖 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑤𝑤𝑤𝑤𝑤𝑤ℎ 𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 # 𝑜𝑜𝑜𝑜 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑖𝑖𝑖𝑖 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠

(7)

Based on the above numbers, the estimated prevalence [131] for this study is:
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃. =

4187
𝐵𝐵𝐵𝐵 − 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 3, 4, 𝑎𝑎𝑎𝑎𝑎𝑎 5
=
= 8.8%
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 # 𝑜𝑜𝑜𝑜 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
47112

For simplicity, the prevalence is rounded up to 10%. To determine sample size, the following
parameters are needed:
•

W – maximum clinically acceptable width of the 95% confidence interval (CI)

•

P – estimate for prevalence of disease in the target population

•

SN – value for expected sensitivity of new screening method

•

SP – value for expected specificity of new screening method

•

Confidence Intervals and coefficients
o Assuming a 2-tailed, 95% CI
o 𝛼𝛼 = 0.05

o Z𝛼𝛼/2 = 1.96
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Calculating the number of patients who have the disease (TP+FN)
𝑆𝑆𝑆𝑆(1−𝑆𝑆𝑆𝑆)

2
𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹 = 𝑍𝑍𝛼𝛼/2
∗

𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹 = (1.96)2 ∗

𝑊𝑊 2

(8)

. 84(1 − .84)
0.12

Calculating the number of patients who do not have the disease (FP + NP)
2
𝐹𝐹𝐹𝐹 + 𝑇𝑇𝑇𝑇 = 𝑍𝑍𝛼𝛼/2
∗

𝑆𝑆𝑆𝑆(1−𝑆𝑆𝑆𝑆)

Calculating the sample size for required sensitivity, N1

𝑁𝑁1 =

𝑇𝑇𝑇𝑇+𝐹𝐹𝐹𝐹

𝑁𝑁2 =

𝐹𝐹𝐹𝐹+𝑇𝑇𝑇𝑇

𝑊𝑊 2

𝑃𝑃

(9)

(10)

Calculating the sample size for required specificity, N2

1−𝑃𝑃

(11)

Calculating these equations with the assumed and estimated parameters leads to a desired sample
size of N. However, if a higher sensitivity and specificity than mammography are desired, then a
variable sample size is calculated. The following calculations and tables give different sample sizes
depending on the desired parameters. Assuming a constant prevalence of 10% with a variable
sensitivity and specificity, the following sample sizes are calculated:
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Table 17. Estimated sample size for a variable sensitivity and specificity for prevalence of 10%
in patients classified as BI-RADS 3, 4 or 5.
Variable Sensitivity
60%
65%
70%
75%
80%
85%
90%
95%
99%

N1
922
874
807
720
615
490
346
182
38

Variable Specificity
60%
65%
70%
75%
80%
85%
90%
95%
99%

N2
102
97
90
80
68
54
38
20
4

Assuming a constant sensitivity and specificity of 84% and 92%, respectively (from
mammography) with a variable prevalence, the following sample sizes are calculated:

Table 18. Estimated sample size for a variable prevalence.
Variable Prevalence
1%
5%
10%
20%
30%
40%
50%
60%
70%
80%
90%

N1
5163
1033
516
258
172
129
103
86
74
65
57

N2
2827
565
283
141
94
71
57
47
40
35
31

Finally, assuming that both the prevalence and sensitivity/specificity are varying, the following
sample sizes are calculated:
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Table 19. Estimated sample size for variable prevalence and sensitivity.
60%
9220
1844
922
461
307
230
184
154
132
115
102

Prevalence
1%
5%
10%
20%
30%
40%
50%
60%
70%
80%
90%

65%
8740
1844
922
461
307
230
184
154
132
115
102

70%
8067
1613
807
403
269
202
161
134
115
101
90

Sensitivity
75%
80%
7203
6147
1441
1229
720
615
360
307
240
205
180
154
144
123
120
102
103
88
90
77
80
68

85%
4898
980
490
245
163
122
98
82
70
61
54

90%
3457
691
346
173
115
86
69
58
49
43
38

99%
380
76
38
19
13
10
8
6
5
5
4

Table 20. Estimated sample size for variable prevalence and specificity.
Prevalence
1%
5%
10%
20%
30%
40%
50%
60%
70%
80%
90%

60%
93
97
102
115
132
154
184
230
307
461
922

65%
88
92
97
109
125
146
175
218
291
437
874

70%
81
85
90
101
115
134
161
202
269
403
807

Specificity
75%
80%
73
62
76
65
80
68
90
77
103
88
120
102
144
123
180
154
240
205
360
307
720
615

85%
49
52
54
61
70
82
98
122
163
245
490

90%
35
36
38
43
49
58
69
86
115
173
346

99%

4
4
4
5
5
6
8
10
13
19
38

Ultimately, assuming similar sensitivity/specificity to mammography and the prevalence rate of
10% of patients diagnosed as BI-RADS 3, 4 or 5 after general population screening, we can
observe Table 21 (seen again below) as the sample size estimation. The larger of the two sample
sizes will be considered the sample size for the next study (516 patients).
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Table 21. Estimated sample size for a variable sensitivity and specificity for prevalence of 10%
in patients classified as BI-RADS 3, 4 or 5.
Variable Sensitivity
60%
65%
70%
75%
80%
84%
85%
90%
95%
99%

N1
922
874
807
720
615
516
490
346
182
38

Variable Specificity
60%
65%
70%
75%
80%
85%
90%
92%
95%
99%

N2
102
97
90
80
68
54
38
31
20
4

The capacity of the hospital and hired staff could handle a 500-patient study with BI-RADS 3, 4
or 5 patients. The numbers seen in Table 22 show the patients recruited over a 6-month timespan
at the Rochester General Hospital (2,836 total patients). Assuming the clinical study would
encompass three years, only 166 patients would need to be recruited every year (or 3 per week).
The number of patients receiving mammograms classified as BI-RADS 3, 4 or 5 at RGH is 456
patients over a six-month period. Therefore, the current IRI-Mammo recruitment of approximately
one patient per week would require a small increase to meet desired patient sample size. This
would constitute hiring a separate individual to directly recruit patients, potentially creating an
additional screening room, and redesigning the clinical equipment for more rapid screening and
diagnosis.
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Table 22. Mammography data and BI-RADS classifications over a six-month period at the
Rochester General Hospital.
July 1, 2018 through December 31, 2018

0
1
2
3
3L
4
5
6

BI-RADS
Not Applicable
Need Additional Imaging
Negative
Benign
Probably Benign
Probably Benign, Post Lumpectomy
Suspicious
Highly Suggestive of Malignancy
Biopsy-Proven Malignancy
TOTAL

RGH Mammography Data
Screening
0
0.0%
88
4.6%
1231
64.5%
589
30.9%
1
0.1%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
1909
100%

Diagnostic
2
0.2%
2
0.2%
208
22.4%
244
26.3%
131
14.1%
125
13.5%
135
14.6%
65
7.0%
15
1.6%
927
100%

All
2
0.1%
90
3.2%
1439 50.7%
833 29.4%
132
4.7%
125
4.4%
135
4.8%
65
2.3%
15
0.5%
2836 100%

5.2 Clinical Setup
Adding upgrades to the clinical setup will ensure more rapid screening and diagnosis. There are
several components that cause patient discomfort that will be mitigated. These include the
following and are discussed in greater detail below:
•

Acclimation Time: Reducing the acclimation time will involve letting both breasts hang
freely at the same time, while allowing for easy imaging access

•

Staircase: Many patients have struggled with the stairs due to bad knees or joint pain

•

Imaging Position: Those with back pain have complained about the position or struggle to
lie in the position for more than 10 minutes

•

Automated Camera Setup: Manual camera setup and image capture required the image
taker to be underneath the table during screening, causing patient discomfort
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•

Cameras: Moving one camera into 49+ different positions takes a great amount of time,
requiring a longer screening period

The proposed changes in the clinical setup will involve upgrades in both the camera setup and the
screening bed. The camera setup will evolve to include at least two cameras (preferably twelve)
located strategically around the breast, seen in Fig. 55. Six cameras will be located at an angle to
the breast while the remaining six cameras will be pointed horizontally. Similar to the previous
setup, the cameras will be located on a turntable. When the initial images are taken, the turntable
will rotate four times to ensure up to 24 images from each angle or forty-eight images in total to
ensure sufficient data for the modeling and analysis process. Additionally, the camera setup will
be automated with motors to rotate the camera setup and cameras as opposed to manual
manipulation. A computer program can be created to capture all the positions simultaneously,
mitigating the need for manual capture. Automating the process will ensure more rapid screening
and increased patient comfort. The cameras used for screening are the same as the IRI-Mammo
study, with a resolution of 640×512 pixels and a thermal sensitivity of 0.02°C, the highest
commercially available.
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Figure 55. Upgraded camera setup with multiple cameras at varying heights.

The screening bed will be adjusted for subject comfort and optimized imaging views. The desired
setup will involve a modular bed with rails on either side and a hole large enough for both breasts.
The setup in both the IRI-MRI and IRI-Mammo studies involve a modified table with a staircase
and handrail, several feet off the ground. For ease-of-use for subjects with disabilities, the new bed
will not involve any staircase but will instead be modular, allowing for the subject to lay down
before the bed is raised into position. An example of the new imaging setup with multi-camera
system can be seen in Fig. 56.
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Figure 56. New modular table setup with IRI camera system and patient in prone position.

Additionally, removing any thermal alterations by utilizing the prone position and allowing both
breasts to hang freely concurrently will aid in subject comfort and shorten the acclimation period,
therefore shortening the imaging time. The future clinical table will be closer in design to a breast
MRI table. One possible design includes two holes, one for each breast, with a perforated cloth
lying between them. The cloth is added to move one breast out of the way so the other breast can
be imaged in a 360° view. In Fig. 57, the first panel shows the compressed breast lying underneath
the subject while the contralateral breast hangs freely through the opening in the table. This is
found in the current clinical design, causing a longer acclimation and imaging period. The second
panel shows the side view of a redesign with two holes cut in the table and the added perforated
cloth in between the two. The final panel shows the perforated cloth swept to the side to move the
second breast out of the way. Although one breast will be touching a perforated cloth, the
perforations will prevent the breast from heating and will reduce acclimation time considerably.
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Figure 57. Close-up schematic (1st panel) the old imaging table with the subject lying on one
breast, (2nd panel) the proposed imaging table with two holes and (3rd panel) the proposed
table with one breast pulled aside with cloth.

5.3 Numerical Modeling
In addition to the proposed clinical changes, the numerical modeling process will also change. The
numerical process discussed in Chapter 3 and Chapter 4 is highly dependent on the addition of
MRI images. However, for the IRI-Mammo study and prospective large-scale clinical study, MRI
images will not be available. This constitutes a different approach to create a patient-specific
digital breast model. As discussed in Chapter 3, the intricacies associated with the breast can be
difficult to capture without the use of MRI slices. The proposed additions include a mixture of IRI
images and depth sensors to create the model.
Similar to the earlier approach, IRI images can be adapted to silhouettes and combined to create a
rough model. However, because the IRI images are two-dimensional and cannot capture the
intricate features, additional depth sensors will be added to find these geometries. The camera
setup discussed above can be adapted to include two different depth sensors at different angles that
capture the breast geometry prior to IRI image capture. A combination of the depth sensor data
and IRI images will create the patient-specific breast model needed for numerical modeling and
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tumor detection. The proposed digital breast model will go through a similar numerical modeling
process as discussed in the current clinical study.

Figure 58. Edge of the IRI image found and silhouette created for patient-specific digital breast
model without the need of MRI images.

5.4 Additional Changes
Additional modifications include clinical considerations and data management are presented here.
In the current studies, the collected data primarily involve breast cancer and breast surgery history,
hormonal changes, and screening reports (ultrasound, screening mammogram, diagnostic
mammogram, and biopsy report, if applicable). While all of this is sufficient, future studies may
want to add further medical history reports, especially factors that could thermally influence the
body. This could include previous surgical history and alterations involving reproductive organs
or hormonal changes. To truly determine the efficacy of the IRI method, a double-blind study
should also be considered. This would mean the imaging personnel have no prior knowledge of
the status of the patient being screened. Removing bias from the screening process would assist in
a more accurate interpretation of the data and therefore a more accurate assessment of the
sensitivity and specificity of the method.
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Finally, for more rapid diagnosis and faster data sharing between all parties involved, a digital
library could be employed to store relevant thermal and geometric data of the breasts. The library
is where information or data is stored in electronic or other media forms. It may contain
geometrical identifiers, thermal identifiers, and infrared images from different orientations and
distances, patient details, tumor identifiers including size, shape and histology, details regarding
how the information was obtained, computer generated thermal images and their geometrical,
thermal identifiers and tumor identifiers. The tumor identifiers may include information regarding
whether a tumor is present or not, its size, shape, pathology, and other tumor location details that
enable location of the tumor in the breast. The thermal identifiers may include information on the
tumor properties and how they affect the surface temperature profile. They will include
information on maximum temperatures, minimum temperatures, and the gradient throughout the
breast. The geometrical identifiers are identifiers that are related to the geometrical details of the
breast. These could include size and shape of the breast and a detailed comparison to other patients
already stored within the digital library. Data is currently stored in both hard copies and digital
copies at RIT while the RGH staff has access to the medical reports for all patients. A more
streamlined process should be created to share all data between all parties involved.
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Chapter 6: Thermal Biomarkers
Breast cancer is not a uniform disease, and management is increasingly complex. Multiple factors
need to be considered for optimal treatment and a trend is developing towards the practice of
personalized medicine. With improvement in imaging technology, the hope is that we can detect
cancer and differentiate aggressive tumors from the indolent tumors that can be safely monitored,
sparing the subjects the potential risks of treatment. If optimized, the IRI approach discussed above
has the potential to identify tumors at varying levels of aggression dependent on the pathological
properties of the tumor.
Infrared imaging has the unique ability of capturing thermal activity in breast tissue resulting from
a tumor. Thermal activity, characterized as thermal biomarkers, include cellular metabolism,
increased vascularity due to angiogenesis, and increased blood perfusion which create areas of
increased hyperthermia. Tumors have different levels of blood perfusion and metabolic activity.
We therefore hypothesize that these different levels will result in varying thermal biomarkers that
can be detected with IRI.

6.1 Gautherie’s Work
Gautherie presented a model, described in Chapter 2, to compare tumor doubling time with
respective metabolic activity. He also explored the effect of vasculature on the heat transfer
properties in the breast (effective thermal conductivity) when a tumor is present. The fundamentals
and key points of Gautherie’s study are reiterated here.
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In 1980, Gautherie [19] used a fine-needle thermocouple to measure the internal temperature
distribution of breasts, both healthy and with cancer. Throughout his studies, approximately 58,000
patients were examined in the Department of Breast Diseases. However, because of the ethical
nature of his study, only 147 patients were consenting and examined between 1969 and 1978. Due
to the low technological advancements of the time, the only means of internal temperature
measurement involved implanted probes into the breast tissue. Despite concerns of thermal and
pathological alterations while the probes were implanted, no such evidence exists. Gautherie also
reports that “this was confirmed by histologic studies following similar intratumoral investigations
carried out on mice with breast carcinomas.” The probes (0.8 mm in diameter) were inserted in the
breast tissue at varying depths in order to capture the evaluation of local temperatures and thermal
conductivity. Two probes were inserted, one in the healthy breast and the other in the contralateral
cancerous breast, in symmetrical locations. The probe in the cancerous breast was inserted into the
tumor and verified to be in approximately the center of the tumor through a radiographic test.
Thermal measurements were made at intervals of 5 mm.

6.1.1 Effective Thermal Conductivity
Although Gautherie performed many studies examining the efficacy of thermography, this study
in particular investigates the “thermal phenomena associated with cancer growth, especially
metabolic heat production, vascular changes, and circadian rhythms.” Perhaps most significant is
Gautherie’s differentiation between thermal conductivity (k) and effective thermal conductivity
(λe). The parameter λe was calculated in both the healthy and cancerous tissues through the use of
the fine-needle probes, in in vivo conditions and after surgical resection. The effective thermal
conductivity considers the convective heat transfer through the capillary vessels. To prove this, λe
was measured in in vivo perfused tissue and in vitro excised tissue. Assuming a symmetrical
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distribution of blood vessels and convective heat flow, the effective thermal conductivity was
found to be significantly higher in perfused tissue. This conclusion makes logical sense as the
convective heat transfer should be higher when blood vessels are actively present. Additionally,
Gautherie mentions that the λe for cancerous tissues is much larger than that of healthy, alluding
to the increasing presence of blood vessels due to angiogenesis. Overall, effective thermal
conductivity combines the perfusion rate and the thermal conductivity of the breast tissue and
tumor and provides a unique comprehensive thermal parameter that defines the heat transfer rate
which can be employed in breast thermal models.
The graphs in Fig. 59, adapted and redrawn from Gautherie [19], show the effect of temperature
and effective thermal conductivity as a result of a growing tumor. A probe was inserted into the
breast, approximately 70 mm deep. It was placed into the breast with tumor, directly into the tumor,
and into the same spot on the contralateral healthy breast. The first graph in Fig. 59(a) shows an
increase in effective thermal conductivity (conductivity accounting for blood perfusion) in the
breast with tumor, particularly where the tumor is within the breast. Additionally, in the areas
surrounding the tumor, there is an increase in effective thermal conductivity. This could be due to
the increase in vasculature and perfusion rate due to angiogenesis. The effective thermal
conductivity of the healthy breast is seen to remain relatively steady. The second graph in Fig.
59(b) shows an in increase in temperature vs the depth of the probe. In the healthy breast, the
temperature steadily increases, as expected, as the depth moves deeper. The deeper the probe is in
the breast, the closer to the chest wall and therefore closer to the internal body temperature of ~37
°C. However, in the cancerous breast, the increase in temperature is more striking and less gradual.
The heat emanating from the tumor creates a sharper increase in temperature, closer to the internal
body temperature, that steadily levels out further away from the tumor.
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Figure 59. (Left) Temperature vs depth and (right) Effective Thermal Conductivity vs depth for
malignant and healthy tissue, redrawn from Gautherie [19].

Gautherie used probes on 147 patients to differentiate thermal factors in cancerous and healthy
breasts. He reports two major conclusions:
•

Temperature and effective thermal conductivity higher in cancerous breast than in
contralateral healthy breast. A ‘bell-shaped profile’ was seen in cancerous breasts. This
could be due to the heat diffusing through the tissue from the tumor.

•

Increases in temperature and blood flow around the tumor are well correlated. The greater
the blood supply to a tissue, the greater the local metabolism and subsequently increased
hyperthermia.

Gautherie postulated that the heat transfer in the breast occurs through ‘effective’ tissue conduction
(conduction through the tissue and blood convection by capillary vessels) and convention through
larger vessels. In Figure 60 (a) and (b), the progression of tumor growth and resulting thermal
activity is examined until surgical resection. The graphs, redrawn from Gautherie [19], show the
149

natural growth of a tumor and the corresponding thermal influences. One notable difference is in
Fig. 60(a) where there is a ‘dip’ in the effective thermal conductivity. This could be due to inner
necrosis within the tumor where the center of the tumor, cut off from the needed blood and
nutrients to favor growth and spread in the outer margins, begins to die off. If the necrosis within
the tumor presents a ‘dead zone’ in terms of hyperthermia, this could potentially be indicative of
more evolved tumors for future interpretation.

(a)
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(b)
Figure 60. (a)Temperature vs. depth of probe and (b) effective thermal conductivity vs. depth of
probe for three different breast cancer patients with varying tumor sizes, redrawn from
Gautherie [19].

6.1.2 Metabolic Activity
Further evaluation of tumor effects on thermal activity is presented in an additional study focusing
on 84 patients with tumors ranging from 0.9-3.8 cm. The tumor volume doubling time (DT) and
metabolic heat production (q*) were evaluated through the use of x-ray images recorded over an
exponential timeframe. The following three categories of growth and relative metabolic heat
production are discussed in Chapter 2 and reiterated here:
•

Cancers with a fast growth rate (DT ≤ 150 days) and intense metabolic heat production (q*
≥ 20 × 10-3 W/cm3)
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•

Cancers with slow growth rate (DT ≥ 250 days) and low metabolic heat production (q* ≤
10 × 10-3 W/cm3)

•

Cancers with intermediary values of DT and q*, classified into (1) or (2) if lymphatic
spread is found or not.

Figure 61. Relationship between metabolic generation and doubling time.

Ultimately, Gautherie used the plot seen in Fig. 61 to develop an equation to calculate the
metabolic heat generation rate of a tumor. The equation, seen below, is used in our IRI-MRI study
to calculate the metabolic heat generation rate using the tumor diameter to detect and localize
tumor within the breast.
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𝑞𝑞𝑡𝑡 =

3.27∗106
468.5 ln(100𝑑𝑑𝑡𝑡 )+50

(12)

Additionally, following surgical resection of the tumors reported in Fig. 61, histologic examination
was completed to determine lymphatic metastases. The graph denotes which cancers had spread
to the surrounding lymphatic system, upgrading the stage of breast cancer. “Most cancers with
rapid growth rate and high heat production exhibited signs of dissemination.” This indicates that
the metabolic heat production is calculated to be higher in tumors at a more advanced stage.

6.1.3 Internal Rhythms
Similar to other authors, Gautherie mentions the concern surrounding the time when imaging takes
place. The ovulation cycle can influence mammary blood flow, causing additional fluctuations in
effective thermal conductivity. An additional study is carried out examining the cyclical rhythms
on mammary skin temperature. Gautherie examined 26 patients with breast cancer ranging from
37-76 years old. The patient’s behavior and daily activities were heavily monitored and are
reported in Table 23. The temperatures on the cancerous and healthy breast were measured
chronologically.

Table 23. Structured regiment for patients in Gautherie’s study for circadian rhythm control.

Retired to Sleep
Awoke or Awakened
Meals 7:00 AM
Ambient Conditions
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9:30 PM
7:00 AM
12:30 PM
22 – 24 °C

6:30 PM

Two groups were examined. The first group had 15 cases and the second had 11 cases. Healthy
breasts showed circadian, circaseptan, and circatrigintan rhythms are consistent over 24 hours, 7
days, and 29 days (approximate length of menstrual cycle).
Conclusions from the first group (15 cases):
•

In the cancerous breast, the circadian rhythm was shortened, and significant changes were
noted at 21 hours, 42 hours, and 84 hours.

•

Circadian rhythm of skin temperature was desynchronized on cancerous breast.

•

Rhythms on the cancerous breast replaced by additional periods that do not correspond to
known cyclic patterns.

•

These patients had a rapid growth rate (DT <100 days) and high q* (>30 mW/cm3).

•

Overall, more rapidly growing tumors are demonstrating extensive changes in normal
cyclical patterns.

Conclusions from the second group (11 cases):
•

Circadian rhythm of cancerous breast 24-hour synchronized.

•

Rhythms are different from each other in cancerous and healthy breasts.

•

These patients had relatively slow growth rate (DT > 200 days) and low q* (<15 mW/cm3).

•

Pathology of tumors in second group are well differentiated.

•

Overall, there are still differences between the cancerous and healthy rhythms however,
the changes appear to be lesser comparably. This could be due to histology and growth rate
of the tumors.

Additionally, he performed a series of thermograms recorded every hour between 8 AM and 9 PM
on another group of patients at the hospital. The resulting changes in temperature from different
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times during the day have led to a conclusion that morning is an ideal time for thermographic
imaging. Gautherie discusses that there are potentially two distinct categories of human breast
cancers: those that alter the circadian variations and therefore the breast skin temperature and those
that do not.
Finally, Gautherie discusses the potential of abnormal thermograms as classifiers for high risk
patients or early breast cancer. Primarily, adding thermal classifications when cancer is given a
“stage”. The TNM (primary tumor, lymph nodes and distance metastasis) nomenclature discussed
in Chapter 1 involves classification of cancer based on the presence of malignant cells in various
regions of the body. Gautherie discusses the addition of a fourth classifier called “Q” dependent
on intensity, extent, and pattern of hyperthermia on the resulting thermogram. However, prior to
additional classification, further understanding on the complex relationships in the body is needed.
The work presented by Gautherie has great potential for the future of infrared imaging. Developing
a better understanding of the heat transfer within the breast and how the body can influence tumor
growth will further optimize the technology. Most notably, the effective thermal conductivity
within the cancerous breast can help with numerical modeling. The models presented in Chapter
3 and 4 utilize Gautherie’s work to calculate tumor doubling time and metabolic heat generation.
The thermal conductivity is also calculated to determine and verify breast density, but the effective
thermal conductivity is not considered. This is primarily due to the complications associated with
calculated perfusion rate within the breast. The current model utilizes a constant perfusion rate
from literature as opposed to a variable rate. However, many tumors grow at different rates with
some more aggressive than others. The perfusion rate into the tumor and within the breast will
vary for each patient, cancer type, and tumor pathology. The following section discusses an
additional solution to perfusion rate calculation within the breast for further model optimization.
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6.2 Calculating Blood Perfusion
As referenced in Chapter 1, angiogenesis is an essential process in cancer growth. Tumors are seen
to have a high amount of angiogenesis activity in order to grow and spread to other parts of the
body. The process of angiogenesis is highly complex, and vascular endothelial growth factor
(VEGF) produced by growing tumors plays a predominant role [132]. Garcia-Figuerias et al. [132]
discuss the use of imaging techniques (MRI, CT, ultrasound and PET) to indirectly measure
angiogenesis and continued growth. Computed tomography (CT) perfusion involves the use of xrays to examine blood perfusion within the body, primarily to the brain [133]. A contrast material
is used to enhance the tumor vasculature network in the CT. The authors discuss the potential of
using CT, particular to characterize lesions within the body. Tumor vasculature structural
abnormalities, particularly an increase in capillary permeability and tumor perfusion, are
suggestive of malignancy.
Satoh et al. [134] utilized CT Perfusion to study the blood flow in gastric cancer. Approximately
50 patients were enrolled in the study with varying stages of gastric cancer. More advanced cases
were seen to have lower blood flow, which is consistent with Gautherie’s study. The authors were
able to visualize decreasing tumor perfusion rate with increasing levels of malignancy.
Additionally, the found a correlation between tumor blood flow and tumor depth. Despite the
higher levels of cancer stage, none of the tumors presented in this study had necrotic tissue. They
present P-CT (perfusion CT) as a potential imaging technique in inoperable cases, a marker for
tumor perfusion, and potential to personalize treatment dependent on tumor characteristics.
Finally, a study presented by [135] measures the vascular networks in malignant breast tumors
through diffuse correlation spectroscopy (DCS). DCS measures blood flow using the intensity
fluctuations of near-infrared light intensity. Most notable is that DCS does not involve the injection
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of a contrast agent. Satoh et al. mention in their study the possible impact contrast agent has on the
microenvironment of the tumor. Removing this element may be important in determining
perfusion rate and other correlations between blood flow and microenvironment. Thirty-two
patients with biopsy-proven breast cancer were imaged in this study. Using this technique, they
were able to differentiate breast cancer from surrounding normal tissue. This suggests that the
blood flow in the tumor can be a useful marker, particularly when differentiating malignancy.
In our study, the perfusion rate for healthy tissue and tumor were assumed to be 0.00018 and 0.009
ml/s/ml, respectively [136]. However, little data is available on a general guideline for perfusion
rate within the breast. In order to have a more optimized model, a perfusion rate range is proposed
as a first step. To find this range, we propose the use of angiograms to study blood flow through
the body, both in healthy tissue and in the presence of malignant cells. An angiogram utilizes xrays to capture blood flow throughout the body for diagnostic purposes. A contrast agent is injected
into the arteries to improve visibility on an x-ray. Angiograms are generally used to view blood
flow but is occasionally used to examine blood supply to a tumor. Several examples of the
techniques discussed above are seen in Fig. 62, 63, and 64.

Figure 62. (a) P-CT image of gastric cancer with indication of tumor and (b) Perfusion map of
blood flow. An average blood flow of 49.8 ml/min/100 g was calculated [134].
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Figure 63. Malignant gastrointestinal stromal tumor. (left) Blood volume map, (center)
maximum intensity projection image and (right) physical specimen. Authors believe that areas
pointed out with arrows are suggestive of necrosis [132].

Figure 64. (top left) A conventional CT image, (top right) CT parametric map of blood volume or
BV, (bottom left) CT parametric map of permeability-surface area product or PS and (bottom
right) CT parametric map of blood flow or BS [132].

158

Determining blood perfusion rate in a patient can be difficult, especially with the random nature
of tumor angiogenesis. Using CT or angiograms to measure the perfusion rate through breast tissue
is not necessarily the future path of this study. However, using pre-existing angiograms with
varying conditions, we can develop a range of blood perfusion rates to enhance the existing
models. By varying blood perfusion within our numerical model, we can examine the subtle
thermal variations and further optimize our detection process.

6.3 Thermal Biomarkers
Many tumors are classified in terms of their cellular structure or extent in the body. However,
perhaps researchers should consider the addition of internal factors characteristic of tumor
hyperthermia. Further classifications could assist in additional screening, interpretation, and
eventual diagnosis.
Based on the above discussion, it is noted that there are thermal biomarkers indicative of breast
cancer. We postulate that perfusion rate, metabolic activity and effective thermal conductivity are
highly indicative of breast cancer. These are all values that, using computational methods and
theoretical calculation, we can evaluate. The values used in our initial numerical methods (seen in
Chapter 3 and repeated in Table 24 below) are derived from several different authors. These values
come from different authors examining different portions of the breast and body.
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Table 24. Values of the parameters used in the simulations.
Parameter

Value

Thermal conductivity (k), W m-1 °C -1 [19]

0.25 – 0.8

Perfusion rate of healthy tissue (ωh), s-1 [19]

1.8×10-4

Perfusion rate of tumor (ωt), s-1 [19]

9×10-3

Metabolic activity of healthy tissue, W/m-3 (qh) [19]

450

Metabolic activity of tumor (qt), W/m-3 [19]

From (2)

Temperature of arteries (Ta), °C [137]

37

Specific heat of blood (cb), J kg-1 °C -1 [137]

3,840

Density of blood (ρb), kg m-3 [137]

1,060

Core temperature (Tc), °C [19]

37

Ambient temperature (T∞), °C [138]

21

Heat transfer coefficient, W m-2 K-1 [139]

13.5

The modeling process utilized in the preliminary study utilizes the thermal characteristics of a
thermal image and compares with a patient-specific digital breast model in order to find the
position and size of a tumor. The process is primarily dependent on the understanding of bioheat
through the body and the metabolic activity of the tumor. The metabolic activity, calculated using
Gautherie’s model, utilizes the diameter of the tumor and the volumetric doubling time. This model
presents a fundamental understanding of the metabolic rate of growing tumors and is vital in
advancing thermography technology. The model also discusses the changing thermal conductivity
of the breast dependent on the density of vasculature within the tissue. An increase in thermal
conductivity and subsequently vasculature can be indicative of a growing tumor within the region.
As seen in Figures 59 and 60, the presence of a tumor drastically alters the temperature within the
breast. The presence of additional vasculature through angiogenesis increases the perfusion rate
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and effective thermal conductivity of the tissue. The variables and constants in Table 24 consider
both healthy and cancerous tissue values. However, to further update and optimize our modeling
process, we must consider updated perfusion rate values.
The first step involves obtaining angiograms at RGH and determining the maximum and minimum
observable blood perfusion rates. These angiograms do not necessarily need to be breast cancer
related, but the vessel size involved should be comparable. Using these angiograms, the relative
perfusion rate within the body will be determine. Due to the presence of disease and other maladies
within the body, there will be a natural range of values. Next, a parametric study will be employed
to examine the range of blood perfusion values in ANSYS with our previously tested models. The
resulting images will validate Gautherie’s theories with increased effective thermal conductivity
dependent on the aggressivity, size, and metabolic rate of the tumor. Additionally, the range of
perfusion rate values will provide insight on the skin temperatures seen in infrared imaging. Our
previous model predicted the size and placement of tumor within the breast but there were cases
where our model was ‘off’. While uncertainty is to be expected in any complex model, it can be
assumed that the addition of perfusion rate and effective thermal conductivity will provide a more
comprehensive model. Finally, perfusion rate will be added into the model parameters as a variable
instead of a constant. The variation in tumor angiogenesis could depend on the placement, size, or
pathology of the mass. These are all suggested future correlations to further optimize the
computational process.

6.4 Tumor Aggressivity
Classifying thermal biomarkers will not only assist with the development of IRI screening
techniques but will also assist with determining tumor aggressivity. Differentiating between highly
aggressive tumors and indolent masses is essential in reducing patient anxiety, medical cost, and
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time for all parties involved. Overdiagnosis is the identification of a condition that would not result
in any symptoms or affect one’s lifespan [140]. By diagnosing indolent breast cancers through
routine screening mammography that would not have otherwise significantly progressed, there is
no overall clinical benefit. This closely relates to overtreatment, which refers to the management
of a breast cancer through surgery, radiation, and chemotherapy and the adverse effects associated
with them for no clinical gain. Overdiagnosis is difficult to definitively measure, but studies
estimate that screening mammography results in 1-10% cases of overdiagnosis [141]. This can
occur more frequently in aging women as overall mortality from other causes increases but can
also happen in younger subjects that suffer from unrelated life-threatening conditions limiting their
life expectancy.
The US Preventive Services Task Force (USPSTF) now recommends that women begin biennial
screening mammography at age 50. This recommendation is based on the idea that there will be
decreased incidence of overdiagnosis when compared to annual screening starting at age 40. The
overdiagnosis and overtreatment of DCIS has increased recently with the increased utilization of
screening mammography [142]. Prior to the institution of routine screening mammography, DCIS
accounted for less than 5% of cancers [143], but now represents approximately 25%. Some
diagnosed cases of DCIS will never progress to invasive cancer [144], [145] which is thought to
be one of the risks of routine breast cancer screening. The natural progression of DCIS is not fully
understood, but studies have shown that low and high-grade DCIS likely follow separate
developmental pathways and low-grade DCIS tends to progress to low-grade invasive carcinoma
that is well differentiated [146], [147]. Oftentimes low-grade DCIS may never actually progress
to any meaningful invasive disease that would affect mortality [148]. Despite this, National
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Comprehensive Cancer Network (NCCN) guidelines still recommend treating DCIS similar to an
early invasive cancer.
Multiple trials are currently taking place to determine whether biopsy proven low-risk DCIS can
be safely and actively observed without affecting invasive cancer-free survival. The Low-risk
DCIS (LORD) trial from the Netherlands, the Low-risk DCIS (LORIS) trial and European
Organization for Research and Treatment of Cancer (EORTC) from the UK are evaluating
observation against surgical management of low-grade DCIS [149], [150]. There remains the
possibility that surgical management and utilization of radiation therapy could qualify as
overtreatment in these diagnosed low-grade DCIS lesions. With advancements in diagnostic
methodology, the consequences of overtreatment can be tamped down with more appropriate
individualized management or active observation. None of the current imaging technology in
widespread use in breast imaging, i.e. mammography, ultrasound and MRI can reliably
differentiate indolent from potentially aggressive DCIS. Grana-Lopez et al. [151] explored the
utility of metabolic imaging with dedicated breast positron emission tomography (dbPET) to
differentiate indolent from potentially aggressive DCIS. FDG-dbPET measures glucose
metabolism reflecting the biological activity of cancer cells. They found that metabolic imaging
with PET could potentially differentiate indolent from aggressive DCIS that can be managed by
active monitoring. The sensitivity and specificity of dbPET to differentiate between indolent and
potentially aggressive DCIS were 90% and 92%, respectively [151].
Developing correlations between tumor biology and thermal biomarkers is vitally important to
determine the correlative nature of deadly vs non-deadly breast cancers. The metabolic activity,
calculated using Gautherie’s model, utilizes the diameter of the tumor and the volumetric doubling
time. This model presents a fundamental understanding of the metabolic rate of growing tumors
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and is vital in advancing thermography technology. The model also discusses the changing thermal
conductivity of the breast dependent on the vascularity within the tissue (effective thermal
conductivity). An increase in effectively thermal conductivity and subsequently vasculature can
be indicative of a growing tumor within the region. Modifying the input parameters in future
models while maintaining the detection and localization algorithm (and verified through
subsequent mammograms) will help in determining tumor aggressivity. Specifically, the predicted
thermal conductivity, perfusion rate and metabolic heat generation can be compared with normal
tissue properties and properties of aggressive tumors as outlined in Gautherie’s work [19] to
determine whether the tumor is aggressive or indolent.
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Chapter 7: Conclusions

7.1 Summary of Work Done
Breast cancer is a debilitating and widespread disease, affecting thousands around the world every
year. The screening techniques currently available have many positive attributes. But
unfortunately, the patient discomfort, added radiation or contrast material, and high cost can be
problematic. There are several key populations with a higher need for more accessible, safer, and
inexpensive screening.
•

Low income populations – Early breast screening is less accessible. There is a need for a
more portable, easy-to-use, and inexpensive breast cancer screening technique,

•

Younger patients – The mammographic radiation has been known to have negative effects,
particularly in younger patients. Mammography is not recommended for women younger
than 40 years. Traditionally, ultrasound and physical examination are used for younger
patients.

•

High risk – Subjects are classified as high risk either due to a genetic predisposition or
other biological/environmental factors. These subjects are strongly encouraged to begin
annual breast cancer screening earlier than most women.

•

Medical issues – Women with allergic reactions to contrast material or issues with
claustrophobia are unable to receive an MRI. Additionally, women with pacemakers or
other medical implants are not able to utilize an MRI for more advanced screening.

•

General population – The lower cost of thermal imaging makes it a more cost effective
adjunct to mammography particularly in a larger population of women at intermediate risk
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or those with dense breast tissue (40%-50%) in whom mammography alone or in
combination with ultrasound is inadequate.
This study focused on the use of steady-state infrared imaging to screen patients with biopsyproven breast cancer. The following points present the work completed in this thesis.
•

Patient population of IRI-MRI study involved patients with biopsy-proven breast cancer
prior to surgical resection. The MRI and pathology data were utilized for scientific
validation. MRI images were also used to help generate the patient-specific digital breast
model for detection and localization process.

•

The patient data of the IRI-MRI study is presented including temperature changes between
the breasts. Details on tumor placement and thermal differences are presented. Additional
pathology can be seen in the Appendix as well as an example patient report.

•

For the second phase of the clinical study, the specificity of the technology is needed. A
new patient population, IRI-Mammo, introduced patients with suspicious masses prior to
biopsy. These patients were screened as suspicious on mammography but had yet to receive
a biopsy. All of the patients screened up to this point are benign.

•

The patient data of the IRI-Mammo study is currently limited due to limited patient
numbers. The data presented here shows the BI-RADS classification and patient
characteristics. The introduction of the global COVID-19 pandemic has limited the
research study and patient recruitment at the hospital.

•

Utilized steady-state infrared imaging without the use of cold stress. Ten minutes were
allowed for the breast to acclimate to the ambient room conditions. The entire imaging
process lasted approximately 25 minutes for acclimation and imaging of both breasts.
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•

The modeling portion performed by Gonzalez-Hernandez [60] utilized clinical images to
create a digital model. Further iterations will require IRI images and depth sensor data.

•

Using a combination of the collected IRI images and model, detected and localized tumor
in seven patients from the IRI-MRI study.

•

Design of a suggested large-scale clinical study including patient population, clinical
changes, and modeling changes. Additional future recommendations towards the efficacy
of this technology are presented.

7.2 Conclusions
Thermography or Infrared Imaging (IRI) is a cost-effective, portable, and noninvasive technique
for breast cancer screening. However, previous studies have failed to convince the medical
community of the merits of the technology. Previous thermography studies have included
inconsistent screening protocol, lack of scientific validation, and empirical human interpretation.
The clinical study discussed here attempts to address the negative qualities of previous approaches
while also introducing new methods for more effective imaging. Additionally, human bias was
removed from image interpretation through patient-specific digital breast model generation. The
major works of Gautherie are introduced as a thermal classification system, pinpointing
biomarkers in the breast associated with abnormal pathology. Finally, the modality presented has
paved the way for a large-scale clinical study and suggestions on the design and implementation
are discussed. The main conclusions of the approach are presented here.
•

Designed a clinical study to determine the efficacy of infrared imaging for early breast
cancer detection.
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•

Developed a screening protocol considering previous clinical studies, patient comfort, and
full-breast views for more accurate infrared imaging.

•

Validated clinical approach using corresponding images and patient reports (MRI,
mammography, and ultrasound).

•

Two studies were conducted: IRI-MRI where we screened 30 patients with biopsy-proven
breast cancer and IRI-Mammo where we screened 6 patients with suspicious
mammograms. Ultimately, the two populations are aimed at determining the sensitivity
and specificity of our method.

•

Acclimation of patients is vitally important, particularly in a steady-state test without the
use of a cold stress. We observed significant temperature changes over a 10-minute time
period, altering the thermal images. At least 10 minutes are required for proper acclimation
to the room temperature although time of day and year may influence this. Acclimation
time and ambient conditions will continue to be explored for further optimization.

•

Focused on proper image analysis without bias human interpretation by developing a
patient-specific digital breast model using MRI images and edge detection software. The
breast model was created and used by Gonzalez-Hernandez [60], [125], [152] for the
detection and localization process.

•

The digital breast model developed here can be effectively utilized to provide an accurate
representation of heat transfer within the breast.

•

Gautherie’s major works are considered significant as a blueprint for thermal activity
within the breast. The key points are discussed including effective thermal conductivity,
metabolic heat generation, natural body rhythms, and the thermal influence on the breast
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and infrared imaging. A thermal classification system is presented to further optimize
image interpretation and screening protocol.
Future recommendations are presented to improve the processes of IRI and modeling. A design is
presented for a large-scale clinical study in Chapter 5 and additional recommendations are
presented in Chapter 8. The major points are summarized here.
•

The recommendations proposed in Chapter 5 discuss the design of a large-scale clinical
study including changes to the screening setup (camera and imaging table), patient
population and sample size, collected clinical data and patient protocol.

•

Animal studies or experimental phantom models can be used to study IRI techniques and
detection methods without the need for patients, especially considering the current global
circumstances (novel coronavirus).

•

Further image interpretation techniques and detection methods are discussed to
differentiate between vasculature and tumor heat signatures.

•

Additions to the modeling process primarily involve updates to the digital model
generation and CFD process, allowing for standalone IRI without the need for MRI. The
imaging setup and image interpretation could be upgraded to ensure more rapid screening
and diagnosis while also improving patient comfort.

The results from this multidisciplinary study have shown great potential for this modality,
especially with the combined imaging/digital model approach. Utilizing medical and engineering
knowledge has led to a scientifically valid method with the patient at the center of development.
The future of thermography is bright and there are many different avenues for further study.
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•

Despite the bad reputation of thermography in previous studies, this novel work combining
infrared imaging and computational methods has great potential to rapidly screen a wider
subset of patients, leading to several major advancements in breast cancer imaging:
o The potential for personalized medicine and reduction of overdiagnosis/
overtreatment. Our method, once refined, can be used to determine whether a
patient needs treatment (that could potentially negatively influence health further)
or disease monitoring.
o Access to a screening method that is inexpensive, nonradiative, no contact, and
noninvasive.
o Rapid screening and diagnosis for a larger subset of patients. Particularly for
younger, high-risk, or rural populations that do not have sufficient access to
screening.

Thermography holds great potential as an adjunctive modality for breast cancer screening,
particularly for younger populations, high risk populations, or those in rural areas. The technique
has been studied for over half a century, yet thermography is widely misunderstood by the medical
community. Many studies in the past have utilized varying methods and protocols that may have
skewed results or painted thermography in a bad light. Nevertheless, the positive attributes
associated with the method potentially outweigh the negative results of the past. The method is
inexpensive, nonradiative, and highly accessible, allowing for wider population screening. Taking
the many attributes discussed above into consideration, further study into the use of thermography
by the medical community is warranted.
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7.3 Research Contributions
7.3.1 Technical Contributions
Major technical contributions involve the clinical imaging process and thermal biomarker
classification. This work provided a novel clinical study aided by computerized digital image
processing to detect breast cancer. The findings have been validated with MRI images for each
patient. The following components were developed to ensure valid experimentation while
considering ethical considerations: IRB documentation, patient protocols, an image acquisition
system (camera setup and screening table), and the necessary tools needed for image analysis
without human interpretation. Further, the developed method provided insight into infrared
features corresponding to other biological images, pathology reports and patient history. The
clinical work was done in collaboration with Dr. Phatak, Dr. Dabydeen, Dr. Medeiros, Dr.
Godbole, and the Clinical Research Team at RGH and the image analysis was done at RIT. This
work resulted in the following contributions in the field of breast cancer detection:

Major Contributions
•

Designed a clinical study to determine the efficacy of infrared imaging for early breast
cancer detection and developed an approach to evaluate the method. The novel method
here combines steady-state infrared imaging in the prone position and computerized digital
modeling for detection and localization.

•

Identified patient populations for two studies: IRI-MRI and IRI-Mammo. The first
population (IRI-MRI) provides patients with biopsy-proven breast cancer to determine the
sensitivity of the method. The second population (IRI-Mammo) provides patients with
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suspicious screening mammograms classified as BI-RADS 3, 4 or 5 to determine the
specificity of the method. Both of these studies are actively ongoing.
•

Obtained clinical IRI images of 35 patients from two different patient populations: (1)
patients with biopsy-proven breast cancer (30 patients) and (2) patients with suspicious
screenings (6 patients).

•

IRI approach validated using clinical data from subsequent MRI images, mammograms,
and pathology data.

•

Developed the screening protocol and process including patient flow, patient questionnaire
with internal and external influencers, patient protocols, patient consent forms, and IRB
documentation.

•

Determined an acclimation time of 10 minutes with a room temperature of approximately
21°C to reach proper steady state conditions. Identified that this period was sufficient to
cool the breast down considerably for more accurate imaging.

•

Identified the tumor in the breast of seven patients, localizing the tumor diameter within 2
mm and the tumor placement within 7 mm [60].

•

Working with the RGH clinicians, introduced a thermal biomarker classification system to
further optimize the computerized digital imaging process and identify tumor aggressivity.
This work provides the basis for a larger study focusing on correlations between tumor
pathology and thermal profiles on the breast surface.

•

Identified key areas of improvement for further model development including patient
specific digital model without MRI.

•

Discussed future recommendations for a suggested large-scale clinical study. The
recommendations presented include a statistically significant patient population, updates
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to the screening setup for more optimized imaging, and a modeling process without the
need for MRI images.
•

Further clinical research needed for developing IRI as an adjunctive screening technique
to mammographic screening is outlined.

Other Contributions
•

Worked closely with RGH clinicians and research teams, participated in self-learning from
cancer experts, and witnessed a surgical mastectomy and lumpectomy to develop a better
understanding of breast anatomy, cancer metastasis, and tumor biology.

•

Published several peer-reviewed journal and conference articles and a non-provisional
patent application.

•

Assisted in the writing and development of thirteen grant applications to various national,
state, and local government entities.

7.3.2 Societal Contributions
Societal contributions primarily involve developing a technique that has great potential to help
many people. I have thoroughly enjoyed working with patients and a disease that is so widespread
across the world. When I finished my bachelor’s degree, I promised to use my degree and my skills
to help other people. Working in the hospital with breast cancer patients has been incredibly
humbling. I have had family members and friends with cancer and have felt the impact of a loved
one struggling against a terrible disease. But working on this study has shown me another side of
cancer, a side filled with virtue and strength. Many of the women I have screened are in a
whirlwind, about to get a tumor removed or their entire breast removed. It has been an incredibly
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humbling experience working with these patients, all of whom are volunteers. I feel strongly that
the goal of engineering is to contribute to the improvement of people’s lives wherever they exist
on this planet. While this technology is still in the early stages, it has immense potential. In the
words of one of the powerful women I have screened, “This may not help me, but it could help my
granddaughter.”

174

Chapter 8: Recommendations for Future Study

Based on current trends, thermography research has increased greatly over the past few decades.
The need for inexpensive and reliable breast cancer screening methods has been steadily growing,
particularly in low-income countries where common diagnostic techniques are not accessible.
Methods such as thermography are highly portable, more comfortable, and inexpensive compared
to other commonly used techniques. Despite the innovation in newer screening methodology,
several factors should be considered for future success. In addition to the suggestions for a largescale clinical study presented in Chapter 5, the recommendations for future study are presented
here including changes to clinical setup, image interpretation, and non-human study.

8.1 Adjunctive Technique
The BCDDP considered thermography as a replacement for mammography when they began their
study. However, thermography, similar to other modalities, is not meant as a replacement but
instead as an adjunctive technique. For future studies observing thermography as a screening
technique for breast cancer, authors should approach their studies using thermography in adjunct
to a scientifically validated technique, such as mammography. Additionally, combining techniques
has proven an increase in sensitivity for screening. The decision for additional screening is often
made on an individual basis by considering breast density and other risk factors. Women at high
risk, such as women with >20% lifetime risk or known BRCA gene mutations, are screened using
mammography and MRI annually. Combining screening methods or allowing for earlier screening
(ultrasound and thermography are perfectly safe for women under the age of 50) may be key for
earlier diagnosis.
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8.2 Screening Setup
In addition to an added perforated cloth in between the two breasts, discussed in Chapter 5,
adjustable holes could be added to fit the patient. The table and the imaging system are designed
to accommodate different ranges in breast size, shoulder width, body contour, and weight. In order
to have one table that matches all patients, it can be made adjustable. A top view and bottom view
of the new table with modular design is seen in Fig. 65.

Figure 65. A top view (left) and bottom view (right) of a clinical bed with two holes and modular
pieces to fit each subject.
There are modular pieces in the horizontal and vertical directions for each breast hole. When the
subject lies on the table, the modular pieces will be adjusted to fit their breast size and weight.
Once everything is adjusted accordingly, the perforated cloth will pull one breast to the side (Fig.
3C) and the acclimation period will begin. Extra padding will be added between the two modular
holes to ensure subject comfort. The perforated cloth serves the function of pulling the non-imaged
breast away so that clear access can be achieved for the IR camera. It needs to move the breast
without causing significant thermal changes due to insulating effect. The perforations serve the
purpose of providing air cooling while the breast is moved away. The perforated cloth may be
replaced with a mesh, be made of different materials including wire, polyester, nylon, etc. Other
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potential modular designs could include a specially made gown for each patient with holes where
the breasts lie and a larger slot within the imaging table. This would significantly reduce the
influence of the chest wall on the resulting thermal images and would provide more comfort for
the patient. Instead of altering the gown, a softer, cloth-made modular design could be
implemented for the same purpose. Altering the clinical imaging table as opposed to the subject
gowns will provide much more control and help with cleanliness.
Breast cancer survival rates range widely throughout the world with 80% in North America, 60%
in middle-income countries and below 40% in low-income countries. “The low survival rates in
less developed countries can be explained mainly by the lack of early detection programs…” [153].
Breast cancer-related mortality rates in the United States have decreased due to advancements in
screening and treatment [154]. The prevalence of breast cancer in the United States is higher than
in the developing countries, but the mortality to incidence ratio in developing countries is higher
[155]. Following successful scientific development, a sturdy and more portable imaging table and
camera stand could be developed. Although the infrared cameras can be heavy and require special
hardware, camera manufacturers have begun to develop smaller and lighter cameras. Different
imaging strategies and table designs should be explored to determine the ideal prone position while
still maintaining patient comfort. Ultimately, developing a compact system that can be easily
transported will be essential for success. A packaging unit will be developed to ensure smooth
transport from one location to the next.

8.3 Clinical Study
The topics associated with past thermography studies (screening positions, screening protocol, and
image interpretation) all represent areas for growth. There are many paths to follow, involving
changes in interpretation, when patients are screened, how they are screened, bodily or
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environmental factors, etc. However, the variation in method is potentially problematic to
furthering the advancement of this technology. Firstly, it is important to consider the
environmental or internal conditions that can affect thermal imaging. There are specific
environmental and internal factors that can be accounted for such as weather conditions, circadian
rhythm, or screening room conditions. More effort should be given to determine the exact
conditions into which a patient should be thermally screened. There are many studies disagreeing
on exact time and temperature needed for proper acclimation. Determining these exact factors and
their influence will ensure proper conditions prior to thermograms.
Next, the imaging position and number of images should be considered. In many current
commercial and research setups, women sit upright with their arms over their head and few images
are taken (front view and side views). However, imaging in this position has resulted in many
potential issues including but not limited to thermal alterations in the inframammary fold,
gravitational deformation of the breasts and limited optical access to the entire breast surface.
Further inspections should be made for imaging in the prone position, particularly for obtaining a
360° view around the entirety of the breast. Screening positions and imaging bed/stand designs
should consider optimal screening conditions as well as patient comfort. Certain positions may be
uncomfortable, particularly for patients with other ailments such as joint inflammation, obesity, or
back pain. Ergonomic screening setups should be designed with the patient in mind while also
considering thermal abnormalities and imaging capacity of the breast.
Finally, researchers should consider the methods in which a thermogram is interpreted. Previous
methods have been dependent on thermal patterns or empirical observation. However, as we have
learned in many fields including thermography, the human eye is not a perfect interpreter.
Advanced computational methods should be utilized to assist in image interpretation and
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diagnosis. Tools such as artificial intelligence, machine learning, mathematical algorithms,
computational fluid dynamics, etc. can all be utilized for automatic image analysis. The slight
variations in temperature resulting from a tumor may not be detectable by the human eye but
computational tools could easily pick up on smaller inconsistencies. Additionally, many authors
use patterns, breast asymmetry, or temperature differentials to classify breast cancer. However,
there is yet to be a comprehensive understanding of the influences of breast geometry, tumor
pathology and natural circadian rhythm on resulting thermal images. Before exploring the efficacy
of the technology itself, a better understanding of bioheat transfer and tumor pathology is needed.

8.4 Non-Human Studies
Testing on patients can be very problematic creating a need for non-subject experimentation.
Animal studies could be conducted to examine additional situations within the body without the
need for human subjects. Existing or implanted tumors within animal subjects could be used to
examine pathology correlations and temperature changes associated with tumor aggressivity.
Infrared imaging of animal subjects is potentially less problematic, leading to accurate imaging
and deeper understanding of cellular relationships.
Experimental phantom models can help replicate a clinical situation of a breast to optimize
screening setups prior to patient usage. Prior to the IRB approval of this clinical study, we
considered agar-agar models to examine thermal situations without the need for patient
recruitment. Examples of potential phantom model setups can be seen below. The setup in Fig. 66
is comprised of a breast model and an infrared camera. The cartridge heater used to simulate the
tumor is a 15W, 0.5” long heater. The components used for experimentation consist of two main
sections: (1) the breast model and (2) the camera setup.
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Figure 66. Entire experimental setup with rotating camera stand and breast model.

A hemisphere 6” in diameter and 3” deep can be used to simulate the breast. For a more accurate
model, future studies can consider 3D printing a mold using the patient-specific modeling process
described in Chapter 3. The intricate breast geometry will more accurately reflect the heat from a
cartridge heater. Agar-agar is one possible substance to simulate the breast tissue with warm water
as a stable chest wall temperature. Agar-agar originates in powder form and mixes with water in
order to become gel-like with similar thermal properties to tissue within the breast. Before
solidification, one or more cartridge heaters can simulate a tumor within the breast, depending on
the desired observable aggressivity and metabolic rate. A piping system can simulate a simplistic
vasculature structure within the breast with varying perfusion rate and temperature.
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Figure 67. Breast model with imposed heaters to simulate chest wall temperature and tumor.

Finally, a parametric study is recommended to determine detectability limits of the technology. A
cartridge heater can easily be placed at any depth or location within the model, allowing for a more
accurate assessment of imaging limits.

8.5 Model Generation and Modeling
The IRI-MRI study utilized MRI images to create patient-specific digital breast models to use for
the numerical simulation process. As discussed in Chapter 5, the digital model could be generated
using different 2D clinical images. Creating a 3D model from 2D images, or 3D image
reconstruction, has been a useful tool in different research areas where the physical object in the
image is not readily available for constant tests or monitoring. Photogrammetry software, such as
Autodesk Recap Photo, use multi-view 2D images of an object and create a 3D model by extracting
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geometric information from the images. One additional future path could involve the development
of a patient-specific digital breast model generated from the multi-view IRI images captured a
combination of IRI images and a depth sensor. Additional depth sensors such as Intel RealSense
Depth Cameras could be used to spatially map the breast during imaging for additional 3D details
needed in generating the digital model. Combining more than one technique to generate a digital
breast model will allow for a patient-specific model for detection and localization without the need
for MRI images or additional imaging techniques.
As discussed in Chapter 6, thermal biomarkers are proposed as additional classifications in cancer
diagnosis when using infrared imaging. The preliminary studies presented here have been used to
further develop steady-state infrared imaging with a paired numerical modeling method.
Additional modifications should be made to the numerical method to enhance the detection and
localization process. Without the use of actual patients, a parametric study should be conducted to
examine the effect of angiogenesis within the breast due to malignancy. If there are any potential
variations due to tumor size, depth or pathology, these situations could be explored.
Finally, the current collected data has not been fully studied. There are many intracies in the
thermal images that have yet to be further explored. The subsequent pathology reports and
additional images associated with each patient should be further examined. This can include more
modeling, developing correlations between pathology reports and IRI images, or optimizing the
screening process by learning from the collected images. The amount of data collected has great
potential to lead to several larger research projects and should be explored.

8.6 Additional Detection Methods
For more rapid diagnosis or first level screening, additional detection methods could be considered.
There are multiple methods that are used to detect hyperthermic regions of interest within tissue.
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The methods proposed here involve gridlines, profile lines, and thermal contours. Additional
mathematical, visual, or statistical parameters can be employed. A region of interest is identified
as a region on the body part surface where further analysis is considered based on the value of its
geometric and thermal identifiers. Tumors within tissue will have a greater amount of heat
propagation throughout the tissue whereas vasculature or other thermally altering features will
have a singular point or line of heat. After an image is taken, these methods are used on the images
to identify regions of interest and analyze them for potential malignant suspicion. Care is taken to
avoid thermal saturation in the image over the tissue so that accurate information on temperature
profile and its variation is obtained. It may or may not represent the exact surface temperature due
to emissivity correction needed in the image. However, assuming the surface emissivity is uniform,
the temperatures indicated by the infrared image are representative of the temperature field which
may be somewhat offset from the true value. Use of lotion and other creams, etc. may cause
changes in emissivity and their use is discouraged prior to imaging. The following thermal features
in an infrared image are used for further analysis.

Figure 68. Potential pathways to detect thermal features within the breast.

Temperature Distribution in a Thermal Grid – One such system of analysis would be the
implementation of a grid along the body part. This grid could be sketched in multiple ways
including a longitude-latitude type pattern with the longitudinal and latitudinal lines matching the
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contours of the body part. Other gridding systems could involve biased lines, changing line density
based on features of focus or an alternate style of grid pattern. Although a few types of grids are
described, any grid pattern that can be generated on the infrared image for further analysis or
comparison will provide the needed information. The goal of implementing a grid is to enable
defining the temperature variation in each segment of the body part. With an overall estimated
average surface temperature, finding the variation in the mean temperature in each section of the
body part can make it much easier to find abnormalities. Using a biased grid or a varying density
grid can help for various purposes. It can also be used to single out various thermal abnormalities.
Thermal abnormalities are defined as hot spots or regions of interest including but not limited to
suspected malignancy, suspected benign masses, suspected vasculature, or suspected scar tissue.
With fewer grid boxes, it will be easier to find the boundaries of the thermal abnormality in order
to determine if malignancy is a concern or if stray vasculature is creating additional heat signatures.
The grid temperatures may be obtained as an average of one or more pixels at known locations in
a grid that is mapped over the infrared image of the skin surface. Additional features such as
elimination of outliers or similar procedures used in image processing may be applied.
Another example gridding system, seen in Fig. 69, can show the importance of a finer mesh. The
hot spot resulting from the tumor is on the left side of the breast and the hot spot resulting from a
vein is on the right side of the breast. The grid system is drawn over the breast surface with
horizontal (latitude) and vertical (longitude) lines. When a region of interest is identified, a finer
meshing system is applied. The average temperature value in each square can be found to
determine the significance of the hot spot. With a finer grid in specified regions of interest, the
average temperature values will change. The temperatures at the hot spot will be significantly
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hotter than the surrounding tissue. Using a grid system can help identify potential regions of
concern as well as differentiate between a tumor and a vein.

Figure 69. (a) Breast with tumor hot spot and vein hot spot, (b) gridding system on breast, (c)
refined mesh highlighting tumor hot spot and (d) refined mesh highlighting vein hot spot.
Initially, a medium density of lines in each of the two directions is recommended, with 5 to 15
lines in each direction, the number of lines in each direction can be either equal or different. Figure
70 shows a thermal grid with latitudinal and longitudinal lines on a breast with a known tumor,
with 12 latitudinal lines and 7 longitudinal lines.
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Figure 70. Images created by Gonzalez-Hernandez [52]. a) Thermal grid composed of
latitudinal and longitudinal lines on a breast thermogram, b) Statistical indicators in selected
regions of the grid.
Temperature profiles – Another method to identify thermal features is to obtain the surface
temperature profile along lines drawn on the skin surface. These lines can be the same as described
for the generation of the thermal grid. The temperature profile along these lines can be treated
without processing or processed to mitigate small temperature variations. Such processing can be
done through Median, Average, Gaussian, Moving Average, Savitzky-Golay, Regression, or any
combination of these filters. If the sign of the temperature gradient along the distance from the
chest wall changes from positive to negative, it may be used as a marker of the presence of cancer.
The distance over which the gradient is obtained is an important consideration. If the slope changes
in certain region, while it may not change the sign, it may also be indicative of the cancer. If the
slope changes by more than 10 percent over the certain distance, it may be used as a threshold. In
other cases, a change from 10-50 percent or higher may be used as a marker. The slope is calculated
over a reasonable distance to avoid any image aberrations.
Thermal Contours – Using thermal contours with the hot spot in question as the central point is
another method to hot spot differentiation and detection. Similar to a topographical map, thermal
contours can be drawn around the hot spot and the diffusion through the tissue measured. Because
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of the increase in blood perfusion, malignant tumors have a stronger heat presence that steadily
warms the surrounding areas, dissimilar to vasculature. Using appropriate markers, it is possible
to identify the thermal changes due to angiogenesis. This may be a result of observing specific
vasculature patterns that are noted in angiogenesis that are different from the regular vasculature.
A comparison may also be made with infrared images obtained from prior visit or visits of the
same subject to observe the thermal artifacts.

Figure 71. IR image of breast with tumor showing two regions of interest.

8.7

Additional Disease Detection

Breast cancer is an ideal candidate for IR imaging because the breasts lie in between the chest wall
and the environment. There is no empty space in the body for other factors to block or alter the
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resulting thermal images. IR imaging could be incredibly beneficial for other cancerous diseases
with a similar ideal setting.
•

Thyroid Cancer – Thyroid cancer is rarer in the United States compared to breast and colon.
It is also highly treatable with a low mortality rate. Similar to breast cancer, it is often
initially discovered through self-examination. A lump or nodule discovered in the thyroid
leads to an ultrasound and biopsy before cancer is diagnosed. Detecting the early signs of
thyroid cancer can be challenging. Although the prognosis of thyroid cancer is particularly
good, early detection is always an issue. Because the thyroid is located close to the neck
surface, surface thermal imaging would be simple.

•

Skin Cancer – Although much of skin cancer can be visually assessed, rarer forms of skin
cancer can be harder to diagnose. Skin cancer involves lesions, bumps, inflammation, or
internal disease. Determining the extent of the cancer and later stage metastasis such as
lymph node involvement is where imaging techniques are needed and where IR imaging
could particularly come into play.

•

Testicular Cancer – Testicular cancer is a rarer form of cancer with only approximately
20,000 cases in the United States per year. Similar to breast cancer, detection is similar by
feeling a lump in either testicle. Due to the similar properties of the breast and breast cancer,
IRI could easily be implemented to screen for testicular cancer.

•

Non-Cancerous Diseases – The heat and increased blood perfusion associated with tumors
provides a good environment for thermal imaging. Other diseases, such as inflammatory
diseases, are also strong contenders for this diagnosis modality. Diseases such as
neuropathy, joint inflammation and arthritis, and various bowel diseases have been imaged
using IR imaging.
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•

Chemotherapy and radiation – Infrared Imaging can also be used to track the progress of
cancer-related treatment. As chemotherapy drugs or radiation is induced into the growing
tumor to shrink the mass, cancer patients can receive periodic infrared screening to observe
the tumor’s activity. As the drugs are added, the tumor should begin to shrink, and its
metabolic activity should reduce. However, some chemotherapy is effective while others
are not. Infrared imaging can be used to analyze the effectiveness of chemotherapy
treatments for various patients to ensure treatment is progressing properly.
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IRI-MRI Data – 1
IRI-MRI Data – 2
IRI-MRI Data – 3
IRI-MRI Data – 4
IRI-MRI Patient Questionnaire
IRI-MRI Consent Form
IRI-MRI IRB Proposal
IRI-Mammo Patient Questionnaire
IRI-Mammo IRB Addendum
IRI-Mammo Data
IRI-MRI Pathology Report – Patient 029a (identifying information removed)
IRI-Mammo Pathology Report – Patient 002b (identifying information removed)
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IRI-MRI Data – 1
Patient Information

Acclimation

Patient
#

Test
Date

Age

Breast
Density

Bra
Size

IC?

001
002
003
004
005

12-Mar
12-Mar
16-Mar
20-Mar
30-Mar

60
70
71
62
53

HD
SF
PF
SF
SF

US
US
US
US
US

yes
yes
yes
yes
yes

Not collected
Not collected
Not collected
Not collected
Not collected

006

19-Apr

68

SF

US

yes

Not collected

007
008
009
010

20-Apr
26-Apr
26-Apr
25-May

51
67
43
67

SF
SF
SF
SF

US
US
US
34B

yes
yes
yes
yes

Not collected
Not collected
Not collected
Not collected

011

4-Jun

46

HD

36D

yes

Not collected

yes
yes
yes
yes

Not collected
3m, 34s 10m, 11s
1m, 36s
7m
5m, 16s 7m, 18s

012
16-Jul 48
SF
46C
013
17-Jul 64
HD
50DD
014
19-Jul 68
HD
36DD
015
9-Aug 68
SF
40D
IC – Informed Consent Signed
HD – Heterogeneously Dense
SF – Scattered Fibroglandular
PF – Predominantly Fat
US – Unspecified or not collected

Right
waiting

9m, 59s
13m, 20s
9m, 25s

Right
imaging

Left
waiting
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Patient Questionnaire
Left
imaging

Sunbathed

Lotion,
Exercise
etc.

Smoked
Tea
Tightor
or
fitted
drank coffee clothing
X

X
X

X

X

X

X
X
X
X
X

3m, 39s
1m, 21s
1m, 40s

X

X
X
X
X
X
X

X

IRI-MRI Data – 2
Patient Information

Acclimation

Patient Questionnaire

Patient
#

Test
Date

Age

Breast
Density

Bra
Size

IC?

Right
waiting

Right
imaging

Left
waiting

Left
SunLotion,
Exercise
imaging bathed
etc.

016
017

10-Aug
13-Aug

56
70

SF
SF

US
38B

yes
yes

7m, 53s
8m, 11s

56s
1m, 38s

1m, 12s
59s

X

018

15-Aug

42

HD

40DD yes

7m, 8s

46s

1m, 2s

X

X

019
020
021
022
023
024

20-Aug
13-Sep
1-Oct
19-Nov
3-Dec
17-Jan

49
70
65
67
72
72

US
SF
HD
ED
SF
SF

SF
US
US
36B
38C
36B

yes
yes
yes
yes
yes
yes

7m, 41s
7m, 24s
8m, 55s
10m, 3s
12m, 5s
10m, 9s

1m, 11s
1m, 54s
55s
1m, 32s
1m, 42s
1m, 57s

X
X

X

025

19-Mar

64

SF

38C

yes

10m, 4s

3m, 15s

38B
38B
38C
42DD
1X

yes
yes
yes
yes
yes

10m, 5s
7m, 59s
9m, 7s
9m, 56s
10m, 3s

1m, 35s
2m, 4s
1m, 40s
2m, 12s
2m, 43s

9m, 34s
9m, 19s
10m,
37s
9m, 15s
9m, 2s
9m, 25s
10m, 3s
9m, 4s
10m, 3s
10m,
10s
10m, 4s
8m, 0s
9m, 3s
9m, 59s
10m, 5s

026
30-May 63
HD
027
7-Aug 75
SF
028
13-Aug 57
SF
029
26-Aug 76
US
030
18-Sep 69
HD
IC – Informed Consent Signed
ED – Extremely Dense
HD – Heterogeneously Dense
SF – Scattered Fibroglandular
PF – Predominantly Fat
US – Unspecified or not collected
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1m, 17s
1m, 41s
1m, 4s
1m, 51s
1m, 20s
1m, 57s

Smoked
Tea
Tightor
or
fitted
drank coffee clothing

X

3m, 2s

X

2m, 3s
1m, 58s
1m, 38s
2m, 15s
1m, 43s

X
X
X
X

X

X

X

IRI-MRI Data – 3

Patient
Affected
#
Breast
001
002
003
004
005

Right
Right
Right
Left
Right
Right
Left
Left
Left
Right
Left

Tumor Details
Size

Quad/
Pos

Pathology
Distance
from
nipple
US
US
3 cm
5 cm
US
2 cm
3 cm
7 cm
5 cm
1 cm
2 cm
4 cm
1 cm
8 cm
US
4 cm
US

Depth

Overall
ER+? PR+? HER2? MR TD NP Histologic
Grade
DCIS
+
+
US
US US US
2
IDC
+
+
2
3
2
2
IDC
+
+
1
1
2
1
ILC
+
+
3
3
2
3
IDC
2
3
3
3
IDC
+
+
3
3
3
3
ILC
+
+
1
3
1
1
IDC
+
+
1
2
3
2
IDC
+
+
1
2
2
1
IDC
+
+
1
3
2
2
IDC
+
+
1
3
1
1
IDC
+
+
1
3
2
2
IDC
+
+
2
2
2
2
IDC
+
+
1
1
2
1
IDC
+
+
1
2
2
1
ADH, DCIS US
US
US
US US US
US
IDC
3
3
3
3
Type of
Cancer

(1.6 x 1.0 x 1.1) cm
LOQ
Posterior
1.4 cm
UOQ
Middle
9.4 mm
12:00
Anterior
(2.0 x 1.1 x 1.4) cm
LOQ
Middle
(2.9 x 1.3) cm
UOQ
Posterior
(3.5 x 2.4 x 2.3) cm
12:00
Middle
006
(0.8 x 0.6 x 0.4) cm
2:00
Middle
007
(1.3 x 1.0 x 0.9) cm
2:00
Anterior
008
(1.8 x 1.2 x 1.3) cm
10:00
Posterior
009
(1.2 x 0.8 x 0.8) cm
12:00
Middle
010
(1.4 x 1.1 x 1.3) cm
12:00
Anterior
(1.1 x 0.8 x 1.0) cm
5:00
Middle
011
Right
(1.0 x 0.8 x 0.7) cm
5:00
Posterior
012
Right
(1.1 x 0.8) cm
10:00
Posterior
013
Right
(1.5 x 0.9 x 1.2) cm
11:00
Middle
014
Left
MCs
3:00
Middle
015
Left
(1.7 x 1.1 x 1.3)
3:00
Posterior
US – Unspecified, MCs – Microcalcifications
LOQ – Left Outer Quadrant, UOQ – Upper Outer Quadrant
IDC – Invasive Ductal Carcinoma, ILC – Invasive Lobular Carcinoma, DCIS – Ductal Carcinoma In Situ, ADH – Atypical Ductal
Hyperplasia
ER – Estrogen Receptor, PR – Progesterone Receptor, HER2 - Human Epidermal Growth Factor Receptor 2
MR – Mitotic Rate, TD – Tubular Differentiation, NP – Nuclear Pleomorphism
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IRI-MRI Data – 4

Patient
Affected
#
Breast
016
017
018
019

Tumor Details
Size

Quad/
Pos

Distance
from
nipple
US
3 cm
8 cm
6 cm
2 cm
2 cm
3 cm
US
US
US
3 cm
US
4 cm
4 cm
US
5 cm

Pathology
Type
Overall
Depth
of
ER+? PR+? HER2? MR TD NP Histologic
Cancer
Grade
Middle
IDC
+
+
1
2
2
1
Posterior
IDC
3
3
3
3
Posterior
IDC
3
3
3
3
Middle
IDC
3
3
3
3
Posterior
LCIS
+
+
1
3
1
1
Anterior
ILC
+
+
2
3
2
2
Middle
IDC
+
+
1
3
1
1
Middle
LCIS
US
US
US
US US US
US
Middle
IDC
+
+
1
3
2
2
Anterior
IDC
3
3
3
3
Middle
IDC
+
+
1
3
1
1
Posterior
IDC
+
+
1
3
1
1
Middle
IDC
+
+
1
2
1
1
Middle
IDC
+
+
1
3
2
2
Anterior
IDC
+
+
1
1
1
1
Posterior
ILC
+
+
1 US 1
3

Left
(0.9 x 1.1) cm
1:00
Right
(0.5 x 0.5 x 0.6) cm
5:00
Right
5 mm
10:00
Right
(2.6 x 2.3 x 2) cm
6:30
Right
(0.8 x 1.0 x 0.7) cm
12:00
020
Left
(2.1 x 1.3 x 1.8) cm
12:00
021
Left
(1.7 x 1.4 x 1.3) cm
12:00
022
Left
MCs
11:00
023
Right
(1.8 x 1.1 x 1.3) cm
10:00
024
Left
(0.7 x 0.7 x 0.9) cm
11:00
025
Left
(1.9 x 1.7 x 2.4) cm
2:00
026
Left
MCs
11:30
027
Right
(1.0 x 0.8 x 0.7) cm
10:00
028
Left
(1.4 x 1.0 x 0.7) cm
10:00
029
Left
(2.4 x 1.7 x 1.8) cm
1:00
030
Left
(0.7 x 0.6 x 0.3) cm
2:00
US – Unspecified, MCs – Microcalcifications
IDC – Invasive Ductal Carcinoma, ILC – Invasive Lobular Carcinoma, DCIS – Ductal Carcinoma In Situ, LCIS – Lobular Carcinoma
In Situ
ER – Estrogen Receptor, PR – Progesterone Receptor, HER2 - Human Epidermal Growth Factor Receptor 2
MR – Mitotic Rate, TD – Tubular Differentiation, NP – Nuclear Pleomorphism
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IRI-MRI Patient Questionnaire
Subject #: __________

Initials: ___________

DOB: ____________________

Name of Medical Professional:
_________________________________________________
Date: __________________
Consent Form signed?

⎕ Yes

⎕ No

Please check off the following if they apply:
⎕ Patient has sunbathed within five days prior to the exam.

⎕ Patient has used lotion, cream, powder, makeup, deodorant/antiperspirants on the
breasts on the day of the exam.
⎕ Patient exercised the day of the exam.

⎕ Patient has smoked or drank alcohol the day of the exam.
⎕ Patient has had coffee or tea to the exam.

⎕ Patient is wearing tight-fitted clothing the day of the exam.
Patient Info
Age of patient: __________
Breast Density: ________________________
(classified as fatty or extremely dense)
Pathology of Tumor
Tumor type: _____________________________________
Tumor location (interior, mid or posterior): __________________________
Tumor size: ___________________________
Tumor stage: ____________________________
Type of cancer: _____________________________
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IRI-MRI Consent Form

RESEARCH SUBJECT INFORMED CONSENT DOCUMENT
Title: A Thermal Imaging Technique for the Detection of Breast Cancer Based on
Computational Simulations
Protocol:

NSF CBT-1511314

Sponsor: National Science Foundation
Investigator/Study Doctor: Donnette Dabydeen, MD
Rochester General Hospital
1425 Portland Avenue Rochester, NY 14621
585-922-3536
Sub-Investigators:

Satish G. Kandlikar, PhD
Lori Medeiros, MD
Pradyumna Phatak, MD

Study Staff:

Tia Albro, NP
Kayla Malchoff, CRA
Alyssa Recinella, RIT PhD student
Jose Luis Gonzalez Hernandez, RIT PhD student

Summary
You are being asked to participate in this research study and your participation is entirely
voluntary. The purpose of this consent form is to explain to you the purpose of the study and
explain what will be required of you if you choose to participate.
Breast cancer remains the second largest cause of death in women; despite major advances in
treatment, over 40,000 women died of breast cancer in 2016 alone. Early detection of breast
cancer increases the chance of survival, increases the options for treatment, and decreases the
possibility of spreading to other parts of the body. Mammography is the use of low-energy x-rays
to detect tumors and malformations in the breasts by pressing on the breasts to get an image. This
technique is currently the gold standard for detection of breast cancer, but there are limitations to
mammography. Patients with dense breasts (breasts that contain more muscle tissue rather than
fat tissue) experience a decrease in sensitivity with mammography screening by approximately
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10-20%. Promising supplemental tools for breast cancer screening are also not without
limitations and risks, such as increased cost, increased radiation, operator dependence, and
increased false-positive rate. There is therefore a continued need to develop better tools for
breast cancer detection. Thermography is the observation of temperature changes throughout an
object. Breast thermography has the potential to detect temperature patterns associated with early
stages of breast cancer.
Purpose of the Study
The purpose of this study is to take thermal images (images that use color to show difference in
temperature) of the breasts using an infrared (IR) camera to determine the accuracy of
thermography in the early detection of breast cancer. An IR camera is a device that is used to
take the thermal images mentioned above. The thermal images and your magnetic resonance
imaging (MRI) (device that uses magnets and energy to make images of your body) or
mammogram (device that uses x-rays and compression to take images of the breast) will then be
sent to the Rochester Institute of Technology (with no personal identifiers) to be compiled and
analyzed. Thermography is a non-invasive (not requiring the introduction of instruments into the
body), rapid, and cost-effective test that we hope will help in improving and enhancing current
screening practices, especially for dense breast tissues.
Procedures
The study will include up to 100 participants at RGH. If you agree to be in the study it will
require approximately an hour of your time. There are no follow-up visits.
If you have a tumor or diagnosed breast cancer, your participation in this study will either occur
on the same day of your MRI or within two weeks of your MRI. If you do not have breast
cancer, your participation in this study will either occur on the same day of your mammogram
or within three weeks of your mammogram.
If you choose to participate in the study you must follow the instructions below prior to the
clinical examination:
•
•
•
•
•
•
•
•

No sunbathing on the breasts within five days prior to examination.
Avoid the use of lotion, cream, powder, makeup, deodorant, and antiperspirants on the
breasts the day of the examination.
Avoid physical stimulation of the breasts 24 hours prior to the examination.
No exercise 4 hours before the examination.
If bathing, it must be at least one hour before examination.
No smoking or alcohol intake before the examination.
Avoid large meals and excessive intake of coffee or tea prior to examination.
Avoid tight fitted clothing the day of the examination.
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If you choose to participate, the following things will be required of you in the Department of
Radiology at RGH
(1) You will enter the clinical room and disrobe from the waist up and wear a gown. You
will remain for at least 15 minutes in the prone position (face down) with the breasts
placed inside a hole and hanging freely. This step is necessary to acclimate the breasts to
the temperature of the clinical room.
(2) Eight different thermograms (temperature images) will be obtained using an infrared
camera that is mounted on a mechanism that allows the camera to cover the entire surface
of the breasts. You are required to lie in a prone position (face down) while the thermal
images are obtained from below using an infrared (IR) camera.
For participants with a tumor or diagnosed breast cancer: The following steps will be
conducted at the Rochester Institute of Technology with your images, which do not contain
any identifying information.
(1) Your MRI study will be used to generate a digital model of your breasts.
(2) The digital model of the breasts will be used to perform a computer analysis to predict the
temperature of your breasts.
(3) The predicted temperature will be compared with the temperature observed in the clinical
study to verify the accuracy of the predictions from the three-dimensional digital model.
For participants without a tumor or diagnosed breast cancer: The following steps will be
conducted at the Rochester Institute of Technology with your images, which do not contain
any identifying information.
(1) Your mammogram study will be used to observe breast density and vasculature.
(2) The collected temperature images observed in the clinical study will be observed for
changing temperature profiles based on procedure, acclimation period, or anatomical
properties.
a. Example: Will breast density or size produce a different profile? Will the
procedure or acclimation time produce a different profile?
Risks and Discomforts
The thermographic examination is noninvasive and therefore does not pose any risk to you.
There is no radiation risk. There are no side effects associated with the examination.
New Study Findings
New findings developed during the course of research may change and may affect your decision
about wanting to participate. In that event, the findings will be told to you and a new consent
form may be necessary.
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Benefits
Although you will help in the development of this technology, you will not receive any direct
benefit from this technology at this time. Participation in this study will assist in further research
of non-invasive imaging techniques. Infrared imaging has the potential to provide earlier
detection of cancerous tumors in a non-invasive, comfortable fashion.
Costs
There is no cost to you to participate in this research study.
Compensation
There are no incentive payments for you in this research study.
Compensation for injury
This study has minimal risks of injury. Rochester Regional Health, in fulfilling its public
responsibilities, has provided professional liability insurance coverage and will be responsible
for any injury only in the event such injury is caused by the negligence of Rochester Regional
Health.
Confidentiality of Records and HIPAA Authorization
A federal government rule has been issued to protect the privacy rights of patients. This rule was
issued under a law called the Health Insurance Portability and Accountability Act of 1996
(HIPAA). This rule is designed to protect the confidentiality of your personal health
information. Your personal health information is information about you that could be used to
find out who you are. For this research study, this includes information in your existing medical
records needed for this study and new information created or collected during the study.
This Data Privacy Statement explains how your personal health information will be used and
who it will be given to (“disclosed”) for this research study. It also describes your privacy rights,
including your right to see your personal health information.
By signing the consent document for this study, you will give permission (“authorization”) for
the uses and disclosures of your personal health information that are described in this Data
Privacy Statement. If you do not want to allow these uses, you should not participate in this
study.
If you agree to participate in the research study, your personal health information will be used
and disclosed in the following ways:
•

The study doctor/investigator and staff will use your medical records and information
created or collected during the study to conduct the study.
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•

The study doctor/investigator and staff will send your study-related health information
(“study data”) to the sponsor (if applicable) of the study and its representatives
(“sponsor”). Because the sponsor conducts business related to clinical research in many
countries around the world, this may involve sending your study data outside of the
United States. Other countries may have privacy laws that do not provide the same
protections as the laws in this country. However, the sponsor will represent the terms of
this Data Privacy Statement in all countries.

•

The study data sent by the study doctor/investigator to the sponsor does not include your
name, address, social security number, or other information that directly identifies you.
Instead, the study doctor/investigator assigns a code number to the study data and may
use your initials. Some study data sent to the sponsor may contain information that could
be used (perhaps in combination with other information) to identify you (e.g. date of
birth). If you have questions about the specific health information that will be sent to the
sponsor, you should ask the study doctor/investigator.

•

The sponsor will use the study data for research purposes to support the scientific
objectives described in the consent document and the process of getting regulatory
approvals for its drugs.

•

The sponsor may add your study data to data from other studies in research databases so
that it can study better measures of safety and effectiveness, study other therapies for
patients, develop a better understanding of diseases, or improve the design of future
clinical trials.

•

Your study data, either alone or combined with data from other studies, may be shared
with regulatory authorities in the United States and other countries, doctors at other
institutions participating in the study, and the Rochester Regional Health Clinical
Investigations Committee overseeing this study at Rochester Regional Health.

•

Study data that does not directly identify you may be published in medical journals or
shared with others as part of scientific discussions.

•

Your original medical records, which may contain information that directly identifies
you, may be reviewed by the sponsor, the Rochester Regional Health Clinical
Investigations Committee overseeing this study at Rochester Regional Health, and
regulatory authorities in the United States and other countries. The purpose of these
reviews is to assure the quality of the study conduct and the study data, or for other uses
authorized by law.

•

The sponsor works with business partners in drug development. The sponsor may share
your study data with these business partners, but only if the business partners need the
information as a part of this work with the sponsor, and only if the business partners signs
a contract that requires it to protect your study data in the same way as the sponsor.
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•

The sponsor will not disclose personal health information to insurance companies unless
required to do so by the law, or unless you provide separate written consent to do so.

•

Your medical records and study data may be held and processed on computers.

•

If research related procedures are performed within the Rochester Regional Health
(RRH) (i.e. laboratory tests, imaging studies and clinical procedures), the results will be
placed in your Electronic Medical Record (EMR). Once placed in your EMR, results are
accessible to appropriate RRH staff who are not part of the research team.

Your personal health information may no longer be protected by HIPAA privacy rule once it is
disclosed by your study doctor/investigator to these other parties.
You have the right to see and copy your personal health information related to the research study
for as long as this information is held by the study doctor/investigator or Rochester Regional
Health. However, to ensure the scientific integrity of the study, you will not be able to review
some of the study information until after the study has been completed.
You may cancel your authorization at any time by providing written notice to the study
doctor/investigator. If you cancel your authorization, the study doctor/investigator and staff will
no longer use or disclose your personal health information in connection with this study, unless
the study doctor/investigator or staff needs to use or disclose some of your personal health
information to preserve the scientific integrity of the study. The sponsor will still use study data
that was collected before you cancelled your authorization. If you cancel your authorization, you
will no longer be able to participate in the study. However, if you decide to cancel your
authorization and withdraw from the study, you will not be penalized or lose any benefits to
which you are otherwise entitled.
Your authorization for the use and disclosures described in this Data Privacy Statement (DPS)
does not have an expiration date.
Note: If there is not a sponsor for the protocol, remove such reference in the HIPAA statement.
Additionally, if the HIPAA statement is altered (either by the request of the sponsor or other
regulatory site, the DPS must be reviewed and approved by the CIC prior to use in the consent
form.
Voluntary Participation and Withdrawal
Your participation in this study is voluntary. You may decide not to participate or you may leave
the study at any time. Your participation may be stopped at any time by the study doctor or the
sponsor without your consent for any reason. Specific reasons are as follows:
•
•
•

If you do not come to the clinical examination
If you do not sign or complete the consent form
If you do not follow the recommendations prior to the examination that you are given.
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Questions
Contact Donnette Dabydeen, MD at 585-747-2713 (24 hours) for any of the following reasons:
• If you have questions about your participation in this study.
• If you feel you have had a research related injury.
• If you have questions, concerns, or complaints about the research.

INFORMED CONSENT
By signing below, I agree to the use of my Protected Health Information for additional research
as described above.
This consent is valid unless and until I revoke it.

PATIENT
I have read (or have had read to me) the contents of this consent form and have been
encouraged to ask questions. I have received answers to my questions. I give my consent
to participate in this study. I will receive a signed copy of this form for my records and
future reference.

(print name)

Signature

Date

PERSON OBTAINING CONSENT
I have read this form to the subject and/or the subject has read this form. An explanation
of the research was given and questions from the subject were solicited and answered to the
subject’s satisfaction. In my judgment, the subject has demonstrated comprehension of the
information.

(print name)

Signature

212

Date

IRI-MRI IRB Proposal

A Thermal Imaging Technique for the
Detection of Breast Cancer Based on
Computational Simulations
______________________________

Satish G. Kandlikar, PhD: 585-475-6728
Donnette Dabydeen, MD
Lori Medeiros, MD
Phatak Pradyumna, MD
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Introduction
Mammography is currently the gold standard for breast cancer screening and is the only
screening tool that has been demonstrated through large randomized clinical trials to decrease
breast cancer mortality. Nevertheless, there are limitations of mammography, particularly in
patients with dense breasts, where sensitivity is decreased by approximately 10-20%. While
ultrasound, MRI, and tomosynthesis have shown promise as supplemental tools for breast cancer
screening, the use of these modalities are not without limitations and risks, such as increased
cost, increased radiation, operator dependence, and increased false positive rate. There is
therefore a continued need to develop better tools for breast cancer detection. Thermography for
breast screening was introduced in 1956 and was approved by the FDA in 1982. Infrared
thermography fell out of favor due to poor sensitivity. With advances in infrared camera
technology, there has been renewed interests on the use of infrared thermography as an adjunct
to mammography for breast cancer screening with advantages such as lack of ionizing radiation,
patient comfort (touchless and does not require compressing the breast), and portability. In this
research study, a methodology for the early detection of breast cancer will be explored using
infrared thermography. First, the typical temperature patterns of both healthy individuals and
patients with cancer will be identified. Second, computer models will be developed to predict the
temperature observed during the clinical study
Purpose of Study
The aim of this study is to determine the feasibility of infrared thermography to detect breast
cancer. This research study consists of two parts. First, a clinical study that will be conducted at
the Rochester General Hospital in the Department of Radiology. Second, a computational study
that will be conducted at the Rochester Institute of Technology in the Thermal Analysis
Laboratory. Success in these parts will enable a novel, non-invasive technique based on
computer simulations for the detection of early breast cancer using breast thermography. Early,
inexpensive, and accurate breast cancer detection can dramatically improve the quality of life of
patients and reduce costs for cancer treatment.
The aim of the first part is to identify the temperature patterns on the breasts of both healthy
individuals and patients with cancer. Participants will lie in the prone position (face down) while
the temperature of the breasts will be obtained from below using an infrared (IR) camera.
Previous thermographic studies of the breasts have been conducted while patients are seated in
front of the IR camera; this position induces deformation of the breasts due to gravity and creates
temperature artifacts due to the contact of the breasts with the chest. The prone position that will
be adopted in this study is expected to eliminate these two drawbacks. We hypothesize that
thermal images of the breasts in the prone position will aid to enhance and identify the
temperature patterns in breasts with and without a tumor.
For the second part, participants are required to have a Magnetic Resonance Imaging (MRI)
study of the breasts within two weeks prior to the participation in the IR research study. The
images from the MRI study will be used to generate a three dimensional model of the breasts.
The digital model of the breasts will be used to predict the temperature through computer
simulations. The predicted temperature will be compared with the clinical temperature images to
determine the validity of the numerical model of the breasts.
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Method
This is a prospective, single center non-invasive study that poses no risk to the enrolled subjects.
Subjects who have provided informed consent will obtain imaging with infrared camera. The
patients will be recruited by Lori Medeiros, MD, from the department of surgery, at the time of
their surgical consultation. A RIT PhD student and a Rochester General Hospital Research
coordinator will be consenting the patients and will both be involved in obtaining the images.
Participants in the study should follow the next recommendations prior to the clinical
examination:
•
•
•
•
•
•
•
•

No sunbathing on the breasts within five days prior to examination.
Avoid the use of lotion, cream, powder, makeup, deodorant, and antiperspirants on the
breasts the day of the examination.
Avoid physical stimulation of the breasts 24 hours prior to the examination.
No exercise 4 hours before the examination.
If bathing, it must be at least one hour before examination.
No smoking or alcohol intake before the examination.
Avoid large meals and excessive intake of coffee or tea prior to examination.
Avoid tight fitted clothing the day of the examination.

The following list of steps of the study will be conducted at the Rochester General Hospital in
the Department of Radiology
(1) When Participants enter the clinical room, Participants will be asked to disrobe from the
waist up and wear a gown.
(2) Participants should remain for at least 15 (fifteen) minutes in the prone position (face down)
with the breasts with the breasts placed inside a hole and hanging freely. This step is
necessary to acclimate the breasts to the temperature of the clinical room.
(3) Eight different temperature images (thermograms) will be obtained using an infrared camera
mounted on a mechanism that allows the camera to cover the entire surface of the breasts.
The following steps will be conducted at the Rochester Institute of Technology with images that
do not contain personal information of the participants:
(4) The MRI study of the participants will be used to generate a digital model of the breasts.
(5) The digital model of the breasts will be used to perform computer simulations to predict the
temperature of the breasts.
(6) The predicted temperature will be compared with the temperature observed in the clinical
study to verify the validity of the predictions.
Risks of Participation
The thermographic examination is noninvasive, does not involve contact with the patient, and
therefore does not pose any risk to participants. There is no radiation risk. There are no study215

related treatments or interventions. Adverse events and serious adverse events reporting are not
required. The definitive treatment for enrolled patients, i.e. surgery/radiation/chemotherapy will
not be delayed for the purposes of the study.
Benefit of Participation
Although participants will help in the development of this technology, they will not receive any
direct benefit from this experimental examination. Participation in this study will assist in further
research of non-invasive imaging techniques. IR imaging has the potential to provide earlier
detection of cancerous tumors in a non-invasive, comfortable fashion.
Study Duration
Study recruitment will continue until up to approximately 100 subjects have been enrolled.
Study Population
Participants in the study will be selected according with the following inclusion criteria:
Table 1. Breast and tumor parameters for selection of prospective Participants
Breast Density
Fatty
Extremely dense

Tumor size
< 1.5 cm
> 3 cm

Tumor position
Center
Two quadrants

Tumor depth
Anterior
Posterior

1. Signed written informed consent
2. Women 21 years or older who have a recent diagnosis of breast cancer and have not yet
had treatment.
3. Women 21 years or older with no diagnosis of breast cancer
4. All participants have had a recent MRI.
Data collection
The following data will be collected during the study
1.
2.
3.
4.
5.

Age
Histopathology
Breast density
Size and location of the tumor
De-identified copies of the IR images and MRI will be sent to RIT for data analysis.

Study Information and Consent
The Investigator will explain the benefits and risks of participation in the study to each subject
and obtain written informed consent using an informed consent form approved by an IRB/Ethics
Committee. This must be obtained before the subject enters the study and before any study
procedure is performed.
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IRI-Mammo Patient Questionnaire
Subject #: __________

Initials: ___________

DOB: ____________________

Date of exam: __________________________
Name of Medical Professional: _________________________________
Consent Form signed?

Yes

No

Please check off the following if they apply:

Patient has sunbathed within five days prior to exam
Patient has used lotion, cream, powder, makeup, deodorant/antiperspirants on the breasts on
the day of the exam

Patient exercised the day of the exam
Patient has smoked or drank alcohol the day of the exam
Patient has had coffee or tea prior to exam
Patient is wearing tight-fitted clothing the day of the exam
Is the patient menstruating or menopausal?

Menopausal

Menstruating

Is the patient on any type of hormonal birth control?

Yes

No

Has the patient has breast cancer before?

Yes

No

Has the patient had breast surgery before?

Yes

No

If yes, circle the type: Lumpectomy
Breast Implant

Mastectomy
Other

Age of patient: ______________
Breast Size: ____________________________
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Breast Reduction

IRI-Mammo IRB Addendum

This IRB has been altered to add an additional depth sensor which will aid in creating a patientspecific 3D model of the breast. Using this model, we are able to localize the tumor and analyze
additional parameters without the need of MRI.

The above changes are being made in order to capture the actual shape of the breast without the
need for other imaging modalities such as MRI. Throughout the past year and a half, we have been
collecting both patient data and MRI data. The MRI data has been used to find the outline of the
breast in order to create a 3D model. With the use of a depth sensor, the sensor can detect the shape
in front of it and map the breast to create a 3D model, without the need for MRI. For the future of
this study, we would like to see the efficacy of using a depth sensor to eliminate the need for MRI.
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IRI-Mammo Data – 1
Patient Information
Test Date
21-Nov
19-Dec
2-Jan-20
9-Jan-20
17-Feb-20
18-Feb-20

Acclimation

Classification

Age

Breast
Density

001b
002b
003b
004b
005b
006b

70
31
43
64
54
78

SF
SF
HD
SF
HD
SF

Consent?

Right
waiting

Right
imaging

Left
waiting

Left
imaging

yes
yes
yes
yes
yes
yes

8m, 0s
10m, 7s
9m, 59s
10m, 29s
10m, 0s
9m, 2s

2m, 41s
3m, 8s
3m, 14s
2m, 49s
2m, 19s
2m, 43s

8m, 2s
10m, 0s
10m, 0s
9m, 56s
10m, 4s
9m, 47s

2m, 49s
2m , 51s
3m, 6s
2m, 16s
2m, 34s
2m, 9s

Patient Questionnaire - Environmental Factors
Classification
001b
002b
003b
004b
005b
006b

SunLotion,
Exercised
bathed
etc.

X

Smoked
Tea
or
or
drank coffee

X
X
X

Positive
Mammo?

BI-RADS

benign
negative
negative
benign
malignant
malignant

3
1
0
3
6
4

Patient Questionnaire - Hormonal Factors

Tightfitted
clothing

X
X
X

X

BI-RADS – Breast Imaging-Reporting and Data System
US – Unspecified, BC – Breast Cancer
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Menstruating
or
Menopausal?

Birth
control?

US
US
Menopausal
N/A
Menopausal
Menopausal

US
US
Yes
No
No
No

If so,
what
type?
US
US
Mirena
N/A
N/A
N/A

History
of BC?
Yes
No
No
No
No
No

Breast
surgery?
Yes
No
No
No
No
Yes

If so, what
type?
lumpectomy
N/A
N/A
N/A
N/A
lumpectomy

IRI-Mammo Data – 2
Tumor Details
Pathology
Patient # Affected
Quad/
Distance
Histologic
Size
Depth Cancer ER+? PR+? HER2? MR TD NP
Breast
Pos
from nipple
Grade
005b
Left
US
7:00
US
Middle
IDC
+
1
3
2
1
006b
Left
1.7 x 1.6 x 1.6 cm
1:00
US
US – Unspecified
IDC – Invasive Ductal Carcinoma, ILC – Invasive Lobular Carcinoma, DCIS – Ductal Carcinoma In Situ, ADH – Atypical Ductal
Hyperplasia
ER – Estrogen Receptor, PR – Progesterone Receptor, HER2 - Human Epidermal Growth Factor Receptor 2
MR – Mitotic Rate, TD – Tubular Differentiation, NP – Nuclear Pleomorphism
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IRI-MRI Pathology Report – Patient 029a (identifying information removed)

221

222

223

224

225

226

227

228

229

230

231

IRI-Mammo Pathology Report – Patient 002b (identifying information removed)

232

233

234

235

236

237

238

239

240

